EPICORE Embase Updates: EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 98

Results Generated From:
Embase <1980 to 2024 Week 31>
Embase Weekly Updates (updates since 2024-07-26)

<1>
Accession Number
2033537213
Title
Outcomes associated with postoperative cognitive dysfunction: a systematic
review and meta-analysis.
Source
Age and Ageing. 53(7) (no pagination), 2024. Article Number: afae160. Date
of Publication: 01 Jul 2024.
Author
Suraarunsumrit P.; Srinonprasert V.; Kongmalai T.; Suratewat S.;
Chaikledkaew U.; Rattanasiri S.; McKay G.; Attia J.; Thakkinstian A.
Institution
(Suraarunsumrit, Srinonprasert, Kongmalai, Chaikledkaew, Thakkinstian)
Mahidol University Health Technology Assessment (MUHTA) Graduate Program,
Mahidol University, Bangkok, Thailand
(Suraarunsumrit, Srinonprasert) Division of Geriatric Medicine, Department
of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University,
Bangkok, Thailand
(Suraarunsumrit, Srinonprasert, Kongmalai) Siriraj Health Policy Unit,
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,
Thailand
(Kongmalai) Division of Endocrinology and Metabolism, Department of
Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University,
Bangkok, Thailand
(Suratewat) Department of Emergency Medicine, Yanhee Hospital, Bangkok
10700, Thailand
(Chaikledkaew) Social Administrative Pharmacy Division, Department of
Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
(Rattanasiri, Thakkinstian) Department of Clinical Epidemiology and
Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol
University, Bangkok, Thailand
(McKay) Centre for Public Health, School of Medicine, Dentistry, and
Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom
(Attia) School of Medicine and Public Health, University of Newcastle,
Callaghan, NSW, Australia
Publisher
Oxford University Press
Abstract
Background: Postoperative cognitive dysfunction (POCD) manifests as a
subtle decline in cognition, potentially leading to unfavourable
postoperative outcomes. We explored the impact of POCD on physical
function, length of hospital stay (LOS), dementia and mortality outcomes.
 Method(s): PubMed and Scopus were searched until May 2023. All
studies of major surgical patients that assessed POCD and outcomes of
interest were included. POCD effects were stratified by surgery type
(cardiac and noncardiac) and time of POCD assessment (<30 and >=30 days
postsurgery). Result(s): Of 2316 studies, 20 met the inclusion
criteria. POCD was not associated with functional decline postsurgery.
Patients who experienced POCD postcardiac surgery had an increased
relative risk (RR) of death of 2.04 [(95% CI: 1.18, 3.50); I2 =
0.00%]. Sensitivity analyses showed associations with intermediate-term
mortality among noncardiac surgical patients, with an RR of 1.84 [(95% CI:
1.26, 2.71); I2 = 0.00%]. Patients who developed POCD <30 days
postcardiac and noncardiac surgeries experienced longer LOS than those who
did not [mean difference (MD) = 1.37 days (95% CI: 0.35, 2.39);
I2 = 92.38% and MD = 1.94 days (95% CI: 0.48, 3.40);
I2 = 83.29%, respectively]. Postoperative delirium (POD) may
contribute to the heterogeneity observed, but limited data were reported
within the studies included. Conclusion(s): Patients undergoing
cardiac and noncardiac surgeries who developed POCD <30 days postsurgery
had poorer outcomes and an increased risk of premature death. Early
recognition of perioperative neurocognitive disorders in at-risk patients
may enable early intervention. However, POD may confound our findings,
with further studies necessary to disentangle the effects of POD from POCD
on clinical outcomes. Copyright © The Author(s) 2024.

<2>
Accession Number
2030741664
Title
Comparative effectiveness of ultrathin vs. standard strut drug-eluting
stents: insights from a large-scale meta-analysis with extended follow-up.
Source
European Journal of Medical Research. 29(1) (no pagination), 2024. Article
Number: 388. Date of Publication: December 2024.
Author
Hassan A.; Amin A.M.; Gadelmawla A.F.; Mansour A.; Mostafa H.A.; Desouki
M.T.; Naguib M.M.; Ali B.; Siraj A.; Suppah M.; Hakim D.
Institution
(Hassan) Faculty of Medicine, October 6 University, Giza, Egypt
(Hassan) Department of Cardiology, Suez Medical Complex, Ministry of
Health and Population, Suez, Egypt
(Amin) Faculty of Medicine, Mansoura University, Mansoura, Egypt
(Gadelmawla) Faculty of Medicine, Menoufia University, Menoufia, Egypt
(Mansour) Faculty of Medicine, Al-Azhar University, Cairo, Egypt
(Mostafa, Naguib) Faculty of Medicine, Al-Azhar University, Damietta,
Egypt
(Desouki) Faculty of Medicine, Alexandria University, Alexandria, Egypt
(Ali) University Hospitals Cleveland Medical Center, Case Western Reserve
University, Cleveland, OH, United States
(Siraj) MetroHealth Medical Center, Case Western Reserve University,
Cleveland Heights, OH, United States
(Suppah) Department of Cardiovascular Medicine, Mayo Clinic, AZ, United
States
(Hakim) Department of Cardiology, Faculty of Medicine, Suez Canal
University, Ismailia, Egypt
Publisher
BioMed Central Ltd
Abstract
Background: Newer generation ultrathin strut stents are associated with
less incidence of target lesion failure (TLF) in patients undergoing
percutaneous coronary intervention (PCI) in the short term. However, its
long-term effect on different cardiovascular outcomes remains unknown.
 Objective(s): We aim to identify the effects of newer-generation
ultrathin-strut stents vs. standard thickness second-generation
drug-eluting stents (DES) on long-term outcomes of revascularization in
coronary artery disease. Method(s): We searched PubMed, Web of
Science, Cochrane Library databases, and Scopus for randomized controlled
trials (RCTs) and registries that compare newer-generation ultrathin-strut
(< 70 mm) with thicker strut (> 70 mm) DES to evaluate cardioprotective
effects over a period of up to 5 years. Primary outcome was TLF, a
composite of cardiac death, target vessel myocardial infarction (TVMI) or
target lesion revascularization (TLR). Secondary outcomes included the
components of TLF, stent thrombosis (ST), and all-cause death were pooled
as the standardized mean difference between the two groups from baseline
to endpoint. Result(s): We included 19 RCTs and two prospective
registries (103,101 patients) in this analysis. The overall effect on the
primary outcome was in favor of second-generation ultrathin struts stents
in terms of TLF at >= 1 year, >= 2 years, and >= 3 years (P value = 0.01,
95% CI [0.75, 0.96]), P value = 0.003, 95% CI [0.77, 0.95]), P value =
0.007, 95% CI [0.76, 0.96]), respectively. However, there was no reported
benefit in terms of TLF when we compared the two groups at >= 5 years (P
value = 0.21), 95% CI [0.85, 1.04]). Some of the reported components of
the primary and secondary outcomes, such as TLR, target vessel
revascularization (TVR), and TVMI, showed the same pattern as the TLF
outcome. Conclusion(s): Ultrathin-strut DES showed a beneficial
effect over thicker strut stents for up to 3 years. However, at the 5-year
follow-up, the ultrathin strut did not differ in terms of TLF, TLR, TVR,
and TVMI compared with standard-thickness DES, with similar risks of
patient-oriented composite endpoint (POCE), MI, ST, cardiac death, and
all-cause mortality. Copyright © The Author(s) 2024.

<3>
Accession Number
2030739946
Title
Infective Endocarditis by Campylobacter Species-A Narrative Review.
Source
Pathogens. 13(7) (no pagination), 2024. Article Number: 594. Date of
Publication: July 2024.
Author
Ioannou P.; Sourris A.; Tsantes A.G.; Samonis G.
Institution
(Ioannou, Samonis) School of Medicine, University of Crete, Heraklion
71003, Greece
(Sourris) Department of Internal Medicine and Infectious Diseases,
University Hospital of Heraklion, Heraklion 71110, Greece
(Tsantes) Laboratory of Hematology and Blood Bank Unit, "Attikon"
University Hospital, School of Medicine, National and Kapodistrian
University of Athens, Athens 12462, Greece
(Samonis) Metropolitan Hospital, Neon Faliron, Athens 18547, Greece
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Infective endocarditis (IE) is a disease that may cause significant
morbidity and mortality. IE is classically caused by Gram-positive
microorganisms; however, Gram-negative bacteria may seldom also be the
cause. Campylobacter species cause zoonosis and may also infect humans,
mainly causing gastrointestinal infection by C. jejuni or invasive disease
by C. fetus, such as bacteremia, sepsis, meningitis, or vascular
infection. Campylobacter species IE has rarely been described, and most
reports are cases and/or case series. Thus, the characteristics of this
disease, including its epidemiology, clinical presentation, treatment, and
outcome, remain largely unknown. This study aimed to review all published
Campylobacter IE cases and describe their characteristics. A thorough
search of PubMed, the Cochrane Library, and Scopus for published studies
providing information on epidemiology, clinical findings, treatment, and
outcome of Campylobacter IE cases was performed for the present narrative
review. A total of 22 studies containing data from 26 patients were
located and included. Among all patients, 73.1% were male; the median age
was 65 years. Among all patients, 36.4% had a history of a prosthetic
valve. The most commonly affected valve was the aortic, followed by the
mitral. Fever, heart failure, and sepsis were the most frequent clinical
findings. The most commonly isolated pathogen was C. fetus, with only one
patient having C. jejuni IE. Antimicrobial resistance was low for all
antimicrobials, with tetracycline having the highest resistance.
Aminoglycosides and beta-lactams were the most commonly used
antimicrobials. Surgery was performed in 48% of patients. The mortality
rate was 26.9%. Patients who died were more likely to have sepsis, shock,
and heart failure and were less likely to have been treated with
aminopenicillins; however, no factor was identified in a multivariate
logistic regression model as an independent factor for overall
mortality. Copyright © 2024 by the authors.

<4>
Accession Number
2030699214
Title
Comparative Analysis of PCI Strategies in Aortic Stenosis Patients
Undergoing TAVI: A Systematic Review and Network Meta-Analysis.
Source
Clinical Cardiology. 47(8) (no pagination), 2024. Article Number: e24324.
Date of Publication: August 2024.
Author
Fallahtafti P.; Soleimani H.; Ebrahimi P.; Ghaseminejad-Raeini A.; Karimi
E.; Shirinezhad A.; Sabri M.; Mehrani M.; Taheri H.; Siegel R.; Shah N.;
Nanna M.; Hakim D.; Hosseini K.
Institution
(Fallahtafti, Soleimani, Ebrahimi, Karimi, Sabri, Mehrani, Hosseini)
Tehran Heart Center, Cardiovascular Disease Research Institute, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Fallahtafti, Ghaseminejad-Raeini, Karimi, Shirinezhad) School of
Medicine, Tehran University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Taheri, Siegel) Smidt Heart Institute, Cedars-Sinai Medical Center, Los
Angeles, CA, United States
(Shah) Independence Health estmoreland Hospital, Greensburg, PA, United
States
(Nanna) Section of Cardiovascular Medicine, Yale University School of
Medicine, New Haven, CT, United States
(Hakim) Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Transcatheter aortic valve implantation (TAVI) has been
increasingly used in patients with severe aortic stenosis (AS). Since
coronary artery disease (CAD) is common among these patients, it is
crucial to choose the best method and timing of revascularization. This
study aims to compare different timing strategies of percutaneous coronary
intervention (PCI) in patients with severe AS undergoing TAVI to clarify
whether PCI timing affects the patients' outcomes or not. Method(s):
A frequentist network meta-analysis was conducted comparing three
different revascularization strategies in patients with CAD undergoing
TAVI. The 30-day all-cause mortality, in-hospital mortality, all-cause
mortality at 1 year, 30-day rates of myocardial infarction (MI), stroke,
and major bleeding, and the need for pacemaker implantation at 6 months
were analyzed in this study. Result(s): Our meta-analysis revealed
that PCI during TAVI had higher 30-day mortality (RR = 2.46, 95% CI =
1.40-4.32) and in-hospital mortality (RR = 1.70, 95% CI = [1.08-2.69])
compared to no PCI. Post-TAVI PCI was associated with higher 1-year
mortality compared to other strategies. While no significant differences
in major bleeding or stroke were observed, PCI during TAVI versus no PCI
(RR = 3.63, 95% CI = 1.27-10.43) showed a higher rate of 30-day MI.
 Conclusion(s): Our findings suggest that among patients with severe
AS and CAD undergoing TAVI, PCI concomitantly with TAVI seems to be
associated with worse 30-day outcomes compared with no PCI. PCI after TAVI
demonstrated an increased risk of 1-year mortality compared to alternative
strategies. Choosing a timing strategy should be individualized based on
patient characteristics and procedural considerations. Copyright
© 2024 The Author(s). Clinical Cardiology published by Wiley
Periodicals, LLC.

<5>
Accession Number
2033464016
Title
A Randomized control study to compare delNido and Saint Thomas
cardioplegia solutions in isolated valvular heart surgery.
Source
European Journal of Cardiovascular Medicine. 13(3) (pp 579-587), 2023.
Date of Publication: 2023.
Author
Sharma P.; Chauhan A.; Guleria K.; Mehta S.; Verma Y.; Jaswal S.
Institution
(Sharma) Department of Cardiothoracic and Vascular Surgery, DRPGMC, Kangra
(H.P.), Tanda, India
(Chauhan, Guleria, Mehta) Department of Cardiothoracic and Vascular
Surgery, Indira Gandhi Medical College, (H.P.), Shimla 171001, India
(Verma) Department of Cardiac Anesthesia, Indira Gandhi Medical College,
(H.P.), Shimla 171001, India
(Jaswal) Department of Biochemistry, Indira Gandhi Medical College,
(H.P.), Shimla 171001, India
Publisher
Healthcare Bulletin
Abstract
Background: The standard cardioplegia solution for adult cardiac surgery,
Saint Thomas Hospital solution, has been used for a long time. However,
the prolonged cardiac arrest period offered by delNido cardioplegia has
generated significant interest. This study aims to compare outcomes and
variables in isolated valvular heart surgery using delNido and Saint
Thomas cardioplegia solutions. Method(s): This randomized controlled
study was conducted in the Department of Cardiothoracic and Vascular
Surgery at IGMC&H, Shimla, Himachal Pradesh. Patients requiring heart
valve surgery between November 2017 and December 2018 were included.
Randomization was computer-generated, and allocation concealment was
achieved using opaque sequentially numbered sealed envelopes. Appropriate
statistical tests were used to assess associations between variables.
 Result(s): The study included 25 patients in each group. Group 1
(control) used Saint Thomas solution, while Group 2 (intervention) used
delNido solution. Baseline parameters were similar between the groups. CPB
and ACC times were slightly lower in the delNido group (114.48+/-37.73,
83.56+/-24.71) compared to the Saint Thomas group (132.64+/-37.73,
89.20+/-41.02), but the difference was not statistically significant.
Cardioplegia volume was significantly lower in the delNido group. The
delNido group required fewer inotropes, had a shorter ICU stay, fewer
blood transfusions, and fewer defibrillations post aortic clamp removal,
but these differences were not statistically significant. Mean duration of
ventilation was higher in the delNido group, but not statistically
significant. The delNido group had a significantly lower percentage of
patients requiring defibrillation. Cardiac output values showed a
significant difference at 72 hours post CPB, with a slight decrease in the
delNido group. The interaction and main effect for CKMB levels were not
statistically significant, but there was a significant main effect for
CKMB values at 24 hours post CPB. Conclusion(s): Intraoperative and
postoperative safety profiles of delNidocardioplegia were found to be
similar to those of Saint Thomas cardioplegia in adult MVR/AVR+/- TV
repair procedures. Copyright © 2023 Healthcare Bulletin. All
rights reserved.

<6>
Accession Number
2032755396
Title
Clinical decision aids and computed tomography coronary angiography in
patients with suspected acute coronary syndrome.
Source
Emergency Medicine Journal. 41(8) (pp 488-494), 2024. Date of Publication:
22 Jul 2024.
Author
Wang K.-L.; Taggart C.; McDermott M.; O'Brien R.; Oatey K.; Keating L.;
Storey R.F.; Felmeden D.; Curzen N.; Kardos A.; Roobottom C.; Smith J.;
Goodacre S.; Newby D.E.; Gray A.J.
Institution
(Wang, Taggart, McDermott, Newby) Centre for Cardiovascular Science,
University of Edinburgh, Edinburgh, United Kingdom
(Wang) School of Medicine, National Yang Ming Chiao Tung University,
Taipei, Taiwan (Republic of China)
(Wang) General Clinical Research Center, Taipei Veterans General Hospital,
Taipei, Taiwan (Republic of China)
(Taggart) Department of Cardiology, Royal Infirmary of Edinburgh,
Edinburgh, United Kingdom
(O'Brien, Gray) EMERGE (Emergency Medicine Research Group Edinburgh),
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
(Oatey) Edinburgh Clinical Trials Unit, University of Edinburgh,
Edinburgh, United Kingdom
(Keating) Department of Emergency Medicine, Royal Berkshire NHS Foundation
Trust, Reading, United Kingdom
(Storey) Division of Clinical Medicine, University of Sheffield,
Sheffield, United Kingdom
(Storey) NIHR Sheffield Biomedical Research Centre, Sheffield Teaching
Hospitals NHS Foundation Trust, Sheffield, United Kingdom
(Felmeden) Department of Cardiology, Torbay and South Devon NHS Foundation
Trust, Torquay, United Kingdom
(Curzen) Faculty of Medicine, University of Southampton, Southampton,
United Kingdom
(Curzen) Department of Cardiology, University Hospital Southampton NHS
Foundation Trust, Southampton, United Kingdom
(Kardos) TCRG (Translational Cardiovascular Research Group), Milton Keynes
University Hospital NHS Foundation Trust, Milton Keynes, United Kingdom
(Roobottom) Department of Radiology, University Hospitals Plymouth NHS
Trust, Plymouth, United Kingdom
(Smith) Emergency Department, University Hospitals Plymouth NHS Trust,
Plymouth, United Kingdom
(Goodacre) School of Health and Related Research, University of Sheffield,
Sheffield, United Kingdom
(Gray) Usher Institute, University of Edinburgh, Edinburgh, United Kingdom
Publisher
BMJ Publishing Group
Abstract
Background The HEART score, the T-MACS model and the GRACE score support
early decision-making for acute chest pain, which could be complemented by
CT coronary angiography (CTCA). However, their performance has not been
directly compared. Methods In this secondary analysis of a multicentre
randomised controlled trial of early CTCA in intermediate-risk patients
with suspected acute coronary syndrome, C-statistics and performance
metrics (using the predefined cut-offs) of clinical decision aids and
CTCA, alone and then in combination, for the index hospital diagnosis of
acute coronary syndrome and for 30-day coronary revascularisation were
assessed in those who underwent CTCA and had complete data. Results Among
699 patients, 358 (51%) had an index hospital diagnosis of acute coronary
syndrome, for which the C-statistic was higher for CTCA (0.80), followed
by the T-MACS model (0.78), the HEART score (0.74) and the GRACE score
(0.60). The negative predictive value was higher for the absence of
coronary artery disease on CTCA (0.90) or a T-MACS estimate of <0.05
(0.83) than a HEART score of <4 (0.81) and a GRACE score of <109 (0.55).
For 30-day coronary revascularisation, CTCA had the greatest C-statistic
(0.80) with a negative predictive value of 0.96 and 0.92 in the absence of
coronary artery disease and obstructive coronary artery disease,
respectively. The combination of the T-MACS estimates and the CTCA
findings was most discriminative for the index hospital diagnosis of acute
coronary syndrome (C-statistic, 0.88) and predictive of 30-day coronary
revascularisation (C-statistic, 0.85). No patients with a T-MACS estimate
of <0.05 and normal coronary arteries had acute coronary syndrome during
index hospitalisation or underwent coronary revascularisation within 30
days. Conclusions In intermediate-risk patients with suspected acute
coronary syndrome, the T-MACS model combined with CTCA improved
discrimination of the index hospital diagnosis of acute coronary syndrome
and prediction of 30-day coronary revascularisation. Trial registration
number NCT02284191. Copyright © Author(s) (or their employer(s))
2024. No commercial re-use. See rights and permissions. Published by BMJ.

<7>
Accession Number
2030734307
Title
Comparison of Morbidity and Mortality Outcomes between Hybrid Palliation
and Norwood Palliation Procedures for Hypoplastic Left Heart Syndrome:
Meta-Analysis and Systematic Review.
Source
Journal of Clinical Medicine. 13(14) (no pagination), 2024. Article
Number: 4244. Date of Publication: July 2024.
Author
Iskander C.; Nwankwo U.; Kumanan K.K.; Chiwane S.; Exil V.; Lowrie L.; Tan
C.; Huddleston C.; Agarwal H.S.
Institution
(Iskander, Nwankwo, Exil) Division of Pediatric Cardiology, Cardinal
Glennon Children's Hospital, Saint Louis, MO 63104, United States
(Kumanan) Advanced Data Health Institution, Saint Louis University, Saint
Louis, MO 63104, United States
(Chiwane) Division of Pediatric Critical Care Medicine, Loma Linda
University, Loma Linda, CA 92354, United States
(Lowrie, Agarwal) Division of Pediatric Critical Care Medicine, Cardinal
Glennon Children's Hospital, Saint Louis, MO 63104, United States
(Tan, Huddleston) Department of Pediatric Cardio-Thoracic Surgery,
Cardinal Glennon Children's Hospital, Saint Louis, MO 63104, United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Hybrid palliation (HP) procedures for hypoplastic
left heart syndrome (HLHS) are increasing. Our objective was to compare
mortality and morbidity following HP and NP (Norwood palliation)
procedures. Method(s): Systematic review and meta-analysis of HLHS
patients of peer-reviewed literature between 2000 and 2023. Mortality
and/or heart transplantation in HP versus NP in the neonatal period,
interstage period, and at 1, 3 and 5 years of age, and morbidity including
completion of Stage II and Stage III palliation, unexpected interventions,
pulmonary artery pressures, right ventricle function, neurodevelopmental
outcomes and length of hospital stay were evaluated. Result(s):
Twenty-one (meta-analysis: 16; qualitative synthesis: 5) studies
evaluating 1182 HLHS patients included. HP patients had higher interstage
mortality (RR = 1.61; 95% CI: 1.10-2.33; p = 0.01) and 1-year mortality
(RR = 1.22; 95% CI: 1.03-1.43; p = 0.02) compared to NP patients without
differences in 3- and 5-years mortality. HP procedure in high-risk HLHS
patients had lower mortality (RR = 0.48; 95% CI: 0.27-0.87; p = 0.01) only
in the neonatal period. HP patients underwent fewer Stage II (RR = 0.90;
95% CI: 0.81-1.00; p = 0.05) and Stage III palliation (RR = 0.78; 95% CI:
0.69-0.90; p < 0.01), had more unplanned interventions (RR = 3.38; 95% CI:
2.04-5.59; p < 0.01), and longer hospital stay after Stage I palliation
(weighted mean difference = 12.88; 95% CI: 1.15-24.62; p = 0.03) compared
to NP patients. Conclusion(s): Our study reveals that HP, compared to
NP for HLHS, is associated with increased morbidity risk without an
improved survival rate. Copyright © 2024 by the authors.

<8>
Accession Number
2030734223
Title
Aortic Valve Calcium Score: Applications in Clinical Practice and
Scientific Research-A Narrative Review.
Source
Journal of Clinical Medicine. 13(14) (no pagination), 2024. Article
Number: 4064. Date of Publication: July 2024.
Author
Gac P.; Jaworski A.; Grajnert F.; Kicman K.; Trejtowicz-Sutor A.;
Witkowski K.; Poreba M.; Poreba R.
Institution
(Gac, Trejtowicz-Sutor, Witkowski) Centre of Diagnostic Imaging, 4th
Military Hospital, Rudolfa Weigla 5, Wroclaw 50-981, Poland
(Gac) Department of Population Health, Division of Environmental Health
and Occupational Medicine, Wroclaw Medical University, J.
Mikulicza-Radeckiego 7, Wroclaw 50-345, Poland
(Jaworski, Kicman) Healthcare Team "County Hospital" in Sochaczew,
Batalionow Chlopskich 3/7, Sochaczew 96-500, Poland
(Grajnert) 4th Military Hospital, Rudolfa Weigla 5, Wroclaw 50-981, Poland
(Poreba) Department of Paralympic Sports, Wroclaw University of Health and
Sport Sciences, Witelona 25a, Wroclaw 51-617, Poland
(Poreba) Department of Internal and Occupational Diseases, Hypertension
and Clinical Oncology, Wroclaw Medical University, Borowska 213, Wroclaw
50-556, Poland
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
In this narrative review, we investigate the essential role played by the
computed tomography Aortic Valve Calcium Score (AVCS) in the
cardiovascular diagnostic landscape, with a special focus on its
implications for clinical practice and scientific research. Calcific
aortic valve stenosis is the most prevalent type of aortic stenosis (AS)
in industrialized countries, and due to the aging population, its
prevalence is increasing. While transthoracic echocardiography (TTE)
remains the gold standard, AVCS stands out as an essential complementary
tool in evaluating patients with AS. The advantage of AVCS is its
independence from flow; this allows for a more precise evaluation of
patients with discordant findings in TTE. Further clinical applications of
AVCS include in the assessment of patients before transcatheter aortic
valve replacement (TAVR), as it helps in predicting outcomes and provides
prognostic information post-TAVR. Additionally, we describe different AVCS
thresholds regarding gender and the anatomical variations of the aortic
valve. Finally, we discuss various scientific studies where AVCS was
applied. As AVCS has some limitations, due to the pathophysiologies of AS
extending beyond calcification and gender differences, scientists strive
to validate contrast-enhanced AVCS. Furthermore, research on developing
radiation-free methods of measuring calcium content is
ongoing. Copyright © 2024 by the authors.

<9>
Accession Number
2033590893
Title
Prognostic relevance of pre-procedural plasma volume status estimation in
patients undergoing transcatheter aortic valve implantation: A
meta-analysis.
Source
Current Problems in Cardiology. 49(10) (no pagination), 2024. Article
Number: 102749. Date of Publication: October 2024.
Author
Papazoglou A.S.; Moysidis D.V.; Anastasiou V.; Daios S.; Kamperidis V.;
Ziakas A.; Giannakoulas G.
Institution
(Papazoglou) Athens Naval Hospital, Athens, Greece
(Moysidis) 424 Military General Hospital of Thessaloniki, Thessaloniki,
Greece
(Anastasiou, Daios, Kamperidis, Ziakas, Giannakoulas) First Department of
Cardiology, AHEPA University Hospital of Thessaloniki, Thessaloniki,
Greece
Publisher
Elsevier Inc.
Abstract
Background: To systematically evaluate the prognostic utility of estimated
plasma volume status (ePVS) on the outcomes of patients undergoing
transcatheter aortic valve implantation (TAVI). Method(s): The
exposure variable of interest was the ePVS, enumerating the percentage
change of the actual plasma volume from the ideal plasma volume, and being
calculated on the basis of weight and hematocrit using sex-specific
constants. A random-effects meta-analysis was performed after a systematic
literature search in PubMed, Scopus and Web Of Science. Result(s):
The systematic literature search yielded 5 eligible observational cohort
studies encompassing a total of 7,121 patients undergoing TAVI. The
meta-analysis suggested that "high ePVS" status was independently
associated with increased risk for 1-year all-cause mortality (pooled
adjusted hazard ratio: 1.63, 95 % confidence intervals: 1.36-1.95)
compared to "low ePVS". Also, the pooled unadjusted odds for 1-year
mortality, 30-day mortality, peri-procedural stroke, major bleeding, and
acute kidney injury were significantly increased in the "high ePVS" group
of patients. Conversely, the unadjusted risk of pacemaker implantation and
major vascular complications did not differ significantly between the 2
groups. Conclusion(s): Plasma volume expansion appears to be linked
with a worse peri-procedural and long-term prognostic course in TAVI. Its
use in clinical practice could refine risk stratification and candidate
selection practices. Copyright © 2024

<10>
Accession Number
2033297070
Title
Diuresis Efficacy in Ambulatory Congested Heart Failure Patients:
Intrapatient Comparison of 3 Diuretic Regimens (DEA-HF).
Source
JACC: Heart Failure. 12(8) (pp 1396-1405), 2024. Date of Publication:
August 2024.
Author
Abbo A.R.; Gruber A.; Volis I.; Aronson D.; Girerd N.; Lund Kristensen S.;
Zukermann R.; Alberkant N.; Sitnitsky E.; Kruger A.; Khasis P.; Bravo E.;
Elad B.; Helmer Levin L.; Caspi O.
Institution
(Abbo, Gruber, Volis, Aronson, Zukermann, Alberkant, Sitnitsky, Kruger,
Khasis, Bravo, Elad, Helmer Levin, Caspi) Heart Failure Unit, Department
of Cardiology and the Rambam Health Care Campus, Haifa, Israel
(Gruber, Aronson, Caspi) Ruth and Bruce Rappaport Faculty of Medicine,
Technion, Haifa, Israel
(Girerd) Universite de Lorraine, INSERM, Centre d'Investigations
Cliniques-Plurithematique 1433, CHRU Nancy, and INSERM U1116, CHRU, F-CRIN
INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France
(Lund Kristensen) Department of Cardiology, Copenhagen University Hospital
- Rigshospitalet, Copenhagen, Denmark
(Caspi) Clinical Research Institute at Rambam (CRIR), Haifa, Israel
Publisher
Elsevier Inc.
Abstract
Background: Limited evidence exists regarding efficacy and safety of
diuretic regimens in ambulatory, congestion-refractory, chronic heart
failure (CHF) patients. Objective(s): The authors sought to compare
the potency and safety of commonly used diuretic regimens in CHF patients.
 Method(s): A prospective, randomized, open-label, crossover study
conducted in NYHA functional class II to IV CHF patients, treated in an
ambulatory day-care unit. Each patient received 3 different diuretic
regimens: intravenous (IV) furosemide 250 mg; IV furosemide 250 mg plus
oral metolazone 5 mg; and IV furosemide 250 mg plus IV acetazolamide 500
mg. Treatments were administered once a week, in 1 of 6 randomized
sequences. The primary endpoint was total sodium excretion, and the
secondary was total urinary volume excreted, both measured for 6 hours
post-treatment initiation. Result(s): A total of 42 patients were
recruited. Administration of furosemide plus metolazone resulted in the
highest weight of sodium excreted, 4,691 mg (95% CI: 4,153-5,229 mg)
compared with furosemide alone, 3,835 mg (95% CI: 3,279-4,392 mg; P =
0.015) and to furosemide plus acetazolamide 3,584 mg (95% CI: 3,020-4,148
mg; P = 0.001). Furosemide plus metolazone resulted in 1.84 L of urine
(95% CI: 1.63-2.05 L), compared with 1.58 L (95% CI: 1.37-1.8); P = 0.039
collected following administration of furosemide plus acetazolamide and
1.71 L (95% CI: 1.49-1.93 L) following furosemide alone. The incidence of
worsening renal function was significantly higher when adding metolazone
(39%) to furosemide compared with furosemide alone (16%) and to furosemide
plus acetazolamide (2.6%) (P < 0.001). Conclusion(s): In ambulatory
CHF patients, furosemide plus metolazone resulted in a significantly
higher natriuresis compared with IV furosemide alone or furosemide plus
acetazolamide. Copyright © 2024 American College of Cardiology
Foundation

<11>
[Use Link to view the full text]
Accession Number
2033522789
Title
A Randomized, Controlled Trial of Continuous Heparin Infusion to Prevent
Asymptomatic Catheter-related Thrombosis at Discharge in Infants After
Cardiac Surgery: The CHIP-CRT Trial.
Source
Journal of Pediatric Hematology/Oncology. 46(6) (pp e406-e411), 2024. Date
of Publication: 01 Aug 2024.
Author
Tan Y.; Sun X.; Zhong J.; Zou Y.; Ren Y.; Liu Y.; Zhao L.; Zhuang J.; Wang
S.; Sun Y.; Wang Y.
Institution
(Tan, Sun, Zhong, Zou, Ren, Liu, Zhao, Zhuang, Sun, Wang) Department of
Pediatrics, Guangdong Provincial People's Hospital (Guangdong Academy of
Medical Sciences), Southern Medical University, China
(Zhuang) Department of Cardiac Surgery, Guangdong Cardiovascular
Institute, Guangzhou, China
(Wang) Capital Medical University Affiliated Anzhen Hospital, Beijing,
China
(Sun) Department of Pediatrics, Shenzhen New Frontier United Family
Hospital, Shenzhen, China
Publisher
Lippincott Williams and Wilkins
Abstract
Objectives: There are conflicting results in preventing catheter-related
thrombosis (CRT). Continuing infusion of unfractionated heparin (UFH) was
a potential option for CRT. This study was to determine the effect of
continuous UFH infusion on asymptomatic CRT at discharge in infants after
cardiac surgery. Study Design: This study was a randomized,
placebo-controlled, clinical trial at a single center. All infants with
central venous catheters after cardiac surgery, below 3 months of age,
were eligible. Stratified by CRT, infants were randomly assigned to the
UFH group or the normal saline group. UFH was initiated at a speed of 10
to 15 units/kg/h for infants with CRT and 2 to 3 units/kg/h without CRT.
The primary outcome was to determine the rate of CRT at discharge. The
secondary outcomes included thrombosis 6 months after surgery, adverse
events of UFH, and post-thrombotic symptoms. Result(s): Due to slow
recruitment during the COVID-19 pandemic, this trial was prematurely
stopped. Only 35 infants were randomly assigned to the UFH or control
groups. There was no statistically significant difference in CRT rate at
discharge (P=0.429) and 6 months after surgery (P=1.000) between groups.
All CRTs except one disappeared at discharge. No thrombosis or
post-thrombotic symptom was reported at follow-up evaluation. There was no
difference between groups in duration of thrombus (P=0.088), D dimer
(P=0.412), catheter in situ days (P=0.281), and post-thrombotic syndrome
(P=1.000), except for activated partial thromboplastin time (P=0.001).
 Conclusion(s): With the early stop of this trial and limited data, it
is difficult to draw a definitive conclusion about the efficacy of UFH on
CRT. Meanwhile, considering the data from 6 months follow-up, in this
population, asymptomatic CRT might resolve with no
intervention. Copyright © 2024 Wolters Kluwer Health, Inc. All
rights reserved.

<12>
Accession Number
2033491577
Title
Study of the intensive care unit activity scale in the early
rehabilitation of patients after direct cardiac surgery.
Source
World Journal of Clinical Cases. 12(26) (pp 5930-5936), 2024. Date of
Publication: 16 Sep 2024.
Author
Wang L.; Lu J.-Y.; Ma X.-X.; Ma L.-O.
Institution
(Wang, Lu, Ma) Intensive Care Unit, Dongyang People's Hospital, Zhejiang
Province, Jinhua 322100, China
(Ma) Department of Rehabilitation Medicine, Dongyang People's Hospital,
Zhejiang Province, Jinhua 322100, China
Publisher
Baishideng Publishing Group Inc
Abstract
BACKGROUND Direct cardiac surgery often necessitates intensive
post-operative care, and the intensive care unit (ICU) activity scale
represents a crucial metric in assessing and guiding early rehabilitation
efforts to enhance patient recovery. AIM To clarify the clinical
application value of the ICU activity scale in the early recovery of
patients after cardiac surgery. METHODS One hundred and twenty patients
who underwent cardiac surgery between September 2020 and October 2021 were
selected and divided into two groups using the random number table method.
The observation group was rated using the ICU activity scale and the
corresponding graded rehabilitation interventions were conducted based on
the ICU activity scale. The control group was assessed in accordance with
the routine rehabilitation activities, and the postoperative
rehabilitation indexes of the patients in both groups were compared (time
of tracheal intubation, time of ICU admission, occurrence of
complications, and activity scores before ICU transfer). The two groups
were compared according to postoperative rehabilitation indicators (time
of tracheal intubation, length of ICU stay, and occurrence of
complications) and activity scores before ICU transfer. RESULTS In the
observation group, tracheal intubation time lasted for 18.30 +/- 3.28 h
and ICU admission time was 4.04 +/- 0.83 d, which were significantly
shorter than the control group (t-values: 2.97 and 2.038, respectively, P
< 0.05). The observation group also had a significantly lower number of
complications and adverse events compared to the control group (P < 0.05).
Before ICU transfer, the observation group (6.7%) had few complications
and adverse events than the control group (30.0 %), and this difference
was statistically significant (P < 0.05). Additionally, the activity score
was significantly higher in the observation (26.89 +/- 0.97) compared to
the control groups (22.63 +/- 1.12 points) (t-value; -17.83, P < 0.05).
CONCLUSION Implementation of early goal-directed activities in patients
who underwent cardiac surgery using the ICU activity scale can promote the
recovery of cardiac function. Copyright © The Author(s) 2024.
Published by Baishideng Publishing Group Inc. All rights reserved.

<13>
Accession Number
2033489899
Title
Coronary artery calcium and the risk of cardiovascular events and
mortality in younger adults: a meta-analysis.
Source
European Journal of Preventive Cardiology. 31(9) (pp 1061-1069), 2024.
Date of Publication: 01 Jul 2024.
Author
Haq A.; Veerati T.; Walser-Kuntz E.; Aldujeli A.; Tang M.; Miedema M.
Institution
(Haq, Walser-Kuntz, Miedema) Minneapolis Heart Institute Foundation,
Abbott Northwestern Hospital, Nolan Family Center for Cardiovascular
Health, 920 East 28th Street, Suite 100, Minneapolis, MN 55407, United
States
(Veerati, Tang) Department of Medicine, Texas A&M University School of
Medicine, 8447 Riverside Pkwy, Bryan, TX 77807, United States
(Aldujeli) Department of Cardiology, Lithuania University of Health
Sciences, Kaunas, Lithuania
Publisher
Oxford University Press
Abstract
Aims American College of Cardiology/American Heart Association 2019
prevention guidelines recommend utilizing coronary artery calcium (CAC) to
stratify cardiovascular risk in selected cases. However, data regarding
CAC and risk in younger adults are less robust due to the lower prevalence
of CAC and lower incidence of events. The objective of this meta-analysis
is to determine the ability of CAC to predict the risk of cardiovascular
events and mortality in adults <50. Methods PubMed and Cochrane CENTRAL
databases were electronically searched through May 2022 for studies with a
primary and results prevention cohort under age 55 who underwent CAC
scoring. Six observational studies with a total of 45 919 individuals with
an average age of 43.1 and mean follow-up of 12.1 years were included. The
presence of CAC was associated with an increased risk of adverse events
[pooled hazard ratio (HR) = 1.80, 95% confidence interval (CI) 1.26-2.56,
P = 0.012, I2 = 65.5]. Compared with a CAC of 0, a CAC of 1-100
did carry an increased risk of cardiovascular events (pooled HR = 1.85,
95% CI 1.08-3.16, P = 0.0248, I2 = 50.3), but not mortality
(pooled HR = 1.20, 95% CI 0.85-1.69, P = 0.2917), while a CAC > 100 did
carry an increased risk of cardiovascular events (pooled HR = 6.57, 95% CI
3.23-13.36, P < 0.0001, I2 = 72.6) and mortality (pooled HR =
2.91, 95% CI 2.23-3.80, P < 0.0001). Conclusion In a meta-analysis of
younger adults undergoing CAC scoring, a CAC of 1-100 was associated with
a higher likelihood of cardiovascular events, while a CAC > 100 was
associated with a higher likelihood of cardiovascular events and
mortality. Lay summary This paper compiles prior studies into a
meta-analysis to clarify the ability of coronary artery calcium (CAC) to
predict cardiovascular risk and mortality risk in adults < 55 years. * A
mildly elevated CAC (1-100) in adults < 55 likely has an increased
cardiovascular risk but does not appear to have an increased mortality
risk. * A moderately or highly elevated CAC (>100) in adults < 55 has a
substantial increase in cardiovascular risk and mortality
risk. Copyright © The Author(s) 2023.

<14>
Accession Number
2033478160
Title
Analysis of causes for revision in unicompartmental knee arthroplasty.
Source
World Journal of Clinical Cases. 12(25) (pp 5642-5645), 2024. Date of
Publication: 06 Sep 2024.
Author
Tripathy S.K.; Pradhan S.S.; Khan S.; Patel H.
Institution
(Tripathy, Pradhan) Department of Orthopaedics, All India Institute of
Medical Sciences, Odisha, Bhubaneswar 751019, India
(Khan) Department of Orthopedics, All India Institute of Medical Sciences,
Bhubaneswar 751019, India
(Patel) Department of Medicine, Kansas City University of Medicine and
Biosciences, Kansas City, MO 64106, United States
Publisher
Baishideng Publishing Group Inc
Abstract
The study by Zhao et al identifies the factors leading to the failure of
unicompartmental knee arthroplasty (UKA) in their patients. These factors
include substandard suturing of the wound, the presence of osteophytes and
intra-articular loose bodies causing impingement, premature loosening of
the tibial component, choosing unsuitable patients for the procedure,
dislocation of the movable insert, and damage to the anterior cruciate
ligament and medial collateral ligament. The findings suggest that
employing the correct surgical techniques and indications is essential for
successful outcomes in the UKA. Copyright © The Author(s) 2024.
Published by Baishideng Publishing Group Inc. All rights reserved.

<15>
[Use Link to view the full text]
Accession Number
2033433736
Title
Impact of chronic kidney disease on left atrial appendage occlusion: A
meta-analysis of procedural outcomes and complications.
Source
Medicine (United States). 103(29) (pp e38935), 2024. Date of Publication:
19 Jul 2024.
Author
Lee W.-C.; Chang W.-T.; Shih J.-Y.; Wu P.-J.; Fang C.-Y.; Chen H.-C.; Fang
Y.-N.; Fang H.-Y.
Institution
(Lee, Chang, Shih) Division of Cardiology, Department of Internal
Medicine, Chi Mei Medical Center, Tainan, Taiwan (Republic of China)
(Lee, Chang, Shih) School of Medicine, College of Medicine, National Sun
Yat-sen University, Kaohsiung, Taiwan (Republic of China)
(Wu, Fang, Chen, Fang, Fang) Division of Cardiology, Department of
Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung
University College of Medicine, Kaohsiung, Taiwan (Republic of China)
(Fang) Division of Cardiology, Department of Internal Medicine, Jen-Ai
Hospital, Taichung, Taiwan (Republic of China)
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Patients with chronic kidney disease (CKD) experience atrial
fibrillation more frequently. The balance of medical management for stroke
prevention and bleeding events presents a challenging issue in CKD
population. Left atrial appendage occlusion (LAAO) may be an effective
solution for stroke prevention in patients who experience frequent
bleeding with oral anticoagulants. However, the specific impact of CKD on
the procedural success, complications, and outcomes of LAAO implantations
remains underexplored. Method(s): We conducted a search of various
databases for articles published before October 31, 2023. This search
yielded 7 studies, comparing outcomes between CKD and non-CKD cohorts
undergoing LAAO implantation. Our analysis focused on CHA2DS2-VASc scores,
average eGFR, use of oral anticoagulants, procedural success rates,
procedural complications, and associated outcomes. Result(s): The
meta-analysis included data from 2576 patients, with 1131 identified as
having CKD. The CKD group also had higher CHA2DS2-VASc scores (4.7 +/- 1.4
vs 4.0 +/- 1.5; P < .001) and HAS-BLED scores (3.8 +/- 1.1 vs 3.1 +/- 1.0;
P < .001) than the non-CKD group. CKD patients showed a nonreduction in
procedural success rates and a nonsignificant increase in total
complications. The risks of stroke and transient ischemic attack, major
bleeding, and cardiovascular mortality were not significantly different
between the 2 groups. However, a significantly lower rate of total
mortality was observed in the non-CKD group (odds ratio: 0.43; 95%
confidence interval, 0.32-0.60). Conclusion(s): While CKD is
associated with a nonsignificant decrease in procedural success and a
nonsignificant increase in complication risks, the outcomes of LAAO
implantation are comparably favorable between CKD and non-CKD groups.
Despite similar procedural outcomes, the CKD group exhibited a higher rate
of all-cause mortality. Copyright © 2024 the Author(s). Published
by Wolters Kluwer Health, Inc.

<16>
Accession Number
2033296980
Title
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From
REDUCE LAP-HF II.
Source
JACC: Heart Failure. 12(8) (pp 1425-1438), 2024. Date of Publication:
August 2024.
Author
Gustafsson F.; Petrie M.C.; Komtebedde J.; Swarup V.; Winkler S.;
Hasenfuss G.; Borlaug B.A.; Mohan R.C.; Flaherty J.D.; Sverdlov A.L.; Fail
P.S.; Chung E.S.; Lurz P.; Lilly S.; Kaye D.M.; Cleland J.G.F.; Cikes M.;
Leon M.B.; Cutlip D.E.; van Veldhuisen D.J.; Solomon S.D.; Shah S.J.
Institution
(Gustafsson) Rigshospitalet, University of Copenhagen, Denmark
(Petrie, Cleland) British Heart Foundation Centre of Research Excellence,
School of Cardiovascular and Metabolic Health, University of Glasgow,
Scotland, Glasgow, United Kingdom
(Komtebedde) Corvia Medical, Inc, Tewksbury, MA, United States
(Swarup) Arizona Heart and Rhythm Center, Phoenix, AZ, United States
(Winkler) B.G. Klinikum Unfallkrankenhaus, Berlin, Germany
(Hasenfus) Heart Center, University Medical Center, Gottingen, Germany
(Borlaug) Mayo Clinic, Rochester, MN, United States
(Mohan) Scripps Health, La Jolla, CA, United States
(Flaherty, Shah) Northwestern University Feinberg School of Medicine,
Chicago, IL, United States
(Sverdlov) John Hunter Hospital, University of Newcastle, New Lambton
Heights, Australia
(Fail) Cardiovascular Institute of the South, Houma, LA, United States
(Chung) The Lindner Research Center at The Christ Hospital, Cincinnati,
OH, United States
(Lurz) Cardiology Center, University Medical Center, Johannes Gutenberg
University, Mainz, Germany
(Lilly) Ohio State University, Columbus, OH, United States
(Kaye) Alfred Hospital, Melbourne, Australia
(Cikes) University of Zagreb School of Medicine, University Hospital
Centre Zagreb, Zagreb, Croatia
(Leon) Cardiovascular Research Foundation, New York, NY, United States
(Cutlip) Baim Clinical Research Institute, Boston, MA, United States
(van Veldhuisen) University Medical Center Groningen, Groningen,
Netherlands
(Solomon) Brigham and Women's Hospital, Boston, MA, United States
Publisher
Elsevier Inc.
Abstract
Background: The REDUCE LAP-HF II (Reduce Elevated Left Atrial Pressure in
Patients With Heart Failure II) trial found that, compared with a sham
procedure, the Corvia Atrial Shunt did not improve outcomes in heart
failure with preserved or mildly reduced ejection fraction. However, after
12-month follow-up, "responders" (peak-exercise pulmonary vascular
resistance <1.74 WU and absence of a cardiac rhythm management device)
were identified. Objective(s): This study sought to determine: 1) the
overall efficacy and safety of the atrial shunt vs sham control after 2
years of follow-up; and 2) whether the benefits of atrial shunting are
sustained in responders during longer-term follow-up or are offset by
adverse effects of the shunt. Method(s): The study analyzed 2-year
outcomes in the overall REDUCE LAP-HF II trial, as well as in responder
and nonresponder subgroups. The primary endpoint was a hierarchical
composite of cardiovascular death or nonfatal ischemic/embolic stroke,
total heart failure events, and change in health status. Result(s):
In 621 randomized patients, there was no difference between the shunt (n =
309) and sham (n = 312) groups in the primary endpoint (win ratio: 1.01
[95% CI: 0.82-1.24]) or its individual components at 2 years. Shunt
patency at 24 months was 98% in shunt-treated patients. Cardiovascular
mortality and nonfatal ischemic stroke were not different between the
groups; however, major adverse cardiac events were more common in those
patients assigned to the shunt compared with sham (6.9% vs 2.7%; P =
0.018). More patients randomized to the shunt had an increase in right
ventricular volume of >=30% compared with the sham control (39% vs 28%,
respectively; P < 0.001), but right ventricular dysfunction was uncommon
and not different between the treatment groups. In responders (n = 313),
the shunt was superior to sham (win ratio: 1.36 [95% CI: 1.02-1.83]; P =
0.037, with 51% fewer HF events [incidence rate ratio: 0.49 [95% CI:
0.25-0.95]; P = 0.034]). In nonresponders (n = 265), atrial shunting was
inferior to sham (win ratio: 0.73 [95% CI: 0.54-0.98]).
 Conclusion(s): At 2 years of follow-up in REDUCE LAP-HF II, there was
no difference in efficacy between the atrial shunt and sham groups in the
overall trial group. The potential clinical benefit identified in the
responder group after 1 and 2 years of follow-up is currently being
evaluated in the RESPONDER-HF (Re-Evaluation of the Corvia Atrial Shunt
Device in a Precision Medicine Trial to Determine Efficacy in Mildly
Reduced or Preserved Ejection Fraction Heart Failure) trial. (Reduce
Elevated Left Atrial Pressure in Patients With Heart Failure II [REDUCE
LAP-HF II]; NCT03088033) Copyright © 2024 American College of
Cardiology Foundation

<17>
[Use Link to view the full text]
Accession Number
2033222898
Title
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial
of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated
Cardiomyopathy.
Source
Circulation: Heart Failure. 17(7) (pp e011548), 2024. Date of Publication:
01 Jul 2024.
Author
Garcia-Pavia P.; Rodriguez Palomares J.F.; Sinagra G.; Barriales-Villa R.;
Lakdawala N.K.; Gottlieb R.L.; Goldberg R.I.; Elliott P.; Lee P.; Li H.;
Angeli F.S.; Judge D.P.; MacRae C.A.
Institution
(Garcia-Pavia) Hospital Universitario Puerta de Hierro Majadahonda,
CIBERCV, IDIPHISA, Uni-versidad Francisco de Vitoria, Centro Nacional de
Investigaciones Cardiovasculares, Madrid, Spain
(Rodriguez Palomares) Servicio de Cardiologia, Hospital Universitario Vall
Hebron, Institut de Recerca Hospital Vall Hebron, Universitat Autonoma de
Barcelona, Spain
(Rodriguez Palomares) Centro Nacional de Investigaciones Cardiovasculares,
Madrid, Spain
(Sinagra) Cardiothoracovascular Department, Azienda Sanitaria
Universitaria Giuliano-Isontina, University of Trieste, Italy
(Barriales-Villa) Complexo Hospitalario Universitario A Coruna, Spain
(Lakdawala, MacRae) Cardiovascular Medicine, Brigham and Women's Hospital,
Harvard Medical School, Boston, MA, United States
(Gottlieb) Baylor Scott & White Research Institute, Dallas, TX, United
States
(Gottlieb) Baylor University Medical Center, Dallas, TX, United States
(Goldberg) Baylor Scott & White Heart and Vascular Hospital, Dallas, TX,
United States
(Goldberg) NYU Langone Health, New York, United States
(Elliott) University College London, United Kingdom
(Lee) Pfizer Inc, Boulder, CO, United States
(Li, Angeli) Pfizer Inc, Collegeville, PA, United States
(Judge) Medical University of South Carolina, Cardiovascular Genetics,
Charleston, United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: LMNA (lamin A/C)-related dilated cardiomyopathy is a rare
genetic cause of heart failure. In a phase 2 trial and long-term
extension, the selective p38alpha MAPK (mitogen-activated protein kinase)
inhibitor, ARRY-371797 (PF-07265803), was associated with an improved
6-minute walk test at 12 weeks, which was preserved over 144 weeks.
 METHOD(S): REALM-DCM (NCT03439514) was a phase 3, randomized,
double-blind, placebo-controlled trial in patients with symptomatic
LMNA-related dilated cardiomyopathy. Patients with confirmed LMNA
variants, New York Heart Association class II/III symptoms, left
ventricular ejection fraction <=50%, implanted cardioverter-defibrillator,
and reduced 6-minute walk test distance were randomized to ARRY-371797 400
mg twice daily or placebo. The primary outcome was a change from baseline
at week 24 in the 6-minute walk test distance using stratified
Hodges-Lehmann estimation and the van Elteren test. Secondary outcomes
using similar methodology included change from baseline at week 24 in the
Kansas City Cardiomyopathy Questionnaire-physical limitation and total
symptom scores, and NT-proBNP (N-terminal pro-B-type natriuretic peptide)
concentration. Time to a composite outcome of worsening heart failure or
all-cause mortality and overall survival were evaluated using Kaplan-Meier
and Cox proportional hazards analyses. RESULT(S): REALM-DCM was
terminated after a planned interim analysis suggested futility. Between
April 2018 and October 2022, 77 patients (aged 23-72 years) received
ARRY-371797 (n=40) or placebo (n=37). No significant differences (P>0.05)
between groups were observed in the change from baseline at week 24 for
all outcomes: 6-minute walk test distance (median difference, 4.9 m [95%
CI, -24.2 to 34.1]; P=0.82); Kansas City Cardiomyopathy
Questionnaire-physical limitation score (2.4 [95% CI, -6.4 to 11.2];
P=0.54); Kansas City Cardiomyopathy Questionnaire-total symptom score (5.3
[95% CI, -4.3 to 14.9]; P=0.48); and NT-proBNP concentration (-339.4 pg/mL
[95% CI, -1131.6 to 452.7]; P=0.17). The composite outcome of worsening
heart failure or all-cause mortality (hazard ratio, 0.43 [95% CI,
0.11-1.74]; P=0.23) and overall survival (hazard ratio, 1.19 [95% CI,
0.23-6.02]; P=0.84) were similar between groups. No new safety findings
were observed. CONCLUSION(S): Findings from REALM-DCM demonstrated
futility without safety concerns. An unmet treatment need remains among
patients with LMNA-related dilated cardiomyopathy. Copyright ©
2024 The Authors. Circulation: Heart Failure is published on behalf of the
American Heart Association, Inc., by Wolters Kluwer Health, Inc. T.

<18>
Accession Number
2032822973
Title
Surgery compared to fibrinolytic therapy for symptomatic left-sided
prosthetic heart valve thrombosis (SAFE-PVT): Rationale and design of a
randomized controlled trial.
Source
Indian Heart Journal. 76(3) (pp 192-196), 2024. Date of Publication: 01
May 2024.
Author
Devasenapathy N.; Devagourou V.; Hote M.P.; Rajashekar P.; Kidambi B.;
Singal A.; Mantoo M.R.; Soni M.; Purohit G.; Singh S.; Karthikeyan G.
Institution
(Devasenapathy, Soni) The George Institute of Global Health, New Delhi,
India
(Devagourou, Hote, Rajashekar, Kidambi, Singal, Mantoo, Purohit, Singh,
Karthikeyan) Cardiothoracic Sciences Centre, All India Institute of
Medical Sciences, New Delhi, India
(Karthikeyan) Translational Health Science and Technology Institute,
Haryana, Faridabad, India
Publisher
Elsevier B.V.
Abstract
Background: Left-sided mechanical prosthetic heart valve thrombosis (PVT)
occurs because of suboptimal anticoagulation and is common in low-resource
settings. Urgent surgery and fibrinolytic therapy (FT) are the two
treatment options available for this condition. Urgent surgery is a
high-risk procedure but results in successful restoration of valve
function more often and is the treatment of choice in developed countries.
In low-resource countries, FT is used as the default treatment strategy,
though it is associated with lower success rates and a higher rate of
bleeding and embolic complications. There are no randomized trials
comparing the two modalities. Method(s): We performed a single center
randomized controlled trial comparing urgent surgery (valve replacement or
thrombectomy) with FT (low-dose, slow infusion tissue plasminogen
activator, tPA) in patients with symptomatic left-sided PVT. The primary
outcome was the occurrence of a complete clinical response, defined as
discharge from hospital with completely restored valve function, in the
absence of stroke, major bleeding or non-CNS systemic embolism. Outcome
assessment was done by investigators blinded to treatment allocation. The
principal safety outcome was the occurrence of a composite of in-hospital
death, non-fatal stroke, non-fatal major bleed or non-CNS systemic
embolism. Outcomes will be assessed both in the intention-to-treat, and in
the as-treated population. We will also report outcomes at one year of
follow-up. The trial has completed recruitment. Conclusion(s): This
is the first randomized trial to compare urgent surgery with FT for the
treatment of left-sided PVT. The results will provide evidence to help
clinicians make treatment choices for these patients. (Clinical trial
registration: CTRI/2017/10/010159). Copyright © 2024
Cardiological Society of India

<19>
Accession Number
2030245248
Title
Effects of perioperative magnesium on postoperative analgesia following
thoracic surgery: a meta-analysis of randomised controlled trials.
Source
Magnesium Research. 36(4) (pp 54-68), 2023. Date of Publication: December
2023.
Author
Hung K.-C.; Yang S.-H.; Liao S.-W.; Yu C.-H.; Liu M.-Y.; Chen J.-Y.
Institution
(Hung, Chen) School of Medicine, National Sun Yat-Sen University, No. 70
Lienhai Road, Kaohsiung 80424, Taiwan (Republic of China)
(Hung, Liao, Yu, Chen) Department of Anesthesiology, Chi Mei Medical
Center, Tainan 71004, Taiwan (Republic of China)
(Yang) Department of Neurology, Chi Mei Medical Center, Tainan 71004,
Taiwan (Republic of China)
(Liao) Chia Nan University of Pharmacy and Science, Tainan 71710, Taiwan
(Republic of China)
(Liao) The center for General Education, Southern Taiwan University of
Science and Technology, Tainan 71004, Taiwan (Republic of China)
(Liu) Department of Nutrition, Chi Mei Medical Center, Tainan 71004,
Taiwan (Republic of China)
(Liu) Department of Food Nutrition, Chung Hwa University of Medical
Technology, Tainan 71703, Taiwan (Republic of China)
Publisher
John Libbey
Abstract
Objectives: To evaluate the analgesic effects of intravenous magnesium in
patients undergoing thoracic surgery. Method(s): Randomised clinical
trials (RCTs) were systematically identified from MEDLINE, EMBASE, Google
Scholar and the Cochrane Library from inception to May 1st,
2023. The primary outcome was the effect of intravenous magnesium on the
severity of postoperative pain at 24 hours following surgery, while the
secondary outcomes included association between intravenous magnesium and
pain severity at other time points, morphine consumption, and haemodynamic
changes. Result(s): Meta-analysis of seven RCTs published between
2007 and 2019, involving 549 adults, showed no correlation between
magnesium and pain scores at 1-4 (standardized mean difference
[SMD]=-0.06; p=0.58), 8-12 (SMD=-0.09; p=0.58), 24 (SMD=-0.16; p=0.42),
and 48 (SMD=-0.27; p=0.09) hours post-surgery. Perioperative magnesium
resulted in lower equivalent morphine consumption at 24 hours post-surgery
(mean difference [MD]=-25.22 mg; p=0.04) and no effect at 48 hours
(MD=-4.46 mg; p=0.19). Magnesium decreased heart rate (MD =-5.31
beats/min; p=0.0002) after tracheal intubation or after surgery, but had
no effect on postoperative blood pressure (MD=-6.25 mmHg; p=0.11). There
was a significantly higher concentration of magnesium in the magnesium
group compared with that in the placebo group (MD = 0.91 mg/dL;
p<0.00001). Conclusion(s): This meta-analysis provides evidence
supporting perioperative magnesium as an analgesic adjuvant at 24 hours
following thoracic surgery, but no opioid-sparing effect at 48 hours
post-surgery. The severity of postoperative pain did not significantly
differ between any of the postoperative time points, irrespective of
magnesium. Further research on perioperative magnesium in various surgical
settings is needed. Copyright © 2023, John Libbey. All rights
reserved.

<20>
Accession Number
644844412
Title
Assessment of LGBTQ+ Diversity, Equity, and Inclusion in Subspecialty
Surgery Literature: A Scoping Review.
Source
World neurosurgery. (no pagination), 2024. Date of Publication: 24 Jul
2024.
Author
Foresi B.; Galbraith L.; Uzoukwu C.; Ezeudu C.; Najafali D.; Pannullo S.
Institution
(Foresi, Galbraith, Uzoukwu) Northeast Ohio Medical University, College of
Medicine, OH, United States
(Ezeudu) Texas A&M, College of Medicine, College Station, TX, United
States
(Najafali) Carle Illinois College of Medicine, University of Illinois
Urbana-Champaign, Urbana, IL, United States
(Pannullo) New York Presbyterian/Weill Cornell, New York, NY, USA
Abstract
OBJECTIVE: To identify LGBTQ+ DEI publications and contextualize the
current frequency of the literature across subspecialty surgical fields.
 METHOD(S): A PRISMA systematic review using PubMed, MEDLINE, and Web
of Science was conducted in April 2024. Inclusion criteria required
intra-field DEI content of defined subspecialties while foreign language
literature, poor methodology, and duplicates were excluded. The primary
endpoint was the number of publications across subspecialties. Secondary
endpoints included publication dates, study design, and sample size.
 RESULT(S): Of the 702 articles identified, 27 were included.
Neurological surgery had 2 studies while plastic surgery, orthopedic
surgery, otolaryngology, and thoracic surgery had 11, 7, 5, and 2
respectively. There was a statistically significant different frequency of
publications across subspecialties (p = 0.031). Post-hoc residual analysis
indicated neurosurgery and thoracic surgery had statistically fewer
publications, while plastic surgery had statistically more (p = 0.04,
0.002, 0.21, 0.42, 0.04 for neurological Surgery, plastic surgery,
orthopedic surgery, otolaryngology, and thoracic surgery, respectively).
Secondary outcomes found a majority of publication dates between 2022 to
2024. Study methodologies involved cross-sectional studies, editorials,
and retrospective reviews (14, 11, and 3 respectively) and contained a
median sample size of 248.5. CONCLUSION(S): This systematic review
provides objective data to contextualize DEI literature across surgical
subspecialties. Overall, this review highlights the lack of LGBTQ+ DEI
literature within neurosurgery and advocates for correcting this gap for
the benefit of both surgeons and patients. Understanding the current
numbers and evaluating progress in other surgical fields might provide
solutions. Copyright © 2024 Elsevier Inc. All rights reserved.

<21>
Accession Number
644844254
Title
Prognostic value of right ventricular involvement in hypertrophic
cardiomyopathy: A systematic review and meta-analysis.
Source
International journal of cardiology. (pp 132390), 2024. Date of
Publication: 24 Jul 2024.
Author
Figliozzi S.; Masci P.-G.; Monti L.; Stankowski K.; Tondi L.; Aivalioti
E.; Mavraganis G.; Francone M.; Condorelli G.; Olivotto I.; Georgiopoulos
G.
Institution
(Figliozzi) IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56,
Rozzano, 20089 Milan, Italy
(Masci) School of Biomedical Engineering and Imaging Sciences-Faculty of
Life Sciences and Medicine, King's College London, Westminster Bridge Rd,
London SE1 7EH, United Kingdom
(Monti, Stankowski, Francone, Condorelli) IRCCS Humanitas Research
Hospital, Via Alessandro Manzoni 56, Rozzano, 20089 Milan, Italy;
Department of Biomedical Sciences, Humanitas University, Via Rita Levi
Montalcini 4, 20090 Pieve Emanuele, Milan, Italy
(Tondi) Multimodality Cardiac Imaging Section, IRCCS Policlinico San
Donato, San Donato Milanese, Milan, Italy; Department of Radiology, IRCCS
Foundation Ca' Granda Ospedale Maggiore Policlinico, University of Milan,
Milan, Italy
(Aivalioti, Mavraganis, Georgiopoulos) Department of Clinical
Therapeutics, National and Kapodistrian University of Athens, Greece
(Olivotto) Cardiomyopathy Unit, Careggi University Hospital, Largo
Brambilla 3, Florence 50134, Italy
Abstract
BACKGROUND: Right ventricular (RV) involvement has been reported in one
out of three patients with hypertrophic cardiomyopathy (HCM), however its
prognostic significance remains unknown. We aimed to assess the prognostic
value of RV involvement in patients with HCM through a systematic review
and meta-analysis. METHOD(S): A literature search was performed on
PubMed, ClinicalTrials.gov and Cochrane Library databases from inception
through November 15, 2023. Original articles enrolling HCM patients
>18years and evaluating the association of RV parameters routinely
assessed in clinical practice through trans-thoracic echocardiography or
cardiac magnetic resonance (i.e., RV hypertrophy, volumes, systolic
function, and late-gadolinium-enhancement) and the risk of a pre-defined
composite endpoint including i) all-cause-death; ii) cardiac-death; iii)
heart-transplantation; iv) heart-failure-related-hospitalization; v)
atrial-fibrillation; vi) ventricular-tachycardia; vii) stroke were
retrieved. We pooled the effect of RV imaging variables on the combined
clinical endpoint in terms of hazard ratio (HR) with 95% confidence
interval (CI). RESULT(S): The meta-analysis included 12 articles and
4634 patients. The pooled analysis demonstrated that the presence of RV
systolic dysfunction conveyed an increased risk of adverse outcomes (HR
2.46; 95% CI 1.80-3.35; P<0.001), whereas other RV imaging parameters were
not significantly associated with patients' prognosis, except for
RV-fractional area change analyzed as a continuous variable (HR 0.96 per %
increase; 95% CI 0.93-0.995; P=0.025). CONCLUSION(S): Our results
pinpoint a prognostic role of RV dysfunction, independent of LV
involvement, in patients with HCM, and future longitudinal studies,
including multi-parametric RV assessment, are encouraged to provide
clinically relevant data to refine risk stratification in patients with
HCM. Copyright © 2024. Published by Elsevier B.V.

<22>
Accession Number
644843705
Title
Clinical practices for defining, detecting, and diagnosing postoperative
atrial fibrillation after coronary revascularization surgery - A scoping
review.
Source
Australian critical care : official journal of the Confederation of
Australian Critical Care Nurses. (no pagination), 2024. Date of
Publication: 25 Jul 2024.
Author
Higgs M.; McDonagh J.; Sim J.
Institution
(Higgs) Southeastern Sydney Local Health District, NSW, Australia
(McDonagh) The Centre for Chronic and Complex Care Research, Blacktown
Hospital, Western Sydney Local Health District, New South Wales,
Australia; School of Nursing, Faculty of Science, Medicine and Health, The
University of Wollongong, New South Wales, Australia
(Sim) School of Nursing, Faculty of Science, Medicine and Health, The
University of Wollongong, New South Wales, Australia; School of Nursing,
Midwifery & Paramedicine, Australian Catholic University, New South Wales,
Australia
Abstract
OBJECTIVES: This scoping review was undertaken to understand the degree of
variation in clinical practices associated with postoperative atrial
fibrillation (POAF), following coronary revascularization surgery by
collating and synthesising key concepts from current published literature.
REVIEW METHODS AND DATA SOURCES: This scoping review was conducted
following the framework outlined by Askey and O'Malley. Reporting of this
scoping review follows the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses extension for Scoping Reviews checklist. Initial
searches were completed in September 2020 and updated in January 2023.
Comprehensive searches to identify relevant published literature were
carried out within CINAHL, MEDLINE, and ProQuest databases. All searches
were limited to full-text papers published in English with human adult
participants. Deductive content analysis using NVivo software was
performed to synthesise the data. RESULT(S): A total of 692 studies
were identified during the database searches. After the deletion of
duplicates and the application of the inclusion and exclusion criteria, 73
studies were included in the scoping review. The included studies were
published between 2001 and 2022 and included a total of 24,833
participants. Forty-six studies included a definition of POAF, with four
of these citing a peak-body definition. A total of 24 included studies
reported on electrocardiogram diagnostic criteria for POAF, with 13/24
[54%] describing these characteristics within their definition. The
time-based diagnostic criteria ranged from a minimum duration of greater
than 30 seconds to greater than 1 hour. The most frequently reported
minimum-time thresholds were >=30 seconds, reported in 12 of 51 (24%)
studies and >=5 min, reported in 13 of 51 (25%) studies.
 CONCLUSION(S): There is a lack of consistency in clinical practice
for defining, detecting, and diagnosing POAF, following coronary
revascularization surgery. Consensus and standardisation of clinical
practices are urgently needed. Copyright © 2024 Australian
College of Critical Care Nurses Ltd. Published by Elsevier Ltd. All rights
reserved.

<23>
Accession Number
2033458485
Title
A wide scope, pan-comparative, systematic meta-analysis of the efficacy of
prophylactic strategies for cardiac surgery-associated acute kidney
injury.
Source
Biomedicine and Pharmacotherapy. 178 (no pagination), 2024. Article
Number: 117152. Date of Publication: September 2024.
Author
Martin-Fernandez M.; Casanova A.G.; Jorge-Monjas P.; Morales A.I.; Tamayo
E.; Lopez Hernandez F.J.
Institution
(Martin-Fernandez) Department of Cell Biology, Genetics, Histology and
Pharmacology, Faculty of Medicine, Universidad de Valladolid, Valladolid
47005, Spain
(Martin-Fernandez, Jorge-Monjas, Tamayo) Centro de Investigacion Biomedica
en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos
III, Madrid, Spain
(Martin-Fernandez, Jorge-Monjas, Morales, Tamayo, Lopez Hernandez) Group
of Biomedical Research on Critical Care (BioCritic), Valladolid, Spain
(Casanova, Morales, Lopez Hernandez) Instituto de Investigacion Biomedica
de Salamanca (IBSAL) de la Fundacion Instituto de Ciencias de la Salud de
Castilla y Leon (ICSCYL), Salamanca, Spain
(Casanova, Morales, Lopez Hernandez) National Network for Kidney Research
REDINREN, RD016/0009/0025, Instituto de Salud Carlos III, Madrid, Spain
(Casanova, Morales, Lopez Hernandez) Department of Physiology and
Pharmacology, Universidad de Salamanca (USAL), Salamanca, Spain
(Casanova, Morales, Lopez Hernandez) Group of Translational Research on
Renal and Cardiovascular Diseases (TRECARD), Salamanca, Spain
(Jorge-Monjas, Tamayo) Department of Anesthesiology and Critical Care,
Clinical University Hospital of Valladolid, Valladolid, Spain
(Jorge-Monjas, Tamayo) Department of Surgery, Faculty of Medicine,
Universidad de Valladolid, Valladolid 47005, Spain
Publisher
Elsevier Masson s.r.l.
Abstract
Acute kidney injury (AKI) is the most common complication of cardiac
surgery. Cardiac surgery-associated AKI (CSA-AKI) is caused by systemic
and renal hemodynamic impairment and parenchymal injury. Prophylaxis of
CSA-AKI remains an unmet priority, for which preventive strategies based
on drug therapies, hydration procedures, and remote ischemic
preconditioning (RIPC) have been tested in pre-clinical and clinical
studies, with variable success. Contradicting reports and scarce or
insufficiently pondered information have blurred conclusions. Therefore,
with an aim to contribute to consolidating the available information, we
carried out a wide scope, pan-comparative meta-analysis including the
accessible information about the most relevant nephroprotective approaches
assayed. After a thorough examination of 1892 documents retrieved from
PubMed and Web of Science, 150 studies were used for the meta-analysis.
Individual odds ratios of efficacy at reducing AKI incidence, need for
dialysis, and plasma creatinine elevation were obtained for each alleged
protectant. Also, the combined class effect of drug families and
protective strategies was also meta-analyzed. Our results show that no
drug family or procedure affords substantial protection against CSA-AKI.
Only, a mild but significant reduction in the incidence of CSA-AKI by
preemptive treatment with dopaminergic and adrenergic drugs, vasodilators,
and the RIPC technique. The integrated analysis suggests that single-drug
approaches are unlikely to cope with the variety of individual
pathophysiological scenarios potentially underlying CSA-AKI. Accordingly,
a theragnostic approach involving the etiopathological diagnosis of kidney
frailty is necessary to guide research towards the development of
pharmacological combinations concomitantly and effectively addressing the
key mechanisms of CSA-AKI. Copyright © 2024 The Authors

<24>
Accession Number
2030686477
Title
Effect of liver abnormalities on mortality in Fontan patients: a
systematic review and meta-analysis.
Source
BMC Cardiovascular Disorders. 24(1) (no pagination), 2024. Article Number:
385. Date of Publication: December 2024.
Author
Liu X.; Han L.; Zhou Z.; Tu J.; Ma J.; Chen J.
Institution
(Liu, Han, Zhou, Tu, Ma, Chen) Department of Cardiac Surgery, Guangdong
Provincial People's Hospital (Guangdong Academy of Medical Sciences),
Guangdong Cardiovascular Institute, Southern Medical University, No. 106,
Zhongshan 2nd Road, Guangzhou 510080, China
(Liu, Han, Zhou, Tu, Ma, Chen) Guangdong Provincial Key Laboratory of
South China Structural Heart Disease, Guangzhou 510080, China
Publisher
BioMed Central Ltd
Abstract
Background: Fontan-associated liver disease (FALD) is one of the most
common complications following Fontan procedure, but the impact of FALD on
survival outcomes remains controversial. The aim of this systematic review
and meta-analysis was to examine and quantify the influence of liver
disease on the survival of Fontan patients. Method(s): The Preferred
Reporting Items for Systematic reviews and Meta-Analyses guidelines were
followed, and relevant human studies published from inception up to 12
August 2022 were searched. Stata (version 17.0) was applied to perform the
meta-analysis, using random effects (Mantel-Haenszel) models. The
I2 statistic was used to assess the heterogeneity. Subgroup
analysis and meta-regression were employed to explore the potential
sources of heterogeneity and sensitivity analysis was performed to
determine the potential influence of each study on the overall pooled
results. Result(s): A total of 312 records were initially identified
and 8 studies involving 2,466 patients were selected for inclusion.
Results revealed a significant association between the severity of liver
disease following Fontan procedure and mortality, which was confirmed by
sensitivity analysis and subgroup analysis assessing post-HT mortality.
Meta-regression showed that diagnostic methods for liver disease may be a
source of heterogeneity. After removal of the FALD patients identified by
international classification of disease codes, heterogeneity was markedly
reduced, and the positive association between all-cause mortality and the
severity of liver disease became significant. Conclusion(s): This
meta-analysis showed the severity of liver disease following the Fontan
procedure has a significant association with mortality. Lifelong follow-up
is necessary and imaging examinations are recommended for routine
surveillance of liver disease. Among patients with failing Fontan and
advanced liver disease, combined heart-liver transplantation may provide
additional survival benefits. Copyright © The Author(s) 2024.

<25>
Accession Number
2030680225
Title
Exploring heart rate variability in polycystic ovary syndrome:
implications for cardiovascular health: a systematic review and
meta-analysis.
Source
Systematic Reviews. 13(1) (no pagination), 2024. Article Number: 194. Date
of Publication: December 2024.
Author
Mirzohreh S.T.; Panahi P.; Heidari F.
Institution
(Mirzohreh, Panahi) Faculty of Medicine, Tabriz University of Medical
Sciences, Tabriz, Iran, Islamic Republic of
(Heidari) Department of Community and Family Medicine, Faculty of
Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, Islamic
Republic of
Publisher
BioMed Central Ltd
Abstract
Objectives: Polycystic ovary syndrome (PCOS) is a prevalent and complex
endocrine disorder that affects women of reproductive age. It has
significant implications for female endocrine function, reproductive
health, and metabolic disturbances, including insulin resistance, impaired
glucose tolerance, and dyslipidemia. Studies have shown that decreased
heart rate variability (HRV), a marker of autonomic dysfunction, is
associated with adverse cardiovascular events. Recent research has focused
on investigating autonomic function in PCOS, and some studies have
suggested altered autonomic drive in these patients. The aim of this
systematic review and meta-analysis was to evaluate cardiac autonomic
function by analyzing HRV in women with PCOS. Method(s): This
systematic review was prepared using PRISMA reporting guidelines. The
databases searched were PubMed, Scopus, Web of Science, and Cochrane. Risk
of Bias was assessed using ROBINS-I for non-RCTs. The GRADE approach was
employed to evaluate the level of certainty in the evidence for each
outcome. In order to identify the underlying cause of high heterogeneity,
a subgroup analysis was conducted. Sensitivity analysis was checked. A
random effect model was used and calculated a pooled standardized mean
difference (SMD) with a 95% confidence interval (CI). Result(s):
Seventeen articles were included in the final analysis, varied in quality,
ranging from a "low" to a "high risk of bias". Combined analyses indicated
a notable decrease in HRV among individuals with PCOS compared to the
control group. Significant changes were observed in SDNN (SMD: -0.763,
95%CI [-1.289 to -0.237], p=0.004), PNN50 (SMD: -1.245, 95%CI [-2.07,
-0.419], p=0.003), LF/HF ratio (SMD: 0.670, 95%CI [0.248, 1.091],
p=0.002), HFnu (SMD: -0.873, 95%CI [-1.257, -0.489], p=0.000), LFnu (SMD:
0.840, 95%CI [0.428, 1.251], p=0.000) and TP (SMD: -1.997, 95%CI [-3.306,
-0.687], p=0.003). The heterogeneity was partially explained by types of
study design. Subgroup analysis revealed significant alterations of HRV in
normal-weighted and overweight PCOS cases. Conversely, no significant
changes in HRV were observed in obese PCOS cases. Conclusion(s): The
findings of this meta-analysis provide evidence suggesting diminished HRV
in individuals with PCOS compared to non-PCOS control group. Copyright
© The Author(s) 2024.

<26>
Accession Number
2033503373
Title
Comparative Outcomes of Surgical and Transcatheter Aortic Valve
Replacement: A Meta-analysis and Parametric Extrapolation of Clinical
Trials.
Source
Journal of Surgical Research. 302 (pp 1-11), 2024. Date of Publication:
October 2024.
Author
Ahmad D.; Dawes A.; Im M.; Vishnevsky A.; Ruggiero N.J.; Plestis K.A.;
Massey H.T.; Morris R.J.; Entwistle J.W.; Tchantchaleishvili V.
Institution
(Ahmad, Dawes, Im, Plestis, Massey, Morris, Entwistle, Tchantchaleishvili)
Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson
University, Philadelphia, Pennsylvania, United States
(Ahmad) Department of Cardiothoracic Surgery, University of Pittsburgh,
Pittsburgh, PA, United States
(Vishnevsky, Ruggiero) Division of Cardiology, Department of Medicine,
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Publisher
Academic Press Inc.
Abstract
Introduction: We aimed to pool randomized clinical trials (RCTs) comparing
surgical aortic valve replacement (SAVR) with transcatheter aortic valve
replacement (TAVR) and extrapolate pooled time-to-event data to compare
long-term outcomes. Method(s): An electronic database search was
performed for RCTs comparing SAVR with TAVR. The most current longest
follow-up data for each RCT were included. Data were pooled using a
random-effects model. Survival data were pooled for Kaplan-Meier analysis
as well as parametric modeling with extrapolation. Result(s): Seven
RCTs comprising 7774 patients were included. Mean valve gradient at 5 y
was comparable between SAVR [11 mmHg (3.7; 18.3)] and TAVR [8.1 mmHg (1.9;
14.3)] (P = 0.38). TAVR had a higher mean valve area at 30 d, 1 y, and 2 y
[1.68 cm2 (1.22; 2.13) versus 1.8 cm2 (1.35; 2.25),
P = 0.02]. SAVR had a higher freedom from any paravalvular leak at 30 d
and 1 y [86% (81; 90) versus 39% (36; 41), P < 0.01]. All-cause death was
lower in the SAVR group at 5 y [39% (29; 50) versus 43% (31; 57), P <
0.01]. Although no differences were seen between SAVR and TAVR in the
pooled Kaplan-Meier analysis of all-cause mortality and composite of
all-cause mortality or stroke, parametric modeling with extrapolation
showed significant divergence for both outcomes. Conclusion(s):
Pooled all-cause mortality as well as pooled composite of all-cause
mortality or stroke indicated better survival with SAVR at 5 y. Long-term
parametric extrapolation also indicated superior survival with
SAVR. Copyright © 2024 Elsevier Inc.

<27>
Accession Number
2033433499
Title
Representation of Older Adults in the ACC/AHA/SCAI Guideline for Coronary
Artery Revascularization.
Source
JAMA Network Open. 7(7) (no pagination), 2024. Date of Publication: 12 Jul
2024.
Author
Jamil Y.; Sibindi C.; Park D.Y.; Frampton J.; Damluji A.A.; Nanna M.G.
Institution
(Jamil, Sibindi) Department of Medicine, Yale School of Medicine, New
Haven, CT, United States
(Park) Department of Medicine, Cook County Health, Chicago, IL, United
States
(Frampton, Nanna) Section of Cardiovascular Medicine, Yale School of
Medicine, New Haven, CT, United States
(Damluji) Johns Hopkins University, School of Medicine, Baltimore, MD,
United States
(Damluji) Inova Center of Outcomes Research, Falls Church, VA, United
States
Publisher
American Medical Association

<28>
[Use Link to view the full text]
Accession Number
2033173507
Title
Culprit-Only Revascularization, Single-Setting Complete Revascularization,
and Staged Complete Revascularization in Acute Myocardial Infarction:
Insights from a Mixed Treatment Comparison Meta-Analysis of Randomized
Trials.
Source
Circulation: Cardiovascular Interventions. 17(7) (pp e013737), 2024. Date
of Publication: 01 Jul 2024.
Author
Maqsood M.H.; Tamis-Holland J.E.; Rao S.V.; Stone G.W.; Bangalore S.
Institution
(Maqsood) Department of Cardiology, DeBakey Heart and Vascular Center, The
Methodist Hospital, Houston, TX, United States
(Tamis-Holland) Cleveland Clinic, Heart, Vascular and Thoracic Institute,
OH, United States
(Rao, Bangalore) Division of Cardiovascular Medicine, New York University,
Grossman School of Medicine, United States
(Stone) The Zena and Michael A. Wiener Cardiovascular Institute, Icahn
School of Medicine at Mount Sinai, New York, NY, United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: Complete revascularization improves cardiovascular outcomes
compared with culprit-only revascularization in patients with acute
myocardial infarction ([MI]; ST-segment-elevation MI or
non-ST-segment-elevation MI) and multivessel coronary artery disease.
However, the timing of complete revascularization (single-setting versus
staged revascularization) is uncertain. The aim was to compare the
outcomes of single-setting complete, staged complete, and culprit
vessel-only revascularization in patients with acute MI and multivessel
disease. METHOD(S): PubMed, EMBASE, and clinicaltrials.gov databases
were searched for randomized controlled trials that compared 3
revascularization strategies. RESULT(S): From 16 randomized
controlled trials that randomized 11 876 patients with acute MI and
multivessel disease, both single-setting complete and staged complete
revascularization reduced primary outcome (cardiovascular mortality/MI;
odds ratio [OR], 0.52 [95% CI, 0.41-0.65]; OR, 0.74 [95% CI, 0.62-0.88]),
composite of all-cause mortality/MI (OR, 0.52 [95% CI, 0.40-0.67]; OR,
0.78 [95% CI, 0.67-0.91]), major adverse cardiovascular event (OR, 0.42
[95% CI, 0.32-0.56]; OR, 0.62 [95% CI, 0.47-0.82]), MI (OR, 0.39 [95% CI,
0.26-0.57]; OR, 0.73 [95% CI, 0.59-0.90]), and repeat revascularization
(OR, 0.30 [95% CI, 0.18-0.47]; OR, 0.46 [95% CI, 0.30-0.71]) compared with
culprit-only revascularization. Single-setting complete revascularization
reduced cardiovascular mortality/MI (OR, 0.70 [95% CI, 0.55-0.91]), major
adverse cardiovascular event (OR, 0.67 [95% CI, 0.50-0.91]), and all-cause
mortality/MI driven by a lower risk of MI (OR, 0.53 [95% CI, 0.36-0.77])
compared with staged complete revascularization. Single-setting complete
revascularization ranked number 1, followed by staged complete
revascularization (number 2) and culprit-only revascularization (number 3)
for all outcomes. The results were largely consistent in subgroup analysis
comparing ST-segment-elevation MI versus non-ST-segment-elevation MI
cohorts. CONCLUSION(S): Single-setting complete revascularization may
offer the greatest reductions in cardiovascular events in patients with
acute MI and multivessel disease. A large-scale randomized trial of
single-setting complete versus staged complete revascularization is
warranted to evaluate the optimal timing of complete
revascularization. Copyright © 2024 American Heart Association,
Inc.

<29>
Accession Number
2033510078
Title
Effectiveness of Hand and Foot Massage Therapy on Post-Operative Pain and
Anxiety among Patients Undergoing Cardiothoracic Surgery.
Source
European Journal of Cardiovascular Medicine. 13(4) (pp 185-190), 2023.
Date of Publication: 2023.
Author
Santh S.R.S.; Raman A.P.; Radhika C.K.
Institution
(Santh) Government College of Nursing, Kerala, Thiruvananthapuram, India
(Raman) Department of Cardiothoracic Surgery, Government Medical College,
Kerala, Thiruvananthapuram, India
(Radhika) Department of Medical Surgical Nursing, Government College of
Nursing, Kerala, Thiruvananthapuram, India
Publisher
Healthcare Bulletin
Abstract
Background: This study was conducted to evaluate the effectiveness of hand
and foot massage therapy on post-operative pain among patients undergoing
cardiothoracic surgery and evaluate the effectiveness of hand and foot
massage therapy on anxiety among patients undergoing cardiothoracic
surgery. Method(s): This was a hospital-based study conducted among
60 patients who underwent cardiothoracic surgery in the cardiothoracic ICU
of Medical College Hospital, Thiruvananthapuram, after obtaining clearance
from the institutional ethics committee and written informed consent from
the study participants. Result(s): It is evident that the mean age of
participants in the experimental group was 50.43 and the standard
deviation was 11.61 and the mean age of the control group was 54.53 and
the standard deviation was 8.25. Hence, the difference was not
statistically significant because both groups were not comparable with
respect to age. 80% of participants in the experimental group and 60% in
the control group were males whereas 40% of participants in the
experimental group and 20% in the control group were females. Hence, the
difference was not statistically significant, both groups were comparable
with respect to gender. In the distribution of participants based on type
of analgesic, effectiveness of hand and foot massage therapy on
postoperative pain among patients undergoing cardiothoracic surgery, the
effectiveness of hand and foot massage therapy on postoperative anxiety
among patients undergoing cardiothoracic surgery were found to be
statistically significant. Conclusion(s): Hand and foot massage
therapy has been found to be effective in reducing postoperative anxiety
among cardiothoracic surgery patients. Copyright © 2023
Healthcare Bulletin. All rights reserved.

<30>
Accession Number
2030685289
Title
Beyond the debut: unpacking six years of Hypotension Prediction Index
software in intraoperative hypotension prevention - a systematic review
and meta-analysis.
Source
Journal of Clinical Monitoring and Computing. (no pagination), 2024. Date
of Publication: 2024.
Author
Pilakouta Depaskouale M.A.; Archonta S.A.; Katsaros D.M.; Paidakakos N.A.;
Dimakopoulou A.N.; Matsota P.K.
Institution
(Pilakouta Depaskouale, Matsota) 2nd Department of Anesthesiology, School
of Medicine, National and Kapodistrian University of Athens, "Attikon"
Hospital, 1 Rimini Street, Athens 12462, Greece
(Pilakouta Depaskouale, Archonta, Katsaros, Dimakopoulou) Department of
Anesthesiology, Athens General Hospital "Georgios Gennimatas", 154
Mesogion Avenue, Athens 11527, Greece
(Paidakakos) Department of Neurosurgery, Athens General Hospital "Georgios
Gennimatas", 154 Mesogion Avenue, Athens 11527, Greece
Publisher
Springer Science and Business Media B.V.
Abstract
Purpose: Intraoperative hypotension (IOH) during general anesthesia is
associated with higher morbidity and mortality, although randomized trials
have not established a causal relation. Historically, our approach to IOH
has been reactive. The Hypotension Prediction Index (HPI) is a machine
learning software that predicts hypotension minutes in advance. This
systematic review and meta-analysis explores whether using HPI alongside a
personalized treatment protocol decreases intraoperative hypotension.
 Method(s): A systematic search was performed in Pubmed and Scopus to
retrieve articles published from January 2018 to February 2024 regarding
the impact of the HPI software on reducing IOH in adult patients
undergoing non-cardio/thoracic surgery. Excluded were case series, case
reports, meta-analyses, systematic reviews, and studies using non-invasive
arterial waveform analysis. The risk of bias was assessed by the Cochrane
risk-of-bias tool (RoB 2) and the Risk Of Bias In Non-randomised Studies
(ROBINS-I). A meta-analysis was undertaken solely for outcomes where
sufficient data were available from the included studies. Result(s):
9 RCTs and 5 cohort studies were retrieved. The overall median differences
between the HPI-guided and the control groups were - 0.21 (95% CI:-0.33,
-0.09) - p < 0.001 for the Time-Weighted Average (TWA) of Mean Arterial
Pressure (MAP) < 65mmHg, -3.71 (95% CI= -6.67, -0.74)-p = 0.014 for the
incidence of hypotensive episodes per patient, and - 10.11 (95% CI=
-15.82, -4.40)-p = 0.001 for the duration of hypotension. Notably a large
amount of heterogeneity was detected among the studies.
 Conclusion(s): While the combination of HPI software with
personalized treatment protocols may prevent intraoperative hypotension
(IOH), the large heterogeneity among the studies and the lack of reliable
data on its clinical significance necessitate further
investigation. Copyright © The Author(s), under exclusive licence
to Springer Nature B.V. 2024.

<31>
Accession Number
2033534772
Title
Cardiologist-Led Sedation for TAVI: A Single Centre Australian Experience.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S580), 2024. Date
of Publication: August 2024.
Author
Norman S.; Brooks M.; Wilson W.; Koshy A.; Gurvitch R.
Institution
(Norman, Brooks, Wilson, Koshy, Gurvitch) Royal Melbourne Hospital, North
Melbourne, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Aims: Transcatheter aortic valve implantation (TAVI) has evolved towards a
'minimalist' approach, including a transition from general anaesthesia to
procedural sedation, with resultant improved outcomes [1]. More recently
cardiologist-led procedural sedation (CLS), rather than anaesthetist-led
procedural sedation (ALS) has gained traction with encouraging results in
small trials [2-3]. There are no Australian data reporting outcomes
following CLS for TAVI; we compared outcomes following ALS-TAVI and
CLS-TAVI from a high-volume Australian centre. Method(s): All
patients who received a TAVI at Royal Melbourne Hospital between July 2021
and December 2023 were retrospectively reviewed. Outcomes assessed
included baseline demographics, procedural outcomes, and readmission and
all-cause mortality at 30 days. Result(s): 195 patients received a
TAVI; 28 patients underwent CLS, 167 ALS. Demographics (age, gender),
comorbidities (prior PCI, prior CABG, T2DM, CKD) and surgical risk (STS
score), were similar in both groups. Procedural success was 100% in both
groups and procedure time was similar (50.4 vs 54.7 minutes; p=0.14). No
patients in the CLS cohort had to convert to ALS. Mean hospital LOS post
TAVI was 2.3 days in the CLS group compared to 3.1 days (p=0.08; 32.1% of
CLS patients were discharged day 1 post TAVI vs 19.2% for ALS; p=0.11).
Complications were uncommon and were not significantly different between
groups. There were no deaths or readmissions at 30 days following
CLS-TAVI. Discussion(s): Cardiologist-led sedation for TAVI appears
to be non-inferior to anaesthetist-led sedation in this retrospective,
single centre review. CLS in appropriately selected patients may have
advantages in patient flow and prompt access to procedures. References:
[1] Wang L, Liu Y, Gao H, Zhang B, Zhou S, Xie M, Sun X. Comparison of
Safety and Effectiveness of Local or General Anesthesia after
Transcatheter Aortic Valve Implantation: A Systematic Review and
Meta-Analysis. J Clin Med. 2023 Jan 7;12(2):508. [2] Kocka V, Novackova M,
Kratochvilova L, Sirakova A, Sulzenko J, et al. Nurse-led sedation for
transfemoral transcatheter aortic valve implantation seems safe for a
selected patient population. Eur Heart J Suppl. 2022 Mar 30;24(Suppl
B):B23-B27. [3] Denimal T, Delhaye C, Pierache A, Robin E, Modine T, et
al. Feasibility and safety of transfemoral transcatheter aortic valve
implantation performed with a percutaneous coronary intervention-like
approach. Arch Cardiovasc Dis. 2021
Aug-Sep;114(8-9):537-549. Copyright © 2024

<32>
Accession Number
2033532946
Title
Same Day Discharge of Suitable Patients After Transcatheter Aortic Valve
Implantation: A Systematic Review and Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S591), 2024. Date
of Publication: August 2024.
Author
Litkouhi P.; Rao K.; Baer A.; Hansen P.; Bhindi R.
Institution
(Litkouhi, Rao, Baer, Hansen, Bhindi) Royal North Shore Hospital, Sydney,
NSW, Australia
Publisher
Elsevier Ltd
Abstract
Background: Next day discharge (NDD) after transcatheter aortic valve
implantation (TAVI) has been shown to be safe. NDD after TAVI is now
implemented in clinical practice. With growing demand for TAVI, there is
need to improve its accessibility. Several studies have investigated the
safety and feasibility of same day discharge (SDD) after TAVI in suitable,
low-risk patients. Method(s): We conducted the first systematic
review and meta-analysis of studies assessing SDD after minimalist,
transfemoral TAVI. Result(s): A total of 1,734 articles were screened
from five databases. Six studies were identified for meta-analysis. Of
3,532 patients, 318 (9.0%) underwent SDD (mean age of 78.07+/-7.9 and
71.8% male). The distribution of valves was 91.5% balloon-expanding and
8.5% self-expanding. Meta-analysis demonstrated no difference in all-cause
mortality (0.3% vs 0.5%, p=0.78), all-cause hospital readmission (5.3% vs
8.3%, p=0.16) and cardiovascular readmission (2.8% vs 5.9%, p=0.14)
between patients in SDD and standard discharge cohorts. Additionally,
there was no difference in rates of stroke (0.7% vs 0.3%, p=0.23), major
vascular complications (0.0% vs 0.0%) or new permanent pacemaker (1.0% vs
1.1%, p=0.14). Conclusion(s): Initial studies demonstrate that SDD
after TAVI can be implemented safely, with comparable outcomes to standard
discharge protocols. These findings have important implications for
clinical practice given the growing demand for TAVI and need to streamline
accessibility. More studies are warranted to validate SDD in other cohorts
and build confidence in the discharge pathway. Additionally, more studies
investigating self-expanding valves are needed. Copyright © 2024

<33>
Accession Number
2033531775
Title
A Novel Mechanical Perfusion Transportation Device (Organ Angel) in a Pig
Heart Model.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S231), 2024. Date
of Publication: August 2024.
Author
Besanko J.; Beltrame J.; Edwards J.; Worthington M.; Coates T.; Ou R.
Institution
(Besanko, Beltrame, Edwards, Worthington, Coates, Ou) Royal Adelaide
Hospital, Adelaide, SA, Australia
Publisher
Elsevier Ltd
Abstract
Evidence from randomised human and experimental trials indicate that the
results of heart transplantation improve with the use of perfusion of
donor hearts. In these studies, we evaluated the efficacy of a novel
mechanical perfusion device in preserving procaine hearts for 6 hours ex
vivo. The device utilises hypothermic perfusion with celsior solution at a
low flow rate of 40 mL/min. This device is small, portable, weight 16 kgs,
operates on batteries, fits in a standard economy domestic airline seat
and facilitates the flow of oxygenated hypothermic fluid. Twelve porcine
hearts were explanted using standard techniques and randomised to either
be preserved via cold storage (n=6) or mechanical perfusion (n=6).
Following preservation, the hearts were reanimated on a bench bypass
circuit and assessed for two hours. Cardiac performance was assessed in
the working model after a stabilisation period in non-working status
(langendorff model). The mechanical perfusion device demonstrated superior
preservation compared to cold storage in terms of cardiac performance
(Cardiac output) on the bench bypass circuit electron microscopy, and
biochemical normality. These findings suggest that the mechanical
perfusion device provides an alternative to cold storage preservations and
has the potential to improve the preservation of hearts for
transplantation. Copyright © 2024

<34>
Accession Number
2033531533
Title
Aortic Valve and Sub-Valvular Calcium and Conduction Abnormalities
Following Transcatheter Aortic Valve Implantation: A Systematic Review and
Meta-analysis.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S579), 2024. Date
of Publication: August 2024.
Author
Litkouhi P.; Rao K.; Baer A.; Hansen P.; Bhindi R.
Institution
(Litkouhi, Rao, Baer, Hansen, Bhindi) Royal North Shore Hospital, Sydney,
NSW, Australia
Publisher
Elsevier Ltd
Abstract
Background: Permanent pacemaker implantation (PPMI) is an important
complication following transcatheter aortic valve implantation (TAVI).
Aortic valve and sub-valvular calcium are hypothesised to influence the
development of new high grade atrioventricular block and requirement for
PPMI after TAVI. A large number of studies have been performed but present
mixed findings. Method(s): We conducted the first systematic review
and meta-analysis of aortic valve complex (AVC) calcium and left
ventricular outflow tract (LVOT) calcium (by total volume and separated by
leaflet) and mitral annular calcium (MAC), and their associations with
post-TAVI atrioventricular block, left bundle branch block and PPMI.
 Result(s): A total of 34 studies (N=11,528) were included for
qualitative analysis and 7 studies (N=1,056) were eligible for
quantitative analysis. Meta-analysis revealed left coronary cusp calcium
(LCC) and right coronary cusp (RCC) calcium were significant predictors of
PPMI, whilst non-coronary cusp (NCC) calcium was not predictive (LCC: mean
difference: 21.05mm3, p<0.001; RCC: mean difference:
46.02mm3, p=0.04, and NCC: mean difference: 9mm3,
p=0.10; see Figures 1-3). Whilst statistically significant, the marginal
volume differences suggest limited clinical significance. Qualitatively,
LVOT calcium in the NCC region was most commonly predictive of post-TAVI
conduction. Total AVC, total LVOT calcium and MAC had no significant
association with post-TAVI conduction. Conclusion(s): AVC and
sub-valvular calcium volume and asymmetric distribution did not predict
post-TAVI conduction abnormalities or requirement for PPMI. [Formula
presented] Copyright © 2024

<35>
Accession Number
2033531456
Title
Efficacy of PCSK9 Inhibitors in the Prevention of Cardiovascular Events: A
Systematic Review, Bayesian Meta-Analysis and Trial Sequential Analysis of
Randomised Controlled Trials.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S517), 2024. Date
of Publication: August 2024.
Author
Grover J.; Yao W.; Amarasekera A.; Leung A.; Sekhar P.; Tian D.; Tan T.
Institution
(Grover, Sekhar, Tan) Western Sydney University, Sydney, NSW, Australia
(Yao, Leung, Tan) Department of Cardiology, Blacktown Hospital, Sydney,
NSW, Australia
(Tan) University of New South Wales, Sydney, NSW, Australia
(Amarasekera) Westmead Heart Rhythm Institute, Sydney, NSW, Australia
(Tian) Department of Anaesthesia and Perioperative Medicine, Westmead
Hospital, Westmead, NSW, Australia
(Tian) Department of Surgery, University of Melbourne, Melbourne, VIC,
Australia
(Tian) Critical Care Division, The George Institute for Global Health,
Sydney, NSW, Australia
Publisher
Elsevier Ltd
Abstract
Background: The landscape of lipid management has transformed with the
LDL-C lowering introduced by proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors. Despite their potent effects on improving patients'
lipid profiles, their impact on major adverse cardiovascular events and
all-cause mortality in the longer-term remains of interest.
 Method(s): A systematic search of databases and grey literature was
conducted to identify randomised controlled trials comparing the use of
PCSK9 inhibitors and placebo on cardiovascular events with a follow up
>=52 weeks. Risk ratios (RR) and confidence intervals (CI) were calculated
using frequentist and Bayesian meta-analysis as well as Trial Sequential
analysis (TSA). Result(s): Amongst eleven studies (52,372 patients),
frequentist meta-analysis demonstrated statistically significant reduction
in myocardial infarction (MI) (RR 0.78; 95%CI 0.68 to 0.89, p<0.001,
I2=20%), coronary revascularisation (CR) (RR 0.83; 95%CI 0.75
to 0.91, p<0.01, I2=9.1%) and ischaemic stroke (IS) (RR 0.76;
95%CI 0.66 to 0.87, p<0.01, I2=0%) for patients on PCSK9
inhibitors compared to placebo. Bayesian analysis confirmed these results
with posterior probabilities that PCSK9 inhibitors resulted in a RR <1 was
83.8%, 82.9% and 69.4% for MI, CR and IS respectively. TSA indicated that
enough events had been accrued in current trials to support these risk
reductions. No statistically significant effect was observed for other
outcomes. Conclusion(s): The observed reductions in MI, CR and IS,
alongside established reductions in LDL-C underscore the potential of
PCSK9 inhibitors as a transformative strategy in improving cardiovascular
outcomes. Copyright © 2024

<36>
Accession Number
2033531445
Title
Balloon Aortic Valvuloplasty as a Bridge to Non-Cardiac Surgery: A
Systematic Review and Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S579-S580), 2024.
Date of Publication: August 2024.
Author
Place A.; Naimo P.; Sampaio Rodrigues T.; Lee M.; Batchelor R.; Norman S.;
Biswas S.; Koshy A.
Institution
(Place, Naimo, Lee, Norman, Biswas, Koshy) Royal Melbourne Hospital,
Parkville, VIC, Australia
(Sampaio Rodrigues, Koshy) The Austin Hospital, Heidelberg, VIC, Australia
(Sampaio Rodrigues) Melbourne University, Parkville, VIC, Australia
(Batchelor) St Vincent's Hospital, Fitzroy, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Background: Severe aortic stenosis (AS) is associated with significant
risks in patients undergoing non-cardiac surgery (NCS). Balloon aortic
valvuloplasty (BAV) is often considered as a bridging procedure to
facilitate NCS candidacy. However, there are discrepant recommendations on
the use of BAV on ESC and ACC/AHA guidelines. Method(s): A systematic
review of EMBASE and MEDLINE was performed to identify relevant studies
(>=4 cases included) that reported on BAV prior to NCS. A pooled analysis
using a random-effects model was performed to calculate risk ratios (RR)
and 95% confidence intervals (CIs). The primary outcome was a comparison
of the rate of major adverse cardiovascular events (MACE) in patients with
severe AS undergoing NCS with BAV versus medical therapy. Result(s):
From 5,351 records, we identified 9 single arm studies (n=83) and two
case-control studies (n=123) highlighting the feasibility of BAV prior to
NCS. Single-arm studies indicated a 31.3% average rate of periprocedural
BAV complications (range 0-46.7%). The risk of MACE post-NCS was 5.0%.
Case-control data showed no significant difference in MACE rates between
BAV-treated patients and controls (RR 0.26 [0.03-2.37], p=0.23), albeit
with substantial heterogeneity (I2=86.65%) (Figure 1).
 Conclusion(s): Despite BAV being feasible as a bridge to NCS, there
exist few studies with only small patient numbers and high heterogeneity.
Here we demonstrate that BAV in this setting is associated with a high
complication rate, raising questions regarding its efficacy and safety.
Consequently, further high-quality research is necessary to conclusively
determine the risks and benefits of BAV to facilitate NCS eligibility.
[Formula presented] Copyright © 2024

<37>
Accession Number
2033531386
Title
Long Term Pacing Dependency for Patients Requiring Permanent Pacemaker
Implantation After Transcatheter Aortic Valve Implantation.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S433-S434), 2024.
Date of Publication: August 2024.
Author
Hall R.; Kempton H.; Cherrett C.; Subbiah R.; Roy D.
Institution
(Hall, Kempton, Cherrett, Subbiah, Roy) St Vincent's Hospital, Sydney,
NSW, Australia
Publisher
Elsevier Ltd
Abstract
Background: The requirement for permanent pacemaker implantation (PPI)
following transcatheter aortic valve implantation (TAVI), remains a
significant consideration in the procedural planning and long-term
management of patients with severe aortic stenosis. Following TAVI, the
incidence of new pacemaker requirement is 2-36%, depending on the type of
device, and patient risk profile [1]. At follow-up, not all patients
remain pacemaker dependent (defined as the absence of an escape or
intrinsic rhythm during temporary back-up pacing at a rate of 30 bpm),
despite requiring pacing for complete heart block in the immediate
post-procedural period. Method(s): We conducted a review of all
patients in our TAVI program who required PPI within 30 days after TAVI,
to determine the number who remain pacing dependent within 12-month
follow-up. Result(s): A total of 1,150 TAVIs were performed from
August 2008 to August 2023. 238 patients had a pre-existing PPM. 113
(12.3%) patients had a pacemaker implanted within 30 days after TAVI.
Since January 2020, 51/632 (8.0%) required PPI. In the entire cohort, 70
(7.7%) patients had a pre-existing right bundle branch block, and 12 (17%)
of these required pacing after TAVI. At 6-12-month follow-up, 63 (58.6%)
of all patients remained pacing dependent, excluding 6 patients who had a
cardiac resynchronisation device. Conclusion(s): While conduction
disturbances are common following TAVI, the experience at our centre
demonstrates that a large number of patients experience recovery of AV
node function after PPI implantation following TAVI. Reference: [1] van
Rosendael PJ, Delgado V, Bax JJ. Pacemaker implantation rate after
transcatheter aortic valve implantation with early and new-generation
devices: a systematic review. Eur Heart J.
2018;39(21):2003-13. Copyright © 2024

<38>
Accession Number
2033531035
Title
Efficacy and Safety of Percutaneous Left Atrial Appendage Closure Versus
Oral Anticoagulation in Non-Valvular Atrial Fibrillation: A Systematic
Review of Randomised Controlled Trials.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S426), 2024. Date
of Publication: August 2024.
Author
Leung A.; Li C.; Khanna S.; Tan T.; Bhat A.
Institution
(Leung, Li, Khanna, Tan, Bhat) Department of Cardiology, Blacktown
Hospital, Sydney, NSW, Australia
(Tan, Bhat) School of Public Health and Community Medicine, University of
New South Wales, Sydney, NSW, Australia
(Tan, Bhat) School of Medicine, Western Sydney University, Sydney, NSW,
Australia
Publisher
Elsevier Ltd
Abstract
Background: Oral anticoagulation (OAC) is the standard of care in stroke
prevention for patients with non-valvular atrial fibrillation (AF).
However, a significant proportion of individuals are considered unsuitable
for long-term OAC due to a significant bleeding diathesis. Left atrial
appendage closure (LAAC) has shown promise as an alternative for such
individuals where long-term OAC is contraindicated. The aim of this
systematic review was to compare the efficacy and safety of percutaneous
LAAC to OAC. Method(s): A systematic literature search of medical
databases was performed using PRISMA principles to identify all randomised
controlled trials comparing percutaneous LAAC to OAC in adults with
non-valvular AF (Jan 2000-Sep 2023; PROSPERO registration CRD42023464783).
Parameters with low heterogeneity were then meta-analysed using a
random-effects model for odds ratios (ORs) using the longest follow-up
duration available by intention-to-treat analysis. Result(s): Three
randomised controlled trials with a total of 1,516 patients (933 patients
randomised to LAAC and 583 patients to OAC) were analysed. There were no
significant differences in baseline characteristics including AF subtype
or CHA<inf>2</inf>DS<inf>2</inf>VASC score between groups (p>0.05). Use of
LAAC was associated with a significant reduction in cardiovascular
mortality in comparison to OAC (OR 0.60; 95% CI 0.40-0.89, p=0.012),
despite no major differences in rates of ischaemic stroke and systemic
embolism (p>0.05). Conclusion(s): These results support the use of
LAAC as a possible alternative to OAC therapy. Further studies are
required to assess the mechanisms of its benefit on cardiovascular
mortality given no significant differences in rates of thromboembolic
events. Copyright © 2024

<39>
Accession Number
2033530887
Title
30-day Outcome of Real-World Tricuspid Edge-to-Edge Repair, Single Centre
Experience.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S576), 2024. Date
of Publication: August 2024.
Author
Haji K.; Thomson H.; Anthony C.; Leet A.; Cheshire C.; Nanayakkara S.;
Stub D.; Noaman S.; Htun N.; Palmer S.; Walton A.
Institution
(Haji, Thomson, Anthony, Leet, Cheshire, Nanayakkara, Stub, Noaman, Htun,
Palmer, Walton) Alfred Health, Melbourne, VIC, Australia
(Haji, Noaman) Department of Cardiology, Western Health, St Albans, VIC,
Australia
Publisher
Elsevier Ltd
Abstract
Background: Severe tricuspid regurgitation (TR) is linked to substantial
morbidity and has a negative impact on quality of life causing right heart
failure, dyspnoea, and fatigue. Data from randomised controlled trials and
large registries demonstrate that the Abbot TriclipTM is a safe
and effective device for reducing TR. Aim(s): To investigate the
short-term outcomes of patients treated with TriclipTM in a
real-world setting at a high-volume centre in Melbourne, Australia, over a
12-month period. Method(s): Retrospective analysis of all TriclipTM
cases performed between November 2022-Novemebr 2023 Looking at procedural
and 30-day outcomes. TR severity was graded according to the upgraded
contemporary classification. All patients were approved by an MDT and were
high-risk surgical candidates. Result(s): Nine patients underwent
treatment with TriclipTM. The average age was 76+/-5 years, with 22% being
female. All patients had two or more major comorbidities and 2 patients
had pacemaker leads. Three patients had torrential or massive TR, with the
remainder severe. Eight out of nine patients experienced NYHA class III or
IV symptoms. Successful implantation of clips with 2 grade TR reduction
was achieved in all patients. Following treatment, there was a significant
improvement in NYHA class to class II or lower for all patients (Figure).
No major adverse cardiovascular events (MACE) were reported
post-discharge, although there was one mortality recorded at 30 days.
 Conclusion(s): Our real-world data demonstrates that transcatheter
tricuspid valve repair is both safe and effective in the short term, in a
diverse range of patients. [Formula presented] Copyright © 2024

<40>
Accession Number
2033530866
Title
Fractional Flow Reserve Versus Angiography-guided Revascularisation in
Patients With Severe Aortic Stenosis.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S558), 2024. Date
of Publication: August 2024.
Author
Mridha N.; Zaka A.; Raffel C.; Murdoch D.; Walters D.
Institution
(Mridha, Raffel, Murdoch, Walters) The Prince Charles Hospital, Brisbane,
QLD, Australia
(Zaka) Gold Coast University Hospital, Gold Coast, QLD, Australia
Publisher
Elsevier Ltd
Abstract
Background: Aortic stenosis (AS) and coronary artery disease (CAD)
commonly co-exist. Although fractional flow reserve (FFR) is the gold
standard for demonstrating functionally significant coronary artery
stenoses, its efficacy in patients with severe AS awaiting transcatheter
aortic valve implantation (TAVI) is unclear. We performed a systematic
review of all available studies comparing clinical outcomes between
FFR-guided and angiography-guided coronary revascularisation in severe AS
patients. Method(s): PubMed, Ovid MEDLINE, Web of Science, and
Cochrane databases were searched to 6 January 2023. Eligible studies
comprised any randomised controlled trials or observational studies
including severe AS patients with concurrent coronary disease comparing
FFR-guided to angiography-guided percutaneous coronary intervention (PCI).
Primary outcomes were all-cause mortality and myocardial infarction.
Secondary outcome was composite major adverse cardiovascular events
(MACE). Result(s): Five retrospective cohort studies were identified,
comprising 1,927 patients. Average follow-up was 34.7 months. FFR-guided
cohorts exhibited higher incidence rates for all-cause mortality (17.4% vs
15.6%), myocardial infarction (4.4% vs 3.3%), and major adverse
cardiovascular events (21.8% vs 18.5%) compared to angiography-guided
cohorts. Based on inconsistent data, there were similar rates of
conversion to PCI with 32.8% in the angiography-guided cohort and 33.1%
from the FFR-guided cohort. Due to insufficient power and heterogeneity of
the available data, a meta-analysis for the primary and secondary outcomes
was not conducted. Conclusion(s): Despite the recognised utility of
FFR in the assessment of coronary artery disease, its clinical efficacy in
patients with severe aortic stenosis undergoing TAVI remains uncertain,
amidst inconclusive, small observational data. Large-scale randomised
controlled trials are required. Copyright © 2024

<41>
Accession Number
2033530849
Title
Components of Home-Based Supportive Care for Adult Patients With Heart
Failure.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S253-S254), 2024.
Date of Publication: August 2024.
Author
Perera E.; Halahakone U.; Senanayake S.; Kularatna S.; Parsonage W.; Yates
P.; Singh G.
Institution
(Perera, Halahakone, Parsonage, Yates, Singh) Centre for Healthcare
Transformation, Queensland University of Technology, Kelvin Grove, QLD,
Australia
(Perera, Halahakone, Kularatna, Parsonage) Australian Centre for Health
Service Innovation, Queensland University of Technology, Kelvin Grove,
QLD, Australia
(Senanayake, Kularatna) Health Services and Systems Research, Duke-NUS
Medical School, Singapore
(Senanayake, Kularatna) National Heart Research Institute Singapore,
National Heart Centre, Singapore
(Yates, Singh) Cancer and Palliative Care Outcomes Centre, School of
Nursing, Queensland University of Technology, Kelvin Grove, QLD, Australia
Publisher
Elsevier Ltd
Abstract
Purpose: Supportive care in the home for people with heart failure holds
the potential to improve patient quality of life, carer wellbeing and
reduce healthcare costs. However, the components of home-based supportive
care in heart failure remain elusive. We aimed to identify and map
components of home-based supportive care in adult patients with heart
failure to optimise care in this setting. Method(s): A scoping review
was undertaken in accordance with Joanna Briggs Institute guidelines.
Embase, PubMed, CINAHL and Cochrane databases were searched from inception
to May 2023. Original research focused on supportive care in the home
setting that included adult patients diagnosed with heart failure who have
not undergone nor awaiting a heart transplant was included. Scoping review
protocol was registered prospectively with Open Science Framework
(https://doi.org/10.17605/OSF.IO/GHCME). Two independent reviewers
conducted the title and abstract review followed by a full text review.
 Result(s): Results were extracted from 13 papers based on eight
studies. There was heterogeneity among care providers and care provided in
home-based supportive care for persons with heart failure. All studies
were published after 2010. The components of home-based care were
summarised under following themes: symptom management; expert
communication; multidisciplinary team involvement; continuity of care;
education; end of life discussion, and caregiver support.
 Conclusion(s): Home-based supportive care has the potential to
improve symptom management and function, taking into consideration the
patient's way of life. Understanding components of home-based supportive
care for persons with heart failure provides an opportunity to improve
access to supportive care for this population. Copyright © 2024

<42>
Accession Number
2033530814
Title
Comparative Systematic Review of Guidelines for Asymptomatic Aortic
Stenosis: Consensus and Controversies in Diagnosis and Management.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S341-S342), 2024.
Date of Publication: August 2024.
Author
Grbac A.; Zhou J.; Bachelor R.; Sharma A.; Gurvitch R.; Biswas S.; Lee M.;
Brooks M.; Lefkovits J.; Wilson W.; Norman S.; Purio C.; O'Brien B.; Koshy
A.
Institution
(Grbac, Zhou, Bachelor, Sharma, Gurvitch, Biswas, Lee, Brooks, Lefkovits,
Wilson, Norman, Purio, O'Brien, Koshy) The Royal Melbourne Hospital,
Melbourne, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Background: Asymptomatic aortic stenosis (AS) poses a clinical challenge
with variations in recommendations for diagnosis, follow-up, and
intervention. We sought to compare and contrast contemporary cardiology
and cardiac surgical guidelines. Method(s): Electronic databases
(EBSCO, MEDLINE, PubMed) were systematically searched by independent
reviewers, and analysed using a comparative matrix. Result(s): Four
guidelines from ACC/AHA, ESC/EACTS, JCS/JSCS/JATS/JSVS and NICE were
included. Eighteen recommendations were analysed for class and level of
evidence with the majority (63.64%) based on class IIa evidence (Figure
1). Consensus was found for transthoracic echocardiography (TTE) in
diagnosis and for intervention thresholds including left ventricular
dysfunction and very severe AS (Class I/IIa). Discrepancies existed in
recommendations for utility and interpretation of exercise stress testing
and severity markers like BNP (Figure 2). Conclusion(s): While there
is broad agreement on the role of TTE, differences in recommendations
reflect variability in evidence interpretation. These discrepancies
underscore the need for research and collaboration to refine guidelines.
[Formula presented] [Formula presented] Copyright © 2024

<43>
Accession Number
2033530810
Title
Effects of Preoperative Nutrition Interventions on Rates of Arrhythmias
Post Cardiac Surgery: A Systematic Review.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S236), 2024. Date
of Publication: August 2024.
Author
Cusso M.; Vaswani K.; McGrath J.; Litton E.; Blekkenhorst L.
Institution
(Cusso) East Metropolitan Health Service, East Perth, WA, Australia
(Vaswani, Blekkenhorst) Nutrition and Health Innovation Research
Institute, School of Medical and Health Sciences, Edith Cowan University,
Perth, WA, Australia
(McGrath) St John of God Subiaco, Perth, WA, Australia
(Litton) Fiona Stanley Hospital, Perth, WA, Australia
(Litton, Blekkenhorst) School of Medicine, University of Western
Australia, Perth, WA, Australia
Publisher
Elsevier Ltd
Abstract
Introduction: Arrhythmias are a known complication of cardiac surgery with
the most common, atrial fibrillation (AF), occurring in 20-40% of patients
[1,2]. Preoperative nutrition optimisation is beneficial for postoperative
outcomes in numerous major surgeries, however evidence in cardiac surgery
is unclear. This systematic review collated evidence on the effects of
preoperative nutrition interventions on postoperative arrhythmias in
cardiac surgical patients. Method(s): A systematic search of CINAHL,
MEDLINE, EMBASE, Scopus, and Web of Science was performed using key search
terms and defined inclusion and exclusion criteria on the 22 November
2022, adhering to PRISMA guidelines. Risk of bias was assessed using the
Cochrane Risk of Bias tool for randomised trials, and the Risk of Bias In
Non-Randomised Studies of Interventions tool. The outcome of interest was
rate of postoperative arrhythmias. Result(s): Sixteen papers
investigated rates of postoperative arrhythmias, with 13 exclusively
looking at AF (total n=1,053 participants). Preoperative interventions
included overall dietary changes or supplementation of polyunsaturated
fatty acids, amino acids, carbohydrates, vitamin D, iron, Coenzyme Q10,
fibre, or nitrates. Vitamin D was the only preoperative intervention
yielding significant results, with all three studies showing significant
reductions in postoperative AF (total n=448 participants), one study in
those with vitamin D deficiency. Risk of bias showed some concern for two
studies and was low for the other. Conclusion(s): Preoperative
vitamin D supplementation prior to cardiac surgery may decrease the risk
of postoperative arrhythmias. Given the low number of studies, it is
difficult to ascertain the clinical significance of other preoperative
nutritional interventions on postoperative arrhythmias. References: [1]
Peretto, G., Durante, A., Limite, L. R., Cianflone, D. Postoperative
arrhythmias after cardiac surgery: incidence, risk factors, and
therapeutic management. Cardiol Res Pract, 2014.
https://doi.org/10.1155/2014/615987. [2] Eikelboom, R., Sanjanwala, R.,
Le, M. L., Yamashita, M. H., Arora, R. C. Postoperative atrial
fibrillation after cardiac surgery: a systematic review and meta-analysis.
Ann Thoracic Surg, 2021;111(2):544-554. Copyright © 2024

<44>
Accession Number
2033530691
Title
Contemporary Incidence of Cognitive Impairment or Dementia in Patients
Undergoing Coronary Artery Bypass Grafting: A Systematic Review and
Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S234), 2024. Date
of Publication: August 2024.
Author
Lo H.; Wee C.; Low C.; Teo Y.; Yun C.; Syn N.; Tan B.; Chai P.; Yeo L.;
Yeo T.; Chong Y.; Poh K.; Kong W.; Wong R.; Chan M.; Sia C.
Institution
(Lo) School of Medicine, Faculty of Medicine, Nursing and Health Sciences,
Monash University, Melbourne, VIC, Australia
(Wee, Low, Teo, Tan, Chai, Yeo, Yeo, Chong, Poh, Kong, Wong, Chan, Sia)
Department of Medicine, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore, Singapore
(Yun, Chai, Yeo, Poh, Kong, Wong, Chan, Sia) Department of Cardiology,
National University Heart Centre Singapore, Singapore
(Syn) Department of Surgery, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore
(Tan, Yeo, Chong) Division of Neurology, Department of Medicine, National
University Hospital, Singapore
Publisher
Elsevier Ltd
Abstract
Background: Despite the high prevalence of cognitive impairment or
dementia post coronary artery bypass grafting (CABG), the incidence of
cognitive impairment or dementia post-CABG in contemporary practice is
currently unclear. Therefore, this paper aims to investigate the incidence
and associated risk factors of cognitive impairment or dementia in
patients undergoing CABG. Method(s): A systematic search across three
databases (PubMed, SCOPUS and Embase) was conducted for studies published
in or after 2013 that reported cognitive impairment or dementia post-CABG.
Subgroup analyses and meta-regression by risk factors were performed to
determine their influence on the results. Result(s): This analysis
included 19 studies with a total of 2,043 patients. The incidence of
cognitive impairment or dementia less than 1 month, 2 to 6 months, and
more than 12 months post-CABG was 35.96 (95% CI: 28.22 to 44.51, I2=87%),
21.33 (95% CI: 13.44 to 32.15, I2=88%) and 9.13 per 100 patients (95% CI:
21.72 to 58.84, I2=84%), respectively. Meta-regression revealed that
studies with more than 80% of the cohort diagnosed with hypertension were
significantly associated with incidence of cognitive impairment or
dementia less than 1-month post-CABG. Conclusion(s): This
meta-analysis demonstrates a high incidence of cognitive impairment or
dementia in patients post-CABG in contemporary practice, particularly less
than 1 month post-CABG. We found that hypertension was a significant risk
factor in the short term (less than 1 month) follow-up period for
cognitive impairment or dementia post-CABG. Future research should be done
to assess strategies to reduce cognitive impairment
post-CABG. Copyright © 2024

<45>
Accession Number
2033530667
Title
A Systematic Comparison of ACC/AHA, ESC and JCS Guidelines on
Intravascular Imaging: Level of Evidence and Clinical Use Scenarios.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S549-S550), 2024.
Date of Publication: August 2024.
Author
Norman S.; Koshy A.; Biswas S.; Batchelor R.; Lefkovits J.
Institution
(Norman, Koshy, Biswas, Batchelor, Lefkovits) Royal Melbourne Hospital,
North Melbourne, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Aims: Recent randomised studies have demonstrated the benefits of
intravascular imaging (IVI) use in percutaneous coronary intervention
(PCI) [1], but current guidelines pertaining to IVI are not consistent. We
undertook a review of guideline recommendations to identify areas of
overlap and discordance. Method(s): We systematically reviewed
electronic databases to identify guidelines from national and
international cardiac societies that contained recommendations for IVI use
including a class of recommendation (COR) and level of evidence (LOE).
 Result(s): Six guideline documents met the inclusion criteria: two
each from the European (ESC) [2-3], American (AHA/ACC) [4-5] and Japanese
(JCS) [6-7] cardiac societies. 26 recommendations are given (15 JCS; 6
ESC; 5 AHA/ACC) across 9 clinical use scenarios; most are given a COR IIa
(69.2%) followed by IIb (15.4%), III (11.5%) and I (3.8%). A grade C LOE
was commonest (53.8%), followed by B (38.5%) and A (7.7%). There was broad
agreement between guidelines with no discrepancies of >1 COR or LOE. Areas
of discordance included definition of complex coronary disease, the role
of IVI in evaluating angiographically normal coronaries in acute coronary
syndromes (ACS), which cohorts IVI should be applied in (stable coronary
disease in the JCS guidelines vs ACS per ESC). Discussion(s): There
is broad agreement between cardiac societies on the applications for IVI,
but differences exist in the populations served by the recommendations,
the class of recommendations and the strength of supporting evidence. Most
recommendations cite moderate- or low-quality supporting evidence, though
several were published prior to the release of notable randomised trials
[1]. References: [1] Stone GW, Christiansen EH, Ali ZA, Andreasen LN,
Maehara A, Ahmad Y, Landmesser U, Holm NR. Intravascular imaging-guided
coronary drug-eluting stent implantation: an updated network
meta-analysis. Lancet. 2024 Mar 2;403(10429):824-837. [2] Neumann FJ,
Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, et al. 2018 ESC/EACTS
Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan
7;40(2):87-165. [3] Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C,
et al. 2023 ESC Guidelines for the management of acute coronary syndromes.
Eur Heart J. 2023 Oct 12;44(38):3720-3826. [4] Lawton JS, Tamis-Holland
JE, Bangalore S, Bates ER, Beckie TM, et al. 2021 ACC/AHA/SCAI Guideline
for Coronary Artery Revascularization. J Am Coll Cardiol. 2022 Jan
18;79(2):e21-e129. [5] Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr,
Ganiats TG, et al. 2014 AHA/ACC Guideline for the Management of Patients
with Non-ST-Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2014
Dec 23;64(24):e139-e228. [6] Nakamura M, Yaku H, Ako J, Arai H, Asai T, et
al. JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary
Artery Disease. Circ J. 2022 Feb 25;86(3):477-588. [7] Hokimoto S, Kaikita
K, Yasuda S, Tsujita K, Ishihara M, et al. JCS/CVIT/JCC 2023 Guideline
Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary
Spastic Angina) and Coronary Microvascular Dysfunction. Circ J. 2023 May
25;87(6):879-936. Copyright © 2024

<46>
Accession Number
2033530659
Title
A 10-year Review of Left Main (LM) Coronary Artery Percutaneous Coronary
Intervention (PCI) in South Western Sydney Local Health District (SWSLHD).
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S549), 2024. Date
of Publication: August 2024.
Author
Boddupalli S.; Dang V.; Rajaratnam R.; Xu J.; Juergens C.; Lo S.
Institution
(Boddupalli, Dang, Rajaratnam, Xu, Juergens, Lo) Liverpool Hospital,
Sydney, NSW, Australia
Publisher
Elsevier Ltd
Abstract
Background: PCI to LM disease is offered if CABG declined or patient
refusal. We aim to retrospectively review LM-PCI indications, management,
outcomes, complications, and intracoronary (IC) imaging use between
2014-2024 in SWSLHD. Method(s): 929 cases extracted, and 170
angiographically confirmed LM-PCI included. LM-PCI indications include
ACS(ACS-PCI), elective(E-PCI) and staged(S-PCI). S-PCI includes rescue-PCI
and non-culprit-PCI, after primary PCI, during index presentation.
 Result(s): 170 LM-PCI cases [males 134 (79%), median age 73 (IQR:
65.4-81)]. 168/170 (99%) successful [TIMI-III 163/170 (96%), TIMI-II 4/170
(2%), TIMI-I 1/170 (1%)]. 2/170 (1%) had no flow restoration [1/2 arrested
on table;1/2 unable to pass guidewire distally]. 107/170 (63%) were
ACS-PCI [68/107 (64%) STEMI, 39/107 (36%) NSTEMI]; 23/170 (14%) E-PCI;
40/170 (24%) S-PCI. 79/107 (74%) LM-lesions culprit in ACS-PCI. 53/107
(50%) in established cardiogenic-shock (ACS-CS) [SCAI-C 9/53 (17%), SCAI-D
18/53 (34%), SCAI-E 26/53 (49%)]. 70/170 (41%) used
mechanical-circulatory-support (MCS) [IABP 48/70 (69%), VA-ECMO 8/70
(11%), Impella 10/70 (14%), IABP+Impella+VA-ECMO 1/70 (1%), IABP+Impella
1/70 (1%), IABP+VA-ECMO 2/70 (1%)]. 61/107 (57%) ACS-PCI used MCS [ACS-CS
48/61 (79%)];3/23 (13%) E-PCI; 6/40 (15%) S-PCI. 57/170 (34%)
distal-LM-bifurcation lesions. [Rx: 1-stent 41/57 (72%), 2-stent 12/57
(21%), DEB 4/57 (7%)]. 14/57 (25%) used KBI. 19/57 (33%) had previous
CABG. IC imaging used in 75/170 (44%)[71/75 (95%) IVUS; 4/75 (5%)OCT].
After 2021: 57/71 (80%) IVUS; 4/4 (100%) OCT. 145/170 (85%) survived to
discharge. Inpatient mortality was 25/170 (15%) [23/25(92%) ACS-CS;
2/25(8%) S-CS]. Non-procedure related bleeding [BARC II-V 17/170 (10%)]
and stroke [1/170 (1%)] observed. Conclusion(s): E-PCI in SWSLHD has
excellent results. ACS-PCI has high rates of mortality in shock.
Increasing use of IC imaging for LM-PCI noted in this
time-period. Copyright © 2024

<47>
Accession Number
2033530618
Title
Improving Risk Prediction After Transcatheter Aortic Valve Implantation: A
Comparison of Machine Learning With Traditional Methods.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S385-S386), 2024.
Date of Publication: August 2024.
Author
Zaka A.; Mutahar D.; Mustafiz C.; Sinhal S.; Gorcilov J.; Evans S.; Gupta
A.; Stretton B.; Kovoor J.; Mridha N.; Sivagangabalan G.; Zaman S.; Chow
C.; Thiagalingam A.; Kovoor P.; Bacchi S.
Institution
(Zaka) Gold Coast University Hospital, Gold Coast, QLD, Australia
(Mutahar) Bond University, Gold Coast, QLD, Australia
(Mustafiz) Griffith University, Gold Coast, QLD, Australia
(Sinhal, Evans, Stretton) The University of Adelaide, Adelaide, SA,
Australia
(Gorcilov) Royal Adelaide Hospital, Adelaide, SA, Australia
(Gupta) Royal North Shore Hospital, Sydney, NSW, Australia
(Kovoor) Ballarat Base Hospital, Ballarat, VIC, Australia
(Mridha) The Prince Charles Hospital, Brisbane, QLD, Australia
(Sivagangabalan, Zaman, Chow, Thiagalingam, Kovoor) Westmead Hospital,
Sydney, NSW, Australia
(Bacchi) Lyell McEwin Hospital, Adelaide, SA, Australia
Publisher
Elsevier Ltd
Abstract
Background: Accurate mortality prediction following transcatheter aortic
valve implantation (TAVI) is essential for mitigating risk, shared
decision-making, and periprocedural planning. Surgical risk models have
demonstrated modest discriminative value for patients undergoing TAVI and
are typically poorly calibrated. Machine learning (ML) models offer an
alternative risk stratification that may offer improved predictive
accuracy. We performed a systematic review and meta-analysis comparing ML
models with traditional risk scores for prediction of all-cause mortality
after TAVI. Method(s): PubMed, EMBASE, Web of Science and Cochrane
databases were searched until 16 December 2023 for studies comparing ML
models with traditional statistical methods for event prediction after
TAVI. The primary outcome was comparative discrimination measured by
C-statistics with 95% confidence intervals between ML models and
traditional methods in estimating the risk of all-cause mortality at
30-days and 1-year. Result(s): Sixteen models were assessed across 9
observational studies (29608 patients). The summary C-statistic of the
top-performing ML models for all-cause mortality was 0.82 (95% CI,
0.77-0.87), compared to traditional methods 0.65 (95% CI, 0.62-0.68). The
difference in C-statistic between ML models and traditional methods was
0.17 (95% CI 0.15-0.19, p<0.00001). Of all included studies, 2 models were
externally validated. Calibration was inconsistently reported.
 Conclusion(s): ML models outperformed traditional risk scores in the
discrimination of all-cause mortality following TAVI. While integration of
ML algorithms into electronic healthcare systems may improve
periprocedural risk stratification, immediate implementation in the
clinical setting remains uncertain. Further research is required to
overcome methodological and validation limitations. Copyright ©
2024

<48>
Accession Number
2033530585
Title
Interventions to Improve Frailty in Adults With Cardiovascular Disease: A
Systematic Review Of Randomised Controlled Trials.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S326), 2024. Date
of Publication: August 2024.
Author
McDonagh J.; Alanazi F.; Ferguson C.
Institution
(McDonagh, Alanazi, Ferguson) The University of Wollongong, Faculty of
Science, Medicine and Health, School of Nursing, Liverpool, NSW, Australia
(McDonagh, Ferguson) Centre for Chronic and Complex Care Research,
Blacktown Hospital, Western Sydney Local Health District, Blacktown, NSW,
Australia
Publisher
Elsevier Ltd
Abstract
Background: Frailty, a devastating syndrome of 'accelerated ageing' is
common in adults with cardiovascular disease (CVD). Frailty can be
improved, yet the evidence regarding effective interventions in this
population is not clear. Aim(s): To determine which interventions are
most effective at improving frailty or physical function measures in
pre-frail and frail adults with living with CVD. Method(s):
Systematic literature review of randomised controlled trials (RCTs).
Literature searches were conducted in Medline, Scopus and CINHAL in
October 2023. Peer-reviewed RCTs reporting improvements in frailty score
or physical function measures in pre-frail or frail adults with diagnosed
CVD were included. Result(s): After removal of duplicates, 2660
studies underwent title and abstract review by two independent reviewers,
56 studies underwent full-text review. Six eligible studies were included.
Included studies recruited adults with heart failure (n=3), post
myocardial infarction (n=1), post cardiac surgery (n=1) and adults with
acute CVD conditions (n=1). All studies included exercise as part of the
intervention, two studies had a nutrition component and one study had
multicomponent intervention. Primary outcome measures were heterogeneous
with two studies reporting improvement in SPPB (p <0.001 for both), two
reporting improvements in 6-minute walk distance (p<0.001 & p=0.03), one
reporting improvement in frailty phenotype scores (p=0.018), and one
reporting improvement in health-related quality-of-life (p=0.03).
 Conclusion(s): Exercise-based interventions are effective at
improving frailty and physical function measures in pre-frail and frail
adults living with CVD. Standardisation of outcome measures is required
for future studies. Copyright © 2024

<49>
Accession Number
2033530560
Title
Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention
in Atrial Fibrillation: A Systematic Review Appraising the Methodological
Quality.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S397), 2024. Date
of Publication: August 2024.
Author
Hewage S.; Noviyani R.; Barnett A.; Parsonage W.; Brain D.; McPhail S.;
Sharma P.; Kularatna S.
Institution
(Hewage, Barnett, Parsonage, Brain, McPhail, Sharma, Kularatna) Australian
Centre for Health Services Innovation and Centre for Healthcare
Transformation, Queensland University of Technology, Kelvin Grove,
Brisbane, QLD, Australia
(Noviyani) Department of Pharmacy, Udayana University, Bali, Indonesia
(Parsonage) Cardiology department, Royal Brisbane and Women's Hospital,
Brisbane, QLD, Australia
(McPhail) Digital Health and Informatics Directorate, Metro South Health,
Metro South Health, Brisbane, QLD, Australia
Publisher
Elsevier Ltd
Abstract
Background: High-quality economic evaluations of stroke prevention
strategies in atrial fibrillation (AF) can play a crucial role in
maximising efficient allocation of resources. In this systematic review,
we assess the methodological quality of such economic evaluations.
 Method(s): Electronic databases of PubMed, EMBASE, CINAHL, Cochrane
Central Register of Controlled Trials, and Econ Lit were searched to
identify model-based economic evaluations comparing the left atrial
appendage closure procedure (LAAC) and oral anticoagulants published in
English since 2000. Methodological quality of these evaluations was
assessed using the modified Economic Evaluations Bias checklist. Studies
were accordingly categorised into one of four groups: low risk, partial
risk, high risk due to inadequate reporting, or high risk. Result(s):
Results varied across the 12 eligible studies. LAAC displayed a
probability exceeding 50% of being the cost-effective option in six out of
nine evaluations compared to warfarin, six out of eight evaluations
compared to dabigatran, in three out of five evaluations against apixaban,
and in two out of three studies against rivaroxaban. The methodological
quality scores for individual studies ranged from 10 to -12 out of a
possible 24. Most high-risk ratings were due to inadequate reporting,
especially in data identification, baseline data, treatment effects, and
data incorporation. Cost measurement omission bias and inefficient
comparator bias were also common. Conclusion(s): While most studies
concluded LAAC to be the cost-effective strategy for stroke prevention in
AF, shortcomings in methodological quality raise concerns about
reliability and validity of results. Future evaluations, free of these
shortcomings, can yield stronger policy evidence. Copyright ©
2024

<50>
Accession Number
2033530532
Title
Coronary Revascularisation for Patients With Obstructive Coronary Artery
Disease Requiring Lung Transplantation.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S234-S235), 2024.
Date of Publication: August 2024.
Author
Adonopulos A.; Kempton H.; Meredith T.; Malouf M.; Jansz P.; Macdonald P.
Institution
(Adonopulos, Kempton, Meredith, Malouf, Jansz, Macdonald) St Vincent's
Hospital, Sydney, NSW, Australia
(Adonopulos) University of New South Wales, Sydney, NSW, Australia
(Meredith) The Victor Chang Cardiac Research Institute, Sydney, NSW,
Australia
Publisher
Elsevier Ltd
Abstract
Background & Methods: Lung transplant candidates often have multiple risk
factors for coexisting coronary artery disease (CAD), which was once a
contraindication to transplantation. As revascularisation technology and
techniques have improved, this has broadened eligibility for transplant
listing, however due to small numbers, and heterogeneous cohorts, it is
unclear whether there is a difference in outcomes based on
revascularisations strategy. We conducted a systematic review to assess
the evidence for clinical outcomes for percutaneous coronary intervention
(PCI) prior to transplant listing, or concomitant coronary artery bypass
grafting (CABG) at transplant. We also analysed the data from our centre
since inception of the transplant program. Result(s): In the
systematic review, 174 studies were identified in the initial search, and
29 studies were considered relevant, however just six retrospective
studies made a comparison between PCI and CABG, with a total 376 patients.
CABG increased ventilation time, and ICU and overall length of stay in
some cohorts, however this was not evident in all studies. At our centre,
just 18 patients had concomitant CABG, and 11 underwent PCI prior to
transplant listing, after obstructive CAD was diagnosed during transplant
assessment. The procedure time in patients undergoing concomitant CABG was
significantly longer (0.9 hours; p<0.05), however there were no
differences in other outcomes, including ventilation time and ICU length
of stay. Conclusion(s): Small and heterogeneous cohort studies
highlight the complexity of this patient cohort, with unique management
challenges in each case. Case-by-case management decisions within the
multi-disciplinary team are therefore warranted to best manage each
patient with obstructive CAD prior to lung transplantation. Copyright
© 2024

<51>
Accession Number
644824714
Title
Frailty response in patients with aortic stenosis undergoing transcatheter
aortic valve implantation: Protocol for a pilot, cluster randomised
controlled trial (FRAIL-AS Response Trial).
Source
European Journal of Cardiovascular Nursing. Conference: Annual Congress of
the Association of Cardiovascular Nursing and Allied Professions, ACNAP
2024. Wroclaw Poland. 23(Supplement 1) (pp i50), 2024. Date of
Publication: July 2024.
Author
Straiton N.; Muller D.; Macdonald P.; Arriagada A.; Roy D.; Mills N.;
Middleton S.
Institution
(Straiton, Middleton) Australian Catholic University, Sydney, Australia
(Muller, Arriagada, Mills) St Vincent's Private Hospital Sydney,
Darlinghurst, Australia
(Macdonald, Roy) St Vincent's Hospital, Sydney, Australia
Publisher
Oxford University Press
Abstract
Background: Three in ten severe aortic stenosis patients undergoing
transcatheter aortic valve implantation (TAVI) are frail. Frailty
correlates with adverse post-procedure patient outcomes, such as higher
1-year mortality, increased adverse events, prolonged hospital stays, and
diminished quality of life. Despite the urgency for evidence-based frailty
management in this population, research in this area is limited.
 Method(s): A pilot, cluster randomised controlled trial to assess the
feasibility of implementing a Frailty Response Program intervention in 10
hospital TAVI programs for frail patients with aortic stenosis undergoing
valve replacement. The intervention includes an implementation strategy
and a Frailty Response Clinical Protocol, focused on malnutrition
identification, patient education, general practitioner notification,
comprehensive geriatric assessment, and cardiac rehabilitation. Eligible
hospitals will be randomised (1:1) to either the intervention or control
(standard care). Primary Outcome: Proportion of patients receiving
nutritional assessment upon frailty identification. Secondary outcomes
include mortality and hospital admissions, frailty improvement, quality of
life, and evidence-based frailty management. Implementation outcomes will
be evaluated through a process assessment. Discussion(s): The trial
aims to bridge the gap between the recognition of frailty in patients with
aortic stenosis undergoing TAVI and the implementation of evidence-based
frailty management practices to improve patient outcomes and care quality.

<52>
Accession Number
2033533683
Title
Improving Treatment Approaches in Cardiogenic Shock: A Systematic Review
and Meta-Analysis Comparing Adjunctive Impella Versus Intra-Aortic Balloon
Pump in Management of Acute Myocardial Infarction Complicated by
Cardiogenic Shock.
Source
Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Perth Convention and
Exhibition Centre, Australia. 33(Supplement 4) (pp S559-S560), 2024. Date
of Publication: August 2024.
Author
Upadhyay J.; Theertham A.; Khanna S.; Bhat A.
Institution
(Upadhyay, Theertham, Khanna, Bhat) Blacktown Hospital, Sydney, NSW,
Australia
(Bhat) Western Sydney University, Blacktown, NSW, Australia
(Bhat) University of New South Wales, Sydney, NSW, Australia
Publisher
Elsevier Ltd
Abstract
Background Treatment of acute myocardial infarction complicated by
cardiogenic shock (AMI-CS) remains challenging, despite improvements in
percutaneous mechanical circulatory support (pMCS) systems. Impella and
intra-aortic balloon pump (IABP), two pMCS modalities, are associated with
variable outcomes. This systematic review and meta-analysis compares
patient demographics, clinical outcomes, and device-related complications
among AMI-CS patients supported by Impella versus IABP. Methods A
literature search of medical databases identified studies including AMI-CS
patients undergoing PCI with utilisation of Impella and IABP as pMCS. Data
for clinical and safety outcomes with low heterogeneity were extracted and
meta-analysed using a random-effect model for odds ratios (OR) or
standardised mean differences (SMD). Results Seven eligible studies (6,484
patients) were included. There were no significant differences in
high-risk patient factors, including comorbid heart failure, type of ACS
presentation, prior CABG, presence of PVD, and the extent of coronary
vessel involvement. Use of Impella was significantly associated with
increased in-hospital mortality (OR 1.51, p<0.001) as well as major
bleeding incidents (OR 2.62, p<0.001) compared to IABP. Other
complications such as peripheral limb ischaemia, sepsis, renal
insufficiency, and stroke were similar between groups (p>0.05). Despite
higher rates of in-hospital mortality with Impella, this association did
not persist at 30-day follow-up (OR 0.94, p=0.82). Conclusions Impella use
in management of AMI-CS is associated with initial higher in-hospital
mortality and bleeding events relative to IABP. However, 30-day mortality
rates remain equivocal between the two modalities, necessitating further
research into this area. Copyright © 2024

<53>
Accession Number
2033509246
Title
Safety and perioperative outcomes of uniportal versus multiportal
video-Assisted thoracoscopic surgery.
Source
Journal of Minimal Access Surgery. 20(3) (pp 294-300), 2024. Date of
Publication: 2024.
Author
Alanwar M.; Elsharawy M.; Brik A.; Ahmady I.; Shemais D.S.
Institution
(Alanwar, Elsharawy, Brik, Ahmady, Shemais) Department of Cardiothoracic
Surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: Uniportal video-Assisted thoracoscopic surgery (U-VATS) has
recently become an alternative approach for many minimally invasive
thoracic procedures, but although its surgical effectiveness has been
proven, still its feasibility and safety are debated and unclear.The
objective of this study was to compare the safety and perioperative
outcomes of U-VATS versus multiportal VATS (M-VATS). Patients and
Methods: This was a comparative follow-up randomised controlled clinical
trial, carried out on 36 randomly selected eligible patients, and
fulfilling the inclusion and exclusion criteria for VATS, they were
assigned randomly into two groups: Study Group I including 18 patients
undergoing U-VATS with conventional treatment using standard chest tube
drainage and Control Group II including 18 patients undergoing M-VATS)
with the same conventional treatment using standard chest tube drainage
and served as a comparable control group. Result(s): Patients in the
U-VATS Group 1 had faster operation time, and with reduced blood loss,
pleural drainage and post-operative hospitalisation, they also experienced
lower average post-operative pain score on comparison with those in M-VATS
Group II (P < 0.001), respectively. For either group, there were no
hospital deaths or infections. There was no noticeable difference between
the two groups in terms of the number of resected lymph nodes or the rates
of intraoperative or post-operative complications (P > 0.05).
 Conclusion(s): U-VATS is feasible and safe in eligible selected
patients with favourable short-Term perioperative outcomes (operative
time, duration of pleural drainage, post-operative pain, early ambulation,
duration of hospital stay as well as the risk of perioperative
complications), and it can be considered the preferred approach in
minimally invasive thoracic procedures that open up for the possibility of
fast-Track thoracic surgeries. Copyright © 2024 Journal of
Minimal Access Surgery.

<54>
Accession Number
2033538360
Title
Standard versus High Cardiopulmonary Bypass Flow Rate: A Randomized
Controlled Subtrial Comparing Brain Injury Biomarker Release.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Keiller A.C.; Axelsson M.; Bragadottir G.; Lannemyr L.; Wijk J.; Blennow
K.; Zetterberg H.; Bagge R.O.
Institution
(Keiller) Department of Perfusion, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Keiller) Department of Surgery, Institute of Clinical Sciences,
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
(Keiller, Bagge) Wallenberg Centre for Molecular and Translational
Medicine, University of Gothenburg, Gothenburg, Sweden
(Axelsson) Department of Clinical Neuroscience, Institute of Neuroscience
and Physiology at Sahlgrenska Academy, University of Gothenburg,
Gothenburg, Sweden
(Bragadottir, Lannemyr, Wijk) Department of Cardiothoracic Anesthesia and
Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden
(Lannemyr, Wijk) Department of Anesthesiology and Intensive Care Medicine,
Sahlgrenska Academy, University of Gothenburg, Sweden
(Blennow, Zetterberg) Department of Psychiatry and Neurochemistry,
Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the
University of Gothenburg, Molndal, Sweden
(Blennow, Zetterberg) Clinical Neurochemistry Laboratory, Sahlgrenska
University Hospital, Molndal, Sweden
(Blennow) Paris Brain Institute, ICM, Pitie-Salpetriere Hospital, Sorbonne
University, Paris, France
(Blennow) Neurodegenerative Disorder Research Center, Division of Life
Sciences and Medicine, and Department of Neurology, Institute on Aging and
Brain Disorders, University of Science and Technology of China and First
Affiliated Hospital of USTC, Hefei, China
(Zetterberg) Department of Neurodegenerative Disease, UCL Institute of
Neurology, Queen Square, London, United Kingdom
(Zetterberg) UK Dementia Research Institute at UCL, London, United Kingdom
(Zetterberg) Hong Kong Center for Neurodegenerative Diseases, Hong Kong,
Clear Water Bay, China
(Zetterberg) Wisconsin Alzheimer's Disease Research Center, University of
Wisconsin School of Medicine and Public Health, University of
Wisconsin-Madison, Madison, WI, United States
(Bagge) Department of Surgery, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Bagge) Sahlgrenska Center for Cancer Research, Department of Surgery,
Institute of Clinical Sciences, Sahlgrenska Academy, University of
Gothenburg, Gothenburg, Sweden
Publisher
W.B. Saunders
Abstract
Objectives: To compare brain injury biomarker release levels between two
different cardiopulmonary bypass (CPB) flow rates in elective cardiac
surgery and to explore differences in postoperative delirium between
groups and associations between age, sex, CPB time, oxygen levels, and
near-infrared spectroscopy, and biomarker levels. Design(s): A
randomized controlled substudy trial Setting: Sahlgrenska University
Hospital, Sweden Participants: Forty patients undergoing elective cardiac
surgery with CPB Intervention: Patients were assigned at random to either
a standard (2.4 L/min/m2) or a high (2.9 L/min/m2)
CPB flow rate. Measurements and Main Results: Glial fibrillary acidic
protein, neurofilament light chain, total-tau, and phosphorylated-tau217
were sampled in plasma before anesthesia induction, after 60 minutes on
CPB, and at 30 minutes, 24 hours, and 72 hours post-CPB. Mixed models for
repeated measures were used to analyze differences in biomarker levels
between groups and to assess relationships, which showed no differences
between the 2 flow rate groups. There also was no difference in the
occurrence of delirium between the 2 groups. Associations were found
between age and increased neurofilament light chain levels. Female sex,
oxygen delivery >330 mL/min/m2, and near-infrared spectroscopy
level >60% were associated with lower biomarker levels.
 Conclusion(s): An increased flow rate did not have any significant
effects on biomarker levels compared to a standard flow rate. Several
associations were identified between treatment characteristics and
biomarker levels. No difference in delirium was seen. Copyright ©
2024 The Author(s)

<55>
Accession Number
644837305
Title
Impact of Small Aortic Annuli on the Performance of Transcatheter Aortic
Valve Replacement Bioprostheses: An Updated Meta-analysis of Recent
Studies.
Source
The American journal of cardiology. (no pagination), 2024. Date of
Publication: 23 Jul 2024.
Author
Pietro G.D.; Improta R.; Bruno F.; De Filippo O.; Leone P.P.; Nebiolo M.;
Giacobbe F.; Caporusso D.; Birtolo L.I.; Ielasi A.; Mohamed A.-W.; Ho
K.W.; Meguro K.; Ferrara J.; Waksman R.; Pilgrims T.; McKay R.G.; Seiffert
M.; Massimo M.; De Ferrari G.M.; D'Ascenzo F.
Institution
(Pietro, Improta) Department of Clinical, Internal, Anesthesiology and
Cardiovascular Sciences, Umberto I Hospital, Sapienza University of Rome,
Italy; Division of Cardiology, Cardiovascular and Thoracic Department,
"Citta della Salute e della Scienza" Hospital, Turin, Italy
(Bruno, De Filippo, Nebiolo, Giacobbe, De Ferrari, D'Ascenzo) Division of
Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e
della Scienza" Hospital, Turin, Italy
(Leone) Department of Biomedical Sciences, Humanitas University, Pieve
Emanuele-Milan,Italy; Cardio Center, IRCCS Humanitas Research Hospital,
Rozzano-Milan,Italy; The Zena and Michael A. Wiener Cardiovascular
Institute, Icahn School of Medicine at Mount Sinai, New York, New York,
United States
(Caporusso) Gefaschirurgie, Klinikum Munchen West, Germany
(Birtolo, Massimo) Department of Clinical, Internal, Anesthesiology and
Cardiovascular Sciences, Umberto I Hospital, Sapienza University of Rome,
Italy
(Ielasi) UO Cardiologia Ospedaliera IRCCS Ospedale Galeazzi Sant'Ambrogio,
Milano, Italy
(Mohamed) Heart Center, Segeberger Kliniken, Germany
(Ho) Department of Cardiology, National Heart Center, Singapore
(Meguro) Department of Cardiovascular Medicine, Kitasato University,
1-15-1 Kitasato ,Minami-ku ,Sagamihara, Japan
(Ferrara) Department de Cardiologie, CHU Timone, Marseille, France
(Waksman) Section of Interventional Cardiology, MedStar Washington
Hospital Center, Washington, District of Columbia
(Pilgrims) Department of Cardiology, Inselspital, University of Bern,
Bern, Switzerland
(McKay) Department of Cardiology, Hartford Healthcare Heart and Vascular
Institute, Hartford Hospital, Hartford, CT, United States
(Seiffert) Department of Cardiology, University Heart and Vascular Center
Hamburg, Hamburg, Germany
Abstract
A metanalysis of available randomized controlled trials and observational
studies comparing self-expanding and balloon-expandable bioprostheses in
patients with small aortic annulus and aortic stenosis for short and
midterm hemodynamic and clinical outcomes was performed. 21 studies with a
total 8647 patients (self-expanding, n=4,336 patients vs
balloon-expandable, n= 4,311 patients) were included. Self-expanding
bioprostheses had a lower post-operative mean gradient at 30 days (MD
-5.16, 95%CI 4.7-5.5, p value <0.001) and at one year (MD -6.6, 95%CI
6.1-7.03, p value <0.001), with a larger indexed Effective Orifice Area
(0.17, 95%CI 0.13-0.22, p value <0.001and 0.17, 95%CI 0.08-0.27, p value <
0.001) at both time intervals. Balloon-expandable bioprostheses had a
higher risk of 30-day and 1-year severe prosthesis-patient mismatch (RR
1.07, 95%CI 1.04-1.09, p value < 0.001; RR 1.07, 95%CI 1.04-1.11, p value
<0.001). 30-day and 1 year paravalvular leaks (RR 0.99, 95%CI 0.98-0.99, p
value < 0.001; RR 0.89, 95%CI 0.82-0.95, p value <0.001) and permanent
pacemaker implantation (RR 0.97, 95%CI .94-0.99, p value 0.01, I2= 40%,)
were lower in balloon-expandable group. Balloon-expandable bioprostheses
were associated with lower risk of in-hospital stroke (RR 0.99, 95%CI
0.98-1,p value= 0.01). In conclusion, in patients with small aortic
annulus and aortic stenosis, SE bioprostheses have superior haemodynamic
performance but higher rates of PVL, PPI and in-hospital stroke. BE
bioprostheses were associated with a higher risk of severe
PPM. Copyright © 2024. Published by Elsevier Inc.

<56>
Accession Number
644836730
Title
Effects of telephone nursing education and counselling on discharge
satisfaction level and self-care strength of patients after coronary
artery bypass grafting.
Source
ANZ journal of surgery. (no pagination), 2024. Date of Publication: 25
Jul 2024.
Author
Ilgin V.E.; Oral S.E.; Gurkan Z.; Ozer N.
Institution
(Ilgin, Ozer) Faculty of Nursing, Department of Surgical Nursing, Ataturk
University, Erzurum, Turkey
(Oral) Faculty of Nursing, Department of Surgical Nursing, Kars
University, Kars, Turkey
(Gurkan) Faculty of Health Sciences, Department of Surgical Nursing,
Yuzuncu Yil University, Van, Turkey
Abstract
BACKGROUND: The aim of this study was to determine the effects of nursing
education and counselling provided by telephone to individuals undergoing
coronary artery bypass graft surgery on their discharge satisfaction
levels and self-care power levels. METHOD(S): The study was conducted
using a randomized controlled experimental research model with a
pre-test-post-test control group (30 individuals in the experiment group
and 30 individuals in the control group). Routine nursing care was applied
to the patients in the control group throughout their attendance, and no
training or intervention was made after discharge. By contrast, in
addition to routine nursing care, the for 4weeks in the experimental group
received nursing education and counselling services by phone in the
post-discharge period. A 'Personal Information Form,' 'Discharge Training
Satisfaction Scale,' and 'Self-Care Strength Scale,' which were prepared
by the researchers and included the personal information of the patients,
were used to collect the data. RESULT(S): The difference between the
pre-test self-care power scale and discharge education satisfaction scale
sub-dimensions of the groups and the mean score of the total score was not
statistically significant. The post-test self-care power scale and
discharge education satisfaction scale sub-dimensions and total score
averages of the patients in the experimental group were higher than in the
control group, and the difference between them was statistically
significant (P<0.05). CONCLUSION(S): The nursing education and
counselling services given to the patients on the phone increased their
self-care skill levels and discharge satisfaction levels. Copyright
© 2024 Royal Australasian College of Surgeons.

<57>
Accession Number
644836114
Title
Contemporary Incidence of Cognitive Impairment or Dementia in Patients
undergoing Coronary Artery Bypass Grafting: A Systematic Review and
Meta-analysis.
Source
Dementia and geriatric cognitive disorders. (no pagination), 2024. Date
of Publication: 24 Jul 2024.
Author
Lo H.Z.; Wee C.F.; Low C.E.; Teo Y.H.; Teo Y.N.; Yun C.Y.; Syn N.L.; Tan
B.Y.; Chai P.; Yeo L.L.; Yeo T.-C.; Chong Y.F.; Poh K.-K.; Kong W.K.; Wong
R.C.; Chan M.Y.; Sia C.-H.
Abstract
INTRODUCTION: Despite the high prevalence of cognitive impairment or
dementia post coronary artery bypass grafting (CABG), the incidence of
cognitive impairment or dementia post-CABG in contemporary practice is
currently unclear. Therefore, this paper aims to investigate the incidence
and associated risk factors of cognitive impairment or dementia in
patients post-CABG. METHOD(S): A systematic search across three
databases (PubMed, SCOPUS and Embase) was conducted for studies published
in or after 2013 that reported cognitive impairment or dementia post-CABG.
Subgroup analyses and meta-regression by risk factors were performed to
determine their influence on the results. RESULT(S): This analysis
included 23 studies with a total of 2620 patients. The incidence of
cognitive impairment or dementia less than one month, two to six months,
and more than twelve months post-CABG was 35.96% (95%CI: 28.22-44.51,
I2=87%), 21.33% (95%CI: 13.44-32.15, I2=88%) and 39.13% (95%CI:
21.72-58.84, I2=84%), respectively. Meta-regression revealed that studies
with more than 80% of the cohort diagnosed with hypertension were
significantly associated with incidence of cognitive impairment or
dementia less than one-month post-CABG. CONCLUSION(S): This
meta-analysis demonstrates a high incidence of cognitive impairment or
dementia in patients post-CABG in contemporary practice, particularly less
than one month post-CABG. We found that hypertension was a significant
risk factor in the short term (less than one month) follow-up period for
cognitive impairment or dementia post-CABG. Future research should be done
to assess strategies to reduce cognitive impairment post-CABG.
. Copyright The Author(s). Published by S. Karger AG, Basel.

<58>
Accession Number
644834415
Title
Cerebral embolic protection for stroke prevention during transcatheter
aortic valve replacement.
Source
Expert review of cardiovascular therapy. (no pagination), 2024. Date of
Publication: 26 Jul 2024.
Author
Basit J.; Ahmed M.; Kidess G.; Zaheer Z.; Fatima L.; Naveed H.; Hamza M.;
Fatima M.; Goyal A.; Loyalka P.; Alam M.; Alraies M.C.
Institution
(Basit, Ahmed) Department of Medicine, Rawalpindi Medical University,
Rawalpindi, Pakistan
(Kidess) Wayne State University, MI, United States
(Zaheer, Fatima) Department of Medicine, King Edward Medical University,
Lahore, Pakistan
(Fatima) Department of Medicine, Allama Iqbal Medical College, Lahore,
Pakistan
(Naveed) University of Houston/HCA kingwood Hospital, TX, United States
(Hamza) Guthrie Medical Group, Cortland, NY, United States
(Goyal) Department of Internal Medicine, Seth GS Medical College and KEM
Hospital, Mumbai, India
(Loyalka) Department of cardiology, HCA medical Center, Houston, TX,
United States
(Alam) Baylor College of Medicine, Houston, TX, United States
(Alraies) Detroit Medical Center, Cardiovascular institute, MI, United
States
Abstract
INTRODUCTION: Cerebral Embolic Protection Device (CEPD) captures emboli
during Transcatheter Aortic Valve Replacement (TAVR). With recently
published pivotal trials and multiple cohort studies reporting new data,
there is a need to re-calibrate available statistical evidence.
 METHOD(S): A systematic literature search was conducted across
databases from inception till February 2023. Dichotomous outcomes were
pooled using Odds Ratio (OR), while continuous outcomes were pooled using
Standardized Mean Difference (SMD) along with 95% corresponding intervals
(95% CIs). RESULT(S): Data was included from 17 studies (7 RCTs, 10
cohorts, n=155,829). Use of CEPD was associated with significantly reduced
odds of stroke (OR=0.60, 95% CI=0.43-0.85, p=0.003). There was no
significant difference in disabling stroke (p=0.25), non-disabling stroke
(p=0.72), and 30-day mortality (p=0.10) between the two groups. There were
no significant differences between the two groups for Diffusion-Weighted
Magnetic Resonance Imaging (DW-MRI) findings, acute kidney injury, risk of
pacemaker implantation life-threatening bleed, major bleed, minor bleed,
worsening National Institute of Health Stroke Scale (NIHSS), modified
Rankin Scale (mRS) and vascular complications (p>0.05).
 CONCLUSION(S): The use of CEPD during TAVR reduced the incidence of
all-stroke (p=0.003); however, there were no significant differences in
any of the other pooled outcomes (p>0.05). REGISTRATION: The protocol of
this meta-analysis was registered with the Open Science framework
[https://doi.org/10.17605/OSF.IO/7W564] before data acquisition was
started.

<59>
Accession Number
644834308
Title
Coronary bypass surgery for multivessel disease after percutaneous
coronary intervention in acute coronary syndromes: why, for whom, how
early?.
Source
European heart journal. (no pagination), 2024. Date of Publication: 26
Jul 2024.
Author
Besola L.; Colli A.; De Caterina R.
Institution
(Besola, Colli) Cardiac Surgery Division, Pisa University Hospital and
Department of Surgical, Medical and Molecular Pathology and Critical Care,
University of Pisa, Via Paradisa 2, Pisa 56124, Italy
(De Caterina) Cardiology Division, Pisa University Hospital and Department
of Surgical, Medical and Molecular Pathology and Critical Care, University
of Pisa, Via Paradisa 2, Pisa 56124, Italy
Abstract
Multivessel coronary artery disease is present in ~50% of patients with
acute coronary syndrome and, compared with single-vessel disease, entails
a higher risk of new ischaemic events and a worse prognosis. Randomized
controlled trials have shown the superiority of 'complete
revascularization' over culprit lesion-only treatment. Trials, however,
only included patients treated with percutaneous coronary intervention
(PCI), and evidence regarding complete revascularization with coronary
artery bypass graft (CABG) surgery after culprit lesion-only PCI ('hybrid
revascularization') is lacking. The CABG after PCI is an open,
non-negligible therapeutic option, for patients with non-culprit left main
and/or left anterior descending coronary artery disease where evidence in
chronic coronary syndrome patients points in several cases to a preference
of CABG over PCI. This valuable but poorly studied 'PCI first-CABG later'
option presents, however, relevant challenges, mostly in the need of
interrupting post-stenting dual antiplatelet therapy (DAPT) for surgery to
prevent excess bleeding. Depending on patients' clinical characteristics
and coronary anatomical features, either deferring surgery after a safe
interruption of DAPT or bridging DAPT interruption with intravenous
short-acting antithrombotic agents appears to be a suitable option.
Off-pump minimally invasive surgical revascularization, associated with
less operative bleeding than open-chest surgery, may be an adjunctive
strategy when revascularization cannot be safely deferred and DAPT is not
interrupted. Here, the rationale, patient selection, optimal timing, and
adjunctive strategies are reviewed for an ideal approach to hybrid
revascularization in post-acute coronary syndrome patients to support
physicians' choices in a case-by-case patient-tailored
approach. Copyright © The Author(s) 2024. Published by Oxford
University Press on behalf of the European Society of Cardiology. All
rights reserved. For commercial re-use, please contact reprints@oup.com
for reprints and translation rights for reprints. All other permissions
can be obtained through our RightsLink service via the Permissions link on
the article page on our site-for further information please contact

<60>
Accession Number
644830324
Title
Post-operative pain relief in thoracic surgery: Paravertebral vs.
intercostal nerve blocks.
Source
Asian journal of surgery. (no pagination), 2024. Date of Publication: 23
Jul 2024.
Author
Gong H.; Huang X.; Liu L.; Wu J.; Wang M.
Institution
(Gong, Wu, Wang) Department of Anesthesiology, Affiliated Hospital,
Southwest Medical University, Sichuan Province, China
(Huang) Department of Anesthesiology, Affiliated Hospital, Southwest
Medical University, Sichuan Province, China
(Liu) Department of Anesthesiology, Affiliated Hospital, Southwest Medical
University, Sichuan Province, China

<61>
Accession Number
2032793584
Title
Factors Associated With Coronary Angiography Performed Within 6 Months of
Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Source
Circulation: Cardiovascular Interventions. 17(6) (pp 457-473), 2024. Date
of Publication: 01 Jun 2024.
Author
Spertus J.A.; Broderick S.; Rockhold F.W.; Demchenko E.; Grossman G.B.;
Stone G.W.; Mancini G.B.J.; Hochman J.S.; Boden W.E.; Mavromatis K.; Doan
J.; Linefsky J.; Lee R.; Patel R.; Miller T.; Cho S.Y.; Milbrandt S.;
Shelstad D.; Banerjee S.; Kamath P.; Tejani I.; Reynolds H.R.; Newman
J.D.; Bangalore S.; Phillips L.M.; Saric M.; Abdul-Nour K.; Schley A.;
Golden H.; Stone P.H.; Osseni H.; Wiyarand C.; Douglass P.; Pomeroy H.;
Craft A.; Harvey B.; Jang J.J.; Anaya O.; Yee G.; Goold P.; Weitz S.;
Giovannone S.; Pritchard L.; Arnold S.; Gans R.; O'Keefe J.H.; Kennedy P.;
Shapiro M.D.; Ganesan S.; Schlichting D.; Naher A.; Fein S.A.; Stewart
W.L.; Torosoff M.T.; Salmi K.M.; Lyubarova R.; Mookherjee S.; Drzymalski
K.; McFalls E.O.; Garcia S.A.; Bertog S.C.; Johnson D.K.; Siddiqui R.A.;
Herrmann R.R.; Ishani A.; Hansen R.A.; Khouri M.G.; Arges K.; LeFevre M.;
Tomfohr J.; Goldberg J.L.; Byrne K.A.; Zappernick T.; Goldweit R.; Canada
S.; Kakade M.; Mieses P.; Cohen R.A.; Mirrer B.; Navarro V.; Rantinella
M.; Rodriguez J.; Mancilla O.; Winchester D.E.; Stinson S.; Kronenberg M.;
Weyand T.; Crook S.C.; Heitner J.F.; Ho J.; Khan S.; Mohamed M.; Dauber
I.M.; Soltau M.R.; Rose D.K.; Wimmer R.J.; Siegel K.E.; Derbyshire S.;
Cannan C.; Dixon M.; Leonard G.; Sudarshan S.; Heard C.; Gabriel V.;
Desire S.; Mehta P.K.; McDaniel M.; Rashid F.; Lerakis S.; Asier S.;
Quyyumi A.; Patel K.; Wenger N.K.; Hedgepeth C.M.; Gillis J.; Hurlburt H.;
Manocchia M.; Rosen A.; Moore S.; Congdon E.; Sahul Z.; Brandt G.;
Marchelletta N.; Wippler K.; Leung S.; Reda H.; Ziada K.; Setty S.;
Halverson K.E.; Roraff C.; Thorsen J.; Barua R.S.; Ojajuni A.; Olurinde
O.; Surineni K.; Hage F.; Valaiyapathi B.; Davies J.E.; Leesar M.; Heo J.;
Iskandrian A.; Al Solaiman F.; Dajani K.; Kartje C.M.; El-Hajjar M.;
Mesropian P.D.; Sacco J.; Rawlins M.; McCandless B.; Thomson J.; Orgera
M.; Sidhu M.S.; Rogge M.C.; Arif I.; Bunke J.; Kerr H.; Unterbrink K.;
Fannon J.; Burman C.; Trejo J.F.; Dubin M.F.; Fletcher G.; Lane G.E.;
Neeson L.M.; Parikh P.P.; Pollak P.M.; Shapiro B.P.; Landolfo K.;
Gemignani A.; Beaudry S.; O'Rourke D.; Meadows J.L.; Tirado S.A.; Halliday
J.; Julian P.; Call J.T.; Lane S.M.; Stanford J.L.; Hannan J.; Bojar R.;
Arsenault P.; Kumar D.; Sigel P.; Mukai J.; Martin E.T.; Brooks M.;
Vorobiof G.; Douangvila L.; Gevorgyan R.; Moor-Man A.; Ranjbaran F.; Smith
B.; Ohmart C.; Kinlay S.; Hamburger R.J.; Rocco T.P.; Ly S.; Bhatt D.L.;
Quinn M.C.; Croce K.; Temiyasathit S.; Quin J.A.; Do J.; Anumpa J.; Tobin
D.; Zenati M.; Faxon D.P.; Rayos G.; Langdon J.; Bayer M.W.; Seedhom A.;
O'Malley A.; Sullenberger L.; Orvis E.; Kumkumian G.; Murphy M.; Greenberg
A.; Iraola M.; Sedlis S.P.; Maranan L.C.; Donnino R.M.; Lorin J.;
Tamis-Holland J.E.; Malinay A.; Kornberg R.; Leber R.; Saba S.; Edillo
C.P.; Lee M.W.; Small D.R.; Nona W.; Alexander P.B.; Rehman I.; Badami U.;
Ostrander A.; Wasmiller S.; Marzo K.; Drewes W.; Patel D.; Robbins I.H.;
Levite H.A.; White J.M.; Shetty S.; Hallam A.; Patel M.; Hamroff G.S.;
Spooner B.J.; Hollenweger L.M.; Little R.W.; Little H.; Zimbelman B.D.;
Little T.; Lui C.Y.; Eskelson N.A.; Smith B.R.; Vezina D.P.; Khor L.L.;
Abraham J.D.; Bull D.A.; McKellar S.H.; Booth D.; Taul Y.; Kotter J.;
Rodgers C.; Abdel-Latif A.; Isaacs J.; Bulkley V.; Hu B.; Kaneshiro R.;
Labovitz A.J.; Berlowitz M.; Kirby B.J.; Rogal P.; Tran N.N.; McFarren C.;
Jahrsdorfer C.; Matar F.; Caldeira C.; Maron D.J.; Rodriguez F.; Yunis R.;
Schnittger I.; Patro J.; Fearon W.F.; Deedwania P.; Vega A.; Reddy K.;
Sweeny J.; Bloise-Adames H.; Jimenez S.; Vrestil N.S.; Bhandari R.;
Spizzieri C.; Schade D.; Yost R.; Hochberg C.P.; Beardsley P.; Fine D.;
Salerno W.D.; Tancredi J.; Arakelian P.; Mathus S.; O'Neill D.; Wyman R.;
Burkhardt J.; Hosino S.; Lubyanaya O.A.; Salas J.D.; Zarka A.; Aguirre M.;
Shah A.V.; Dhawan M.; Parra D.; Tran T.; Haldis T.; Fowler-Lehman K.;
Spitzer N.; Riedberger C.; Weick C.; Kohn J.A.; Girotra S.; Drum C.;
Miller-Cox K.; Ollinger A.; Almousalli O.; Capasso-Gulve E.; Loehr A.M.;
Mosley M.; Krishnam M.S.; Heydari S.; Mil-Liken J.C.; Lundeen A.M.; Patel
P.M.; Karanjah E.; Seto A.H.; Marfori W.C.; Harley K.T.; Hernandez-Rangel
E.; Gibson M.A.; Singh P.; Allen B.J.; Coram R.; Webb A.M.; Fridell E.;
Wilson H.; Thomas S.; Kim A.; Schwartz R.G.; Wilmot P.; Chen W.; El
Shahawy M.; Stevens R.; Stafford J.; Black L.; Abernethy W.B.; Hull A.B.;
Lim O.J.; Tucker H.C.; Putnam N.C.; Hall L.L.; Cauthren T.; Tucker T.;
Zurick A.; Horton H.; Orga J.; Meyer T.M.; White J.R.; Morford R.G.;
Baumann C.; Rutkin B.; Seeratan V.; Bokhari S.; Jimenez M.; Sokol S.I.;
Schultz C.; Meisner J.; Russo J.; Hamzeh I.; Misra A.; Huda Z.; Wall M.;
Boan A.; De Rosen V.L.; Alam M.; Turner M.C.; Hinton C.R.; Mulhearn T.J.;
Good A.P.; Archer B.A.; Dionne J.S.; Allardyce C.A.; Sikora L.N.; Czerniak
J.H.; Mull J.A.; Ferguson E.; Laube F.; Shammas N.W.; Shammas G.A.;
Christensen L.; Park H.; Chilton R.; Hecht J.; Nguyen P.K.; Vo D.; Hirsch
J.; Jezior M.; Bindeman J.; Salkind S.; Desimone L.-A.; Gordon P.C.;
Felix-Stern L.; Crain T.; Gomes J.; Gordon C.; Stenberg R.; Mann A.;
McCreary T.; Pedalino R.P.; Cobos S.E.; Dwyer R.R.; Espinosa D.; Quiles
K.J.; Wiesel J.; Juang G.J.; Gopaul C.; Hultberg K.; Huk T.; Hussain A.;
Al-Amoodi M.; Zambrano Y.; Rodriguez S.M.; Milner T.; Wohns D.; Mulder A.;
Van Oosterhout S.; Lader E.W.; Meyer M.; Mumma M.; Clapp N.L.; Barrentine
H.; Dharmarajan L.; Jose J.M.; Manchery J.; McGarvey J.F.X.; McKinney V.;
Schwarz L.; Downes T.R.; Kaczkowski S.M.; Luckasen G.J.; Jaskowiak A.J.;
Klitch J.; Cheong B.; Dees D.; Potluri S.; Vasquez P.; Mastouri R.A.;
Breall J.A.; Hannemann E.L.; Revtyak G.E.; Foltz J.M.; Bazeley J.W.;
DeRosa E.; Jorgenson B.; Riestenberg-Smith J.; Giedd K.; Old W.; Bariciano
R.; Burt F.; Sokhon K.; Waldron J.; Mayon M.; Gopal D.; Valeti U.S.;
Peichel G.A.; Kobashigawa J.; Starks B.; Garcia L.; Thottam M.; Anand A.;
Govindan S.C.; Raj J.; Nair R.G.; Ravindran R.; Rajalekshmi V.S.;
Manjunath C.N.; Nataraj N.; Moorthy N.; Nayak S.; Manjunath S.C.;
Mylarappa M.; Narayanappa S.; Pandit N.; Bajaj S.; Nath R.K.; Yadav V.;
Mishra G.; Dwivedi S.K.; Tewari R.; Narain V.S.; Mishra M.; Chandra S.;
Patel S.; Wander G.S.; Tandon R.; Ralhan S.; Kaur B.; Aslam N.; Gupta S.;
Pharmacy B.; Goyal A.; Bhargava B.; Suvarna C.; Karthikeyan G.;
Ramakrishnan S.; Seth S.; Yadav R.; Singh S.; Roy A.; Parakh N.; Verma
S.K.; Narang R.; Mishra S.; Naik N.; Sharma G.; Choudhary S.K.; Patel C.;
Gulati G.; Sharma S.; Bahl V.K.; Mathew A.; Kurian B.M.; Punnoose E.;
Gadkari M.A.; Karwa S.R.; Gadage S.; Kolhe S.; Pillay T.U.; Satheesh S.;
Vindhya R.J.; Jain P.; Seth A.; Meharwal Z.S.; Mathur A.; Verma A.; Bhatia
M.; Sachdeva A.; Devi T.I.; Jungla N.; Rani K.M.; Menon R.; Reddy M.S.;
Oomman A.; Sidh R.R.; Mao R.; Ramakrishnan T.; Solomon H.; Francis R.;
Priya V.P.; Khan S.P.; Preethi K.; Kumar N.; Grant P.; Hande S.; Sonawane
P.; Kachru R.; Dubey A.; Rawat K.; Kumar A.V.K.; Ganapathi S.; Jayakumar
K.; Vineeth C.P.; Sivadasanpillai H.; Chacko M.; Sasidharan B.; Babu S.;
Kapilamoorthy T.R.; Christopher J.; Reddy S.; Polamuri P.; Rani M.; Kaul
U.; Arambam P.; Singh B.; Senior R.; Fox K.A.A.; Carruthers K.; Elghamaz
A.; Gurunathan S.; Karogiannis N.; Young G.M.; Shah B.N.; Kinsey C.;
Trimlett R.H.J.; Kavalakkat R.; Rubens M.B.; Evans J.; Nicol E.D.; Hassan
I.; Mittal T.K.; Hampson R.; Gamma R.A.; Williams S.; Holland K.; Swan K.;
de Belder M.A.; Atkinson B.; Thambyrajah J.; Nageh T.; Kunhunny S.; Davies
J.R.; Lindsay S.J.; Atkinson C.; Kurian J.; Krannila C.; Jamil H.; Vinod
M.; Raheem O.; Hoye A.; Chaytor L.; Cox L.; Morrow J.; Rowe K.; Donnelly
P.; Kelly S.; Valecka B.; Regan S.; Turnbull D.; Chauhan A.; Fleming C.;
Ghosh A.; Gratrix K.; Preston S.; Barr C.; Cartwright A.; Alfakih K.;
Knighton A.; Byrne J.; Martin K.; Webb I.; Henriksen P.; Flint L.;
Harrison J.; OKane P.; Lake-Man N.; Ljubez A.; de Silva R.; Conway D.S.G.;
Wright J.; Exley D.; Sirker A.A.; Andiapen M.; Richards A.J.; Hoole S.P.;
Wong L.; Witherow F.N.; Munro M.J.; Harbinson M.; McEvoy M.; Walsh S.; Bao
B.; Brown C.; Douglas H.; Luckie M.; Charles T.; Kolakaluri L.; Phillips
H.; Sobolewska J.; Morby L.; Hallett K.; Corbett C.; Winstanley L.;
Jeetley P.; Smit A.; Patel N.; Kotecha T.; Travill C.; Gent S.; Karimullah
I.; Hussain N.; Al-Bustami M.; Braganza D.; Haines F.; Taaffe J.;
Henderson R.; Burton J.; Pointon K.; Colton M.; Naik S.; King R.; Mathew
T.; Brown A.; Docherty A.; Berry C.; McCloy L.; Collison D.; Robb K.;
Roditi G.; Paterson C.; Crawford W.; Kelly J.; McGregor L.; Moriarty A.J.;
Mackin A.; Glover J.D.; Knight J.P.; Pradhan J.; Mikhail G.; Bose T.;
Francis D.P.; Dzavik V.; Proietti A.; Brousseau M.; Corfias M.; Blaise P.;
Harvey L.; Diaz A.; Rheault P.; Barrero M.; Gagne C.-E.; Alarie P.;
Pepin-Dubois Y.; Arcand L.; Costa R.; Roy I.; Sia Y.T.; Montpetit E.;
Lemay C.; Gisbert A.; Gervais P.; Rheault A.; Drouin K.; Phaneuf D.C.;
Bergeron C.; Gosselin G.; Shelley C.; Masson C.; Garg P.; Carr S.; Bone
C.; Chow B.J.W.; Moga E.; Hessian R.C.; Kourzenkova J.; Beanlands R.S.;
Walter O.; Davies R.F.; Bainey K.R.; Hogg N.; Welsh S.; Bagai A.; Wald R.;
Goodman S.; Graham J.J.; Peterson M.; Bello O.; Chow C.-M.; Abramson B.;
Cheema A.N.; Syed I.; Vakani M.T.; Hussain M.; Kushniriuk K.; Cha J.; Otis
J.; Otis R.; Howarth A.G.; Seib M.M.; Rivest S.M.; Sandonato R.; Chow J.;
Starovoytov A.; Uchida N.; Meadows N.; Uxa A.; Asif N.; Tavares S.;
Galiwango P.; Bozek B.; Kassam S.; Shier M.; Mukherjee A.; Larmand L.-A.;
Ricci A.J.; Janmohamed A.; Hart B.; Lam A.; Marucci J.; Tai S.; Mehta S.;
Brons S.; Beck C.; Wong G.; Etherington K.; Arumairajah T.; Udell J.;
Aprile M.; Karlsson S.; Webber S.; Genereux P.; Mercure C.; Hameed A.;
Aedy N.; Daba L.; Farquharson F.; Siddiqui A.; Lopes R.D.; Hueb W.;
Takiuti M.E.; Rezende P.C.; Silva E.E.R.; Hueb A.C.; Smanio P.E.P.;
Caetano L.P.; de Quadros A.S.; Kalil R.A.K.; Deiro A.P.; da Costa Vieira
J.L.; Muller A.M.; Grossmann G.; de Moraes M.A.P.; de Oliveira P.P.;
Ascoli B.M.; Bridi L.; Poletti S.Z.; Savaris S.; Vitola J.V.; Cerci R.J.;
Zier S.S.; Farias F.R.; Veiga V.; Fernandes M.M.; Marin-Neto J.A.; Schmidt
A.; de Oliveira Lima Filho M.; da Cunha D.F.; Oliveira R.M.; Chierice
J.R.A.; Polanczyk C.A.; Rucatti G.G.; Furtado M.V.; Igansi F.; Smidt L.F.;
Haeffner M.P.; Carvalho A.C.; Almeida V.; Pucci G.; de Souza G.S.; Lyra
F.; Alves A.R.; Almeida M.; dos Santos V.; Dracoulakis M.D.A.; Oliveira
N.S.; Lima R.G.S.D.; Figueiredo E.; Azevedo B.E.P.; Caramori P.R.; Santos
M.B.; Germann A.; Gomes V.; Homem R.; Magedanz E.; Tumelero R.; Laimer R.;
Tognon A.; Dall'Orto F.; Mesquita C.T.; Santos R.P.; Colafranseschi A.S.;
Oliveira A.C.; Carvalho L.A.; Palazzo I.C.; Sousa A.S.; da Silva E.E.R.;
de Barros e Silva P.G.M.; Okada M.Y.; de Padua Silva Baptista L.; Batista
A.P.; Rodrigues M.J.; Rabaca A.N.; de Resende M.V.C.; Saraiva J.F.; Trama
L.M.; de Souza Ormundo C.T.; Vicente C.; Costantini C.; Pinheiro C.; Komar
D.; Ruzyllo W.; Demkow M.; Pracon R.; Kepka C.; Teresinska A.; Walesiak
O.; Kryczka K.; Malinowska K.; Henzel J.; Solecki M.; Kaczmarska E.;
Mazurek T.; Maksym J.; Wojtera K.; Fojt A.; Szczerba E.; Drozdz J.;
Czarniak B.; Frach M.; Szymczyk K.; Niedzwiecka I.; Sobczak S.; Ciurus T.;
Jakubowski P.; Misztal-Teodorczyk M.; Teodorczyk D.; Swiderek M.; Fratczak
A.; Wojtala E.; Szkopiak M.; Lebioda P.; Wlodarczyk M.; Plachcinska A.;
Kusmierek J.; Miller M.; Marciniak H.; Wojtczak-Soska K.; Luczak K.;
Tarchalski T.; Cichocka-Radwan A.; Szwed H.; Karwowski J.; Szulczyk G.A.;
Witkowski A.; Kukula K.; Celinska-Spodar M.; Zalewska J.; Gajos G.; Bury
K.; Pruszczyk P.; Labyk A.; Roik M.; Szramowska A.; Zdonczyk O.;
Loboz-Grudzien K.; Jaroch J.; Sokalski L.; Brzezinska B.; Lesiak M.;
Lanocha M.; Reczuch K.W.; Kolodziej A.; Kalarus Z.; Swiatkowski A.; Szulik
M.; Musial W.J.; Marcinkiewicz-Siemion M.; Bockeria O.; Bockeria L.;
Petrosyan K.; Kudzoeva Z.; Trifonova T.; Aripova N.; Chernyavskiy A.M.;
Naryshkin I.A.; Kretov E.I.; Kuleshova A.; Grazhdankin I.O.; Malaev D.;
Bershtein L.L.; Sayganov S.A.; Subbotina I.; Kuzmina-Krutetskaya A.M.;
Gumerova V.; Zbyshevskaya E.V.; Katamadze N.O.; Demchenko E.A.; Nikolaeva
O.B.; Kozlov P.S.; Kozulin V.Y.; Lubinskaya E.I.; Lopez-Sendon J.L.;
Lopez-Sendon J.; Fernandez-Figares V.; Castro A.; Salicio E.R.; Guzman G.;
Galeote G.; Valbuena S.; Peteiro J.; Martinez-Ruiz M.D.; Perez-Fernandez
R.; Blanco-Calvo M.; Cuenca-Castillo J.J.; Alonso-Alvarez E.; Flores-Rios
X.; Garcia-Gonzalez P.; Prada-Delgado O.; Barge-Caballero G.; Juanatey
J.R.G.; Amigo J.S.; Bayarri M.S.; Nunez V.P.; Sanchez R.O.; Alvarez B.C.;
Gil C.P.; Monzonis A.M.; Sionis A.; Martinez A.F.; Perales M.V.; Padro
J.M.; Penaranda A.S.; Picart J.G.; Iglesias A.G.; Marimon X.G.-M.; Llado
G.P.; Costa F.C.; Miro V.; Igual B.; Diez J.L.; Calvillo P.; Ortuno F.M.;
Chavarri M.V.; Giner M.Q.; Montolliu A.T.; Aniorte A.I.R.; Bermudez E.P.;
Caravaca J.M.R.; De La Morena G.; Blancas M.G.; Canavate O.; Guerrero S.;
Riera S.; Luena J.E.C.; Lasala M.; Fernandez-Aviles F.; Lorenzo M.;
Sobrino O.; Vazquez A.; Jiang L.; Chen J.; Dong H.; He P.; Xia C.; Yang
J.; Zhong Q.; Wu Y.; Tian Y.; Li D.; Ma Y.; Yang Y.; Ma X.; Yu Z.; Zhao
Q.; Ji Z.; Li C.; Zhu B.; Yang X.; Chen M.; Chi H.; Zhang J.; Lin W.; Jing
R.; Liu J.; Zeng H.; Zhou Q.; Xu C.; Li Z.; Xiong L.; Fu X.; Gao D.; Jiang
D.; Leng R.; Yuan Q.; Zhang L.; Bai Z.; Li J.; Qi J.; Wang F.; Wang H.;
Yang B.; Yue Z.; Zhang Z.; Wang S.; Dong Y.; Mao J.; Zhang B.; Cheng G.;
Li X.; Yao X.; Zhong N.; Zhou N.; Huang Y.; Zhou P.; Fang X.; Su W.; Zeng
Q.; Kunwu Y.; Peng Y.; Su X.; Wang C.; Zhao Y.; Li Q.; Geng Y.; Wang Y.;
Nie S.-P.; Fan J.-Y.; Feng S.-T.; Wang X.; Yan Y.; Zhang H.-M.; Yu Q.; Chi
L.; Liu F.; Chen H.; Jiang J.; Li H.; Wang J.; Han Y.; Xu L.; Zhang S.;
Liu Z.; Chen G.; Hu R.; Perna G.P.; Pietrucci F.; Marini M.; Gabrielli G.;
Provasoli S.; Di Donato A.; Verna E.; Monti L.; Nardi B.; Di Chiara A.;
Pezzetta F.; Mortara A.; Casali V.; Galvani M.; Attanasio C.; Ottani F.;
Sicuro M.; Leone G.; Pisano F.; Bare C.; Calabro P.; Fimiani F.; Formisano
T.; Tarantini G.; Barioli A.; Cucchini U.; Ramani F.; Andres A.L.; Racca
E.; Rolfo F.; Goletto C.; Briguori C.; De Micco F.; Amati R.; Di Marco S.;
Vergoni W.; Tricoli M.; Russo A.; Villella M.; Fanelli R.; Poh K.-K.; Chai
P.; Lau T.; Loh J.P.; Tay E.L.; Teoh K.; Tan S.-Y.V.; Teo L.L.; Sia W.C.;
Ong C.-C.; Leong A.W.; Wong R.C.; Loh P.-H.; Kofidis T.; Chan W.X.; Chan
K.H.; Foo D.; Yan L.H.; Kong J.L.K.; Er C.M.; Jafary F.-H.H.; Chua T.;
Ismail N.; Kyaw M.T.; Yip D.; Doerr R.; Stumpf J.; Grahl D.; Matschke K.;
Guenther F.; Simonis G.; Bonin K.; Kadalie C.T.; Sechtem U.; Wenzelburger
I.; Ong P.; Gruensfelder S.; Schulze P.C.; Goebel B.; Lenk K.; Nickenig
G.; Sinning J.-M.; Weber M.; Werner N.; Schuchlenz H.; Steinmaurer G.;
Weikl S.; Lang I.M.; Winter M.-P.; Andric T.; Huber K.; Maximilian T.;
Gabriele J.-K.; Claudia W.; Bernhard J.; Florian E.; Keltai M.; Vertes A.;
Sebo J.; Davidovits Z.; Matics L.; Varga A.; Agoston G.; Fontos G.; Dekany
G.; Merkely B.; Bartykowszki A.; Maurovich-Horvat P.; Kerecsen G.; Jakal
A.; Hinic S.; Djokic J.; Zdravkovic M.; Mudrenovic V.; Crnokrak B.;
Beleslin B.D.; Boskovic N.N.; Djordjevic-Dikic A.D.; Petrovic M.T.; Giga
V.L.; Dobric M.R.; Stepanovic J.J.; Markovic Z.Z.; Mladenovic A.S.;
Cemerlic-Adjic N.; Velicki L.; Pupic L.; Davidovic G.; Simovic S.M.; Vucic
R.; Dekleva M.N.; Martinovic M.S.; Stevanovic G.; Stankovic G.; Dobric M.;
Apostolovic S.; Martinovic S.S.; Stanojevic D.; Escobedo J.; de
Jesus-Perez R.; Juarez B.; Baleon-Espinosa R.; Campos-Santaolalla A.S.;
Duran-Cortes E.; Flores-Palacios J.M.; Garcia-Rincon A.; Jimenez-Santos
M.; Penafiel J.V.; Ortega-Ramirez J.A.; Valdespino-Estrada A.; Rosas E.A.;
Brassetti M.F.C.; Anaya D.A.V.; Garcia M.P.; Juarez I.E.C.; Rovalo M.M.;
Rodriguez E.D.M.; Selvanayagam J.B.; Rankin J.; Murphy D.; Lee S.; Joseph
M.X.; Thomas P.; Thambar S.T.; Chaplin M.D.; Boer S.C.; Beltrame J.F.;
Stansborough J.K.; Black M.; Hillis G.S.; Bonner M.M.; Ireland K.F.;
Venn-Edmonds C.; Steg P.-G.; Thobois C.; Thuaire C.; Tachot E.; Dutoiu T.;
Laure C.; Vassaliere C.; Steg P.G.; Abergel H.; Juliard J.-M.; Fuentes A.;
Slama M.S.; Eliahou L.; Mahmoud R.E.; Dubourg O.; Michaud P.; Nicollet E.;
Hadjih S.; Goube P.; Brito P.; Barone-Rochette G.; Furber A.; Cornet C.;
Biere L.; Rautureau J.; Juceviciene A.; Kalibataite-Rutkauskiene I.;
Keinaite L.; Laucevicius A.; Laukyte M.; Celutkiene J.; Mikolaitiene G.;
Smigelskaite A.; Tamasauskiene I.; Urboniene A.; Kedhi E.; Timmer J.;
Bouwhuis I.; Hermanides R.; Nijmeijer L.; Kaplan E.; Riezebos R.K.; Samadi
P.; Schoep J.J.M.; van Dongen E.; Janzen E.M.; Niehe S.R.; Suryapranata
H.; Ahoud S.; van Vugt S.; Ramos R.; Cacela D.; Santana A.; Fiarresga A.;
Sousa L.; Marques H.; Patricio L.; Selas M.; Bernanrdes L.; Silva F.; Rio
P.; Freixo C.; Carvalho R.; Ferreira R.; Silva T.; Rodrigues I.; Modas P.;
Portugal G.; Fragata J.; Pinto F.J.; Cabrita I.Z.; Menezes M.N.; Rocha A.;
Lopes G.C.; Figueiras F.P.; Almeida A.G.; Coelho A.; Silva P.C.; Capinha
M.; Nobre A.; Caetano M.I.; Francisco A.R.; Silva S.; Ferreira N.; Lopes
R.L.; Diaz R.; Guzman L.; Tinnirello V.; Figal J.C.; Mungo M.N.; Mendiz
O.; Cortes C.; Favaloro R.R.; Alvarez C.; Garcia M.; Courtis J.; Godoy V.;
Zeballos G.; Schiavi L.; Actis M.V.; Rubio M.; Scaro G.; Devlin G.P.; Low
L.; Fisher R.; Scales J.; Abercrombie K.; Stewart R.A.H.; Howell L.;
Patten C.; Benatar J.; Kedev S.; Mitevska I.P.; Kostovska E.S.; Pejkov H.;
Held C.; Eggers K.; Frostfelt G.; Bjorklund C.; Johnston N.; Andreasson
M.; Olsowka M.; Essermark M.; Akerblom A.; Soveri I.; Aspberg J.; Persson
L.; Beyar R.; Nikolsky E.; Sharir T.; Harel O.; Elian D.; Kerner A.;
Bentzvi M.; Massalha S.; Helmer L.; Fukuda K.; Ueda I.; Kohsaka S.; Fujita
J.; Yasuda S.; Furukawa A.; Nagai T.; Otsuka F.; Nishimura S.; Nakano S.;
Goetschalckx K.; Robesyn V.; Van de Werf F.; Claes K.; Hung C.-L.; Yang
Y.-H.; Yun C.-H.; Hou C.J.-Y.; Kuo J.-Y.; Yeh H.-I.; Hung T.-C.; Li J.-Y.;
Chien C.-Y.; Tsai C.-T.; Liu C.-C.; Yu F.-C.; Lin Y.-H.; Lan W.-R.; Yen
C.-H.; Tsai J.-P.; Sung K.-T.; Ntsekhe M.; Pandie S.; Philander C.;
Viljoen C.A.; Mtana N.; De Andrade M.; Maggioni A.P.; Moccetti T.; Anesini
A.; Rossi M.G.; Maspoli S.; Mombelli M.; Abdelhamid M.; Talaat A.; Adel
A.; Kamal A.; Mahrous H.; El Kaffas S.; El Fishawy H.; Pop C.; Claudia M.;
Popescu B.A.; Ginghina C.; Rosca M.; Deleanu D.; Beladan C.C.; Iliescu
V.A.; Al-Mallah M.H.; Zahrani S.; Aljzeeri A.; Najm H.; Alghamdi A.; Ramos
W.E.M.; Davila M.A.M.; Kuanprasert S.; Prommintikul A.; Nawarawong W.;
Khwakhong S.; Woragidpoonpol S.; Chaiyasri A.; Tepsuwan T.; Mekara W.;
Taksaudom N.; Kulthawong S.; Rimsukcharoenchai C.; Amaritakomol A.;
Euathrongchit J.; Wannasopha Y.; Yamwong S.; Panpunuan P.; Sritara P.;
Aramcharoen S.; Meemuk K.; White H.D.; Alsweiler C.; Khairuddin A.;
Mokhtar N.S.; Hadi H.A.; Basri N.A.; Yahaya S.A.; Yusnida I.; Hashim H.;
Bugiardini R.
Institution
(Pracon, Ruzyllo) National Institute of Cardiology, Warsaw, Poland
(Spertus) Saint Luke's Mid America Heart Institute, University of
Missouri-Kansas City, Durham, NC, United States
(Broderick, Rockhold) Duke Clinical Research Institute, Durham, NC, United
States
(Bangalore, Newman, Reynolds, Hochman) Cardiovascular Clinical Research
Center, New York University Grossman School of Medicine, Durham, NC,
United States
(Rockhold) Department of Biostatistics and Bioinformatics, Duke University
School of Medicine, Durham, NC, United States
(Demchenko) Almazov National Medical Research Centre, Saint Petersburg,
Russian Federation
(Nageh) Southend University Hospital, United Kingdom
(Grossman) Moinhos de Vento Hospital, Porto Alegre, Brazil
(Grossman) Cardionuclear Clinic, Porto Alegre, Brazil
(Mavromatis) Emory University, Atlanta VA Healthcare System, GA, United
States
(Manjunath) Sri Jayadeva Institute of Cardiovascular Sciences and
Research, Bengaluru, India
(Smanio) Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
(Stone) Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Mancini) Center for Cardiovascular Innovation, The University of British
Columbia, Vancouver, Canada
(Boden) VA New England Healthcare System, Boston University School of
Medicine, MA, United States
(Maron) Department of Medicine, Stanford University, CA, United States
(Boden, Mavromatis, Doan) Atlanta VA Medical Center, Decatur, GA, United
States
(Linefsky, Lee, Patel, Miller, Cho) Mayo Clinic, Rochester, MN, United
States
(Milbrandt, Shelstad, Banerjee, Kamath) V.A. North Texas Health Care
System, Dallas, TX, United States
(Tejani) NYU Langone Medical Center-Bellevue Hospital, New York, NY,
United States
(Reynolds, Newman, Bangalore, Donnino, Phillips, Saric, Abdul-Nour,
Schley) Henry Ford Health System, Detroit, MI, United States
(Golden, Stone, Osseni) Brigham & Women's Hospital, Harvard Medical
School, Boston, MA, United States
(Wiyarand, Douglass, Pomeroy, Craft, Harvey, Jang, Anaya) Kaiser
Permanente San Jose, San Jose, CA, United States
(Yee, Goold, Weitz, Giovannone) Cardiology Associates of Schenectady P.C.,
Schenectady, NY, United States
(Pritchard, Arnold, Gans) Saint Luke's Hospital, Kansas City, MO, United
States
(O'Keefe, Kennedy, Shapiro, Ganesan) Oregon Health & Science University,
Portland, OR, United States
(Schlichting, Naher) Albany Medical Center Hospital, Albany, NY, United
States
(Fein, Stewart, Torosoff, Salmi, Lyubarova, Mookherjee, Drzymalski,
McFalls) Minneapolis VAMC, Minneapolis, MN, United States
(Garcia, Bertog, Johnson, Siddiqui, Herrmann, Ishani, Hansen, Khouri,
Arges) Duke University Medical Center, Durham, NC, United States
(LeFevre, Tomfohr, Goldberg, Byrne) Louis Stokes Cleveland Veterans
Affairs Medical Center, Cleveland, OH, United States
(Zappernick, Goldweit, Canada) Englewood Hospital and Medical Center,
Englewood, NJ, United States
(Kakade) NYU-HHC Woodhull Hospital, Brooklyn, NY, United States
(Mieses, Cohen, Mirrer, Navarro, Rantinella, Rodriguez, Mancilla,
Winchester, Stinson) Malcom Randall VAMC, Gainesville, FL, United States
(Kronenberg, Weyand) Vanderbilt University Medical Center, Nashville, TN,
United States
(Rogal, Crook, McFarren, Heitner, Ho) New York -Presbyterian/Brooklyn
Methodist Hospital, Brooklyn, NY, United States
(Khan, Mohamed, Dauber, Soltau) South Denver Cardiology Associates, P.C.,
Littleton, CO, United States
(Rose, Wimmer, Siegel, Derbyshire, Cannan, Dixon) Providence Heart and
Vascular Institute, Portland, OR, United States
(Leonard, Sudarshan, Heard) Wichita Falls Heart Clinic, Wichita Falls, TX,
United States
(Gabriel, Desire, Mehta) Emory University, Atlanta, GA, United States
(McDaniel, Rashid, Lerakis, Asier, Quyyumi, Patel, Wenger, Hedgepeth,
Gillis) Kent Hospital, Warwick, RI, United States
(Hurlburt, Manocchia, Rosen, Moore, Congdon, Sahul, Brandt) Michigan
Heart, PC, Ypsilanti, MI, United States
(Marchelletta, Wippler, Booth, Taul) University of Kentucky, Lexington,
KY, United States
(Leung, Isaacs, Abdel-Latif, Bulkley, Reda, Rodgers, Ziada, Setty,
Halverson) Gundersen Lutheran Medical Center, La Crosse, WI, United States
(Roraff, Thorsen, Barua, Ojajuni) Kansas City VA Medical Center, Kansas
City, MO, United States
(Olurinde, Surineni, Hage, Valaiyapathi) UAB Vascular Biology and
Hypertension Program, Birmingham, AL, United States
(Caldeira, Davies, Leesar, Heo, Iskandrian, Al Solaiman, Singh, Dajani,
Kartje) Loyola University Medical Center, Maywood, IL, United States
(El-Hajjar) Samuel Stratton VA Medical Center of Albany NY, Albany, NY,
United States
(Mesropian, Sacco, Rawlins, McCandless, Thomson, Orgera, Sidhu, Rogge)
Cincinnati VA Medical Center, Cincinnati, OH, United States
(Arif, Bunke, Kerr, Unterbrink, Fannon, Burman, Trejo, Dubin) Mayo Clinic
Florida, Jacksonville, FL, United States
(Fletcher, Lane, Neeson, Parikh, Pollak, Shapiro, Landolfo, Gemignani,
Beaudry) VAMC-White River Junction, White River Junction, VT, United
States
(O'Rourke, Meadows, Tirado) VA Connecticut Healthcare System, West Haven,
CT, United States
(Halliday, Julian, Call, Lane) Winchester Cardiology and Vascular
Medicine, PC, Winchester, VA, United States
(Stanford, Hannan) Saint Vincent Hospital, Worcester Medical Center,
Worcester, MA, United States
(Bojar, Arsenault, Kumar, Sigel, Mukai, Martin, Brooks) Oklahoma Heart
Institute, Tulsa, OK, United States
(Vorobiof, Douangvila) Ronald Reagan UCLA Medical Center, Los Angeles, CA,
United States
(Gevorgyan, Moor-Man, Ranjbaran) University of Washington Medical Center,
Seattle, WA, United States
(Smith, Ohmart, Kinlay) VA Boston Healthcare System, West Roxbury, MA,
United States
(Hamburger, Rocco, Ly, Bhatt, Quinn, Croce, Temiyasathit, Quin, Do,
Anumpa, Tobin, Zenati, Faxon, Rayos, Langdon) Daytona Heart Group, Daytona
Beach, FL, United States
(Bayer, Seedhom, O'Malley) Capital Cardiology Associates, Albany, NY,
United States
(Sullenberger, Orvis, Kumkumian, Murphy) NIH Heart Center, Suburban
Hospital, Bethesda, MD, United States
(Greenberg, Iraola, Sedlis, Maranan) VA New York Harbor Health Care
System, New York, NY, United States
(Donnino, Lorin, Tamis-Holland, Malinay) Mount Sinai Saint Luke's
Hospital, Ridgewood, NJ, United States
(Kornberg, Leber, Saba, Edillo) Providence - Providence Park Hospital,
Southfield, MI, United States
(Lee, Small, Nona, Alexander, Rehman, Badami, Ostrander) Covenant Medical
Center, Inc., Saginaw, MI, United States
(Wasmiller, Marzo, Drewes) NYU Winthrop, Mineola, NY, United States
(Patel, Robbins) AtlantiCare Regional Medical Center, Pomona, NJ, United
States
(Levite, White, Shetty, Hallam, Patel, Hamroff, Spooner) NYP Medical
Medical Group Hudson Valley Cardiology, Cortlandt Manor, NY, United States
(Hollenweger, Little, Little) Houston Heart & Vascular Associates,
Houston, TX, United States
(Zimbelman, Little, Lui, Eskelson) Salt Lake City VA Medical Center, Salt
Lake City, UT, United States
(Smith, Vezina, Khor, Abraham, Bull, McKellar, Booth, Taul) Lexington VA
Medical Center, Lexington, KY, United States
(Kotter, Rodgers, Abdel-Latif, Isaacs, Bulkley, Hu, Kaneshiro) Palo Alto
Medical Foundation Research Institute, Palo Alto, CA, United States
(Labovitz) University of South Florida, Tampa, FL, United States
(Berlowitz, Kirby, Rogal, Tran, McFarren, Jahrsdorfer, Matar, Caldeira,
Maron) Stanford University School of Medicine, Stanford, CA, United States
(Rodriguez, Yunis, Schnittger, Patro, Fearon, Deedwania, Vega) UCSF -
Fresno Community Regional Medical Center, Fresno, CA, United States
(Reddy, Sweeny, Bloise-Adames) Icahn School of Medicine at Mount Sinai,
New York, NY, United States
(Jimenez, Vrestil, Bhandari, Spizzieri, Schade) Holy Spirit Hospital
Cardiovascular Institute, Camp Hill, PA, United States
(Yost, Hochberg, Beardsley) Boston Medical Center, Boston, MA, United
States
(Fine, Salerno, Tancredi) Hackensack University Medical Center, Saddle
Brook, NJ, United States
(Arakelian, Mathus, O'Neill, Wyman, Burkhardt) Torrance Memorial Medical
Center, Torrance, CA, United States
(Hosino, Lubyanaya) Coastal Heart Medical Group, Santa Ana, CA, United
States
(Salas, Zarka, Aguirre, Shah, Dhawan, Parra, Tran, Haldis, Weick) Sanford
Health, Fargo, ND, United States
(Fowler-Lehman, Spitzer, Riedberger, Weick, Kohn) NYU New York Medical
Associates, New York, NY, United States
(Cobos, Quiles, Girotra, Drum) University of Iowa Hospitals and Clinics,
Iowa City, IA, United States
(Miller-Cox, Ollinger, Almousalli, Capasso-Gulve) Advanced Heart Care
Group, Fairview Heights, IL, United States
(Loehr, Mosley, Krishnam, Heydari) University of California Irvine Medical
Center, Orange, CA, United States
(Mil-Liken, Lundeen, Patel, Karanjah, Seto, Marfori, Harley,
Hernandez-Rangel, Gibson, Singh, Allen, Coram, Webb) University of
Louisville, Louisville, KY, United States
(Fridell, Wilson, Thomas, Kim) University of Rochester, Rochester, NY,
United States
(Schwartz, Wilmot, Chen, El Shahawy, Stevens) Cardiovascular Center of
Sarasota, Sarasota, FL, United States
(Stafford, Black) University of Maryland Medical Center, Baltimore, MD,
United States
(Abernethy, Hull) Asheville Cardiology Associates, Asheville, NC, United
States
(Lim, Tucker, Putnam, Hall, Cauthren, Tucker, Zurick, Horton) Saint Thomas
Hospital, Nashville, TN, United States
(Orga, Meyer, White) Stroobants Cardiovascular Center, Lynchburg, VA,
United States
(Morford, Baumann, Rutkin, Seeratan) Northwell Health - Manhasset,
Manhasset, NY, United States
(Bokhari, Jimenez) Columbia University Medical Center, New York, NY,
United States
(Sokol, Schultz) Jacobi Medical Center, Bronx, NY, United States
(Meisner, Russo, Hamzeh) Baylor College of Medicine, Houston, TX, United
States
(Misra, Huda, Wall, Boan, De Rosen, Alam, Turner, Hinton) Cardiovascular
Specialists of Southwest Louisiana, Lake Charles, LA, United States
(Mulhearn, Good, Archer) Ohio Health Grant Medical Center, Columbus, OH,
United States
(Dionne, Allardyce, Sikora, Czerniak, Mull, Ferguson, Laube, Shammas,
Shammas) Midwest Cardiovascular Research Foundation, Davenport, IA, United
States
(Christensen, Park, Chilton, Hecht) Audie Murphy V.A., San Antonio, TX,
United States
(Nguyen, Vo) VA Palo Alto Healthcare System, Palo Alto, CA, United States
(Hirsch, Jezior, Bindeman) Walter Reed National Military Medical Center,
Bethesda, MD, United States
(Salkind, Espinosa) Miriam Hospital, Providence, RI, United States
(Desimone, Gordon, Felix-Stern, Crain, Gomes, Gordon, Stenberg, Mann)
Conemaugh Valley Memorial Hospital, Johnstown, PA, United States
(McCreary, Pedalino, Cobos) NYU-HHC Kings County Hospital Center,
Brooklyn, NY, United States
(Dwyer, Espinosa, Quiles, Wiesel) New York University - Langone
Cardiovascular Associates, Flushing, NY, United States
(Juang, Gopaul) Coney Island Hospital, Brooklyn, NY, United States
(Hultberg, Huk, Hussain, Al-Amoodi, Zambrano) Yuma Regional Medical
Center, Yuma, AZ, United States
(Rodriguez, Milner, Wohns, Mulder) Spectrum Health, Grand Rapids, MI,
United States
(Van Oosterhout, Lader, Meyer) Mid Valley Cardiology, Kingston, NY, United
States
(Mumma, Clapp) Sarasota Memorial Hospital, Sarasota, FL, United States
(Barrentine, Dharmarajan, Jose) NYU-HHC Lincoln Medical and Mental Health
Center, Bronx, NY, United States
(Manchery, McGarvey, McKinney) Doylestown Health Cardiology, Doylestown,
PA, United States
(Schwarz, Downes, Kaczkowski) Medical Center of the Rockies, Loveland, CO,
United States
(Luckasen, Jaskowiak, Klitch, Cheong, Dees) Baylor St. Luke's Medical
Center, Houston, TX, United States
(Potluri, Vasquez) Baylor Research Institute, Legacy Heart Center, Plano,
TX, United States
(Mastouri) Indiana University, Krannert Institute of Cardiology,
Indianapolis, IN, United States
(Breall, Hannemann, Revtyak, Foltz, Bazeley, Li, DeRosa) HealthEast Saint
Joseph's Hospital, St. Paul, MN, United States
(Jorgenson, Riestenberg-Smith, Giedd) Beth Israel Medical Center, New
York, NY, United States
(Old, Bariciano) Cardiovascular Associates, Ltd., Chesapeake, VA, United
States
(Burt) Saint Luke's Hospital and Health Network, Bethlehem, PA, United
States
(Sokhon, Waldron) Medicus Alliance Clinical Research Org., Inc., Sugar
land, TX, United States
(Mayon, Gopal) The Heart Hospital Baylor, Plano, TX, United States
(Valeti, Peichel) University of Minnesota, Minneapolis, MN, United States
(Kobashigawa, Starks) Cedars Sinai Medical Center, Beverly Hills, CA,
United States
(Garcia, Thottam, Bhargava, Anand) Government Medical College, Calicut,
India
(Govindan, Raj, Nair, Ravindran, Rajalekshmi, Manjunath, Nataraj) Sri
Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru,
India
(Moorthy, Nayak, Manjunath, Mylarappa, Narayanappa, Pandit, Bajaj) Dr Ram
Manohar Lohia Hospital, New Delhi, India
(Nath, Yadav, Mishra, Dwivedi, Tewari) King George's Medical University,
Department of Cardiology, Lucknow, India
(Narain, Mishra, Chandra, Patel, Singh, Wander) Hero DMC Heart Institute,
Dayanand Medical College and Hospital, Ludhiana, India
(Tandon, Ralhan, Kaur, Aslam, Gupta, Pharmacy, Goyal, Bhargava, Suvarna)
All India Institute of Medical Sciences, New Delhi, India
(Karthikeyan, Ramakrishnan, Seth, Yadav, Singh, Roy, Parakh, Verma,
Narang, Mishra, Naik, Sharma, Choudhary, Patel, Gulati, Sharma, Bahl,
Mathew, Kurian) MOSC Medical College Hospital, Kolenchery, India
(Punnoose, Gadkari, Karwa) KEM Hospital Pune, Pune, India
(Gadage, Kolhe, Pillay, Satheesh, Vindhya) Jawaharlal Institute of
Postgraduate Medical Education & Research (JIPMER), Pondicherry, India
(Jain) Fortis Escort Heart Institute, New Delhi, India
(Seth, Meharwal, Mathur, Verma, Kaul, Bhatia, Sachdeva, Devi, Jungla,
Christopher, Rani) Gurunanak CARE Hospital, Hyderabad, India
(Menon, Reddy, Kumar, Preethi, Oomman, Sidh) Apollo Research and
Innovation, Chennai, India
(Mao, Ramakrishnan, Solomon, Francis, Naik, Priya) Apollo Research &
Innovations, Hyderabad, India
(Khan, Christopher, Preethi) CARE Nampally, Hyderabad, India
(Kumar, Grant, Hande) Ruby Hall Clinic, Grant Medical Foundation, Pune,
India
(Sonawane, Kachru, Dubey) Fortis Healthcare Fl.t Lt. Rajan Dhall Hospital,
New Delhi, India
(Rawat, Kumar) Sree Chitra Tirunal Institute for Medical Sciences and
Technology, Trivandrum, India
(Ganapathi, Jayakumar, Vineeth, Sivadasanpillai, Chacko, Sasidharan, Babu,
Kapilamoorthy, Christopher, Reddy) CARE Hospital, Hyderabad, India
(Polamuri, Rani, Kaul, Arambam) Batra Hospital and Medical Research Centre
(BHMRC), New Delhi, India
(Singh, Senior, Fox, Young, Carruthers) Northwick Park Hospital Harrow,
Royal Brompton Hospital London, Harrow, United Kingdom
(Elghamaz, Gurunathan, Karogiannis, Young, Shah, Kinsey, Trimlett,
Kavalakkat, Rubens, Evans, Nicol, Hassan, Mittal, Hampson, Gamma,
Williams) Broomfield Hospital, Chelmsford, United Kingdom
(Holland, Swan, de Belder, Atkinson) The James Cook University Hospital,
Middlesbrough, Middlesbrough, United Kingdom
(Thambyrajah, Nageh, Kunhunny) Southend University Hospital, Westcliffe on
Sea, United Kingdom
(Davies, Lindsay, Atkinson) Bradford Royal Infirmary, Bradford, United
Kingdom
(Kurian, Krannila, Jamil, Vinod, Raheem, Hoye, Chaytor) The University of
Hull, Castle Hill Hospital, Cottingham, United Kingdom
(Cox, Morrow, Rowe, Donnelly, Kelly) South Eastern Health and Social Care,
Belfast, United Kingdom
(Valecka, Regan, Turnbull, Chauhan, Fleming) Blackpool Teaching Hospitals,
Blackpool, United Kingdom
(Ghosh, Gratrix, Preston, Barr, Cartwright) Russells Hall Hospital,
Dudley, United Kingdom
(Alfakih, Knighton) King's College NHS Foundation Hospital, London, United
Kingdom
(Byrne, Martin, Webb, Henriksen, Flint) Royal Infirmary of Edinburgh,
Edinburgh, United Kingdom
(Harrison, OKane, Lake-Man) Royal Bournemouth Hospital, Bourneouth, United
Kingdom
(Ljubez, de Silva) Bedford Hospital NHS Trust, Bedford, United Kingdom
(Conway, Wright) Pinderfields Hospital, Wakefield, United Kingdom
(Exley, Sirker, Andiapen) University College London Hospitals NHS
Foundation Trust, London, United Kingdom
(Richards) BartsHealth NHS Trust, United Kingdom
(Hoole, Wong) Papworth Hospital, Cambridge, United Kingdom
(Witherow, Munro) Dorset County Hospital, Dorchester, United Kingdom
(Johnston, Bao) Belfast Trust, Belfast, United Kingdom
(Harbinson, Bao, McEvoy, Walsh, Bao, Brown, Douglas, Luckie, Charles)
Central Manchester University Hospital, Manchester, United Kingdom
(Kolakaluri, Phillips, Sobolewska, Morby) The Pennine Acute Hospitals NHS
Trust, Oldham, United Kingdom
(Hallett, Corbett, Winstanley, Jeetley, Smit) Royal Free London NHS
Foundation Trust, London, United Kingdom
(Patel, Kotecha, Travill, Gent) Luton and Dunstable University Hospital
NHS FT, Luton, United Kingdom
(Karimullah, Hussain, Al-Bustami, Braganza, Haines) Peterborough City
Hospital, Peterborough, United Kingdom
(Taaffe, Henderson, Burton) Nottingham University Hospitals, Nottingham,
United Kingdom
(Pointon, Colton, Naik, King, Mathew, Brown) University of Glasgow,
Clydebank, United Kingdom
(Docherty, Berry, McCloy, Collison, Robb, Roditi, Paterson, Crawford,
Kelly, McGregor, Moriarty, Mackin) Cardiovascular Research Unit, Craigavon
Area Hospital, Craigavon, United Kingdom
(Glover, Knight) Hampshire Hospitals NHS Foundation Trust, Basingstoke,
United Kingdom
(Pradhan, Mikhail, Bose) Imperial College Healthcare NHS Trust, London,
United Kingdom
(Francis, Dzavik, Goodman, Gosselin, Proietti) Montreal Heart Institute,
Montreal, QC, Canada
(Brousseau, Corfias, Blaise, Harvey, Diaz) Centre Hospitalier de Regional
Trois-Rivieres, Trois-Rivieres, QC, Canada
(Rheault, Barrero, Gagne, Alarie, Pepin-Dubois, Arcand, Costa, Roy, Sia,
Montpetit, Lemay, Gisbert, Gervais, Rheault, Drouin) CISSSL - Hopital
Pierre-Le Gardeur, Terrebonne, QC, Canada
(Phaneuf, Bergeron, Gosselin, Shelley, Masson, Garg, Carr) London Health
Sciences Centre, London, ON, Canada
(Bone, Chow, Moga) University of Ottawa Heart Institute, Ottawa, ON,
Canada
(Hessian, Kourzenkova, Beanlands, Walter, Davies, Bainey, Hogg) University
of Alberta, Edmonton, AB, Canada
(Welsh, Cheema) St. Michael's Hospital, Toronto, ON, Canada
(Bagai, Wald, Goodman, Kushniriuk, Graham, Hussain, Peterson, Bello, Chow,
Abramson, Cheema, Syed) Dixie Medical Group, Mississauga, ON, Canada
(Vakani, Hussain, Kushniriuk, Cha, Otis) Dr James Cha, Oshawa, ON, Canada
(Otis, Howarth, Seib) University of Calgary, Calgary, AB, Canada
(Rivest, Sandonato, Wong, Chow) Vancouver General Hospital, Vancouver, BC,
Canada
(Starovoytov, Uchida, Meadows, Uxa, Asif) University Health Network,
Toronto, ON, Canada
(Tavares, Galiwango, Bozek) Scarborough Cardiology Research, Scarborough,
ON, Canada
(Kassam, Shier, Mukherjee, Larmand, Ricci, Janmohamed, Hart, Lam, Marucci)
West Lincoln Memorial Hospital East Grimsby, ON, Canada
(Tai, Mehta, Brons) Hamilton General Hospital, Hamilton, ON, Canada
(Beck, Wong, Etherington, Arumairajah, Udell, Aprile) Women's College
Hospital, Toronto, ON, Canada
(Karlsson, Webber, Genereux, Mercure) Centre Integre Universitaire de
Sante et de Services Sociaux du Montreal, Montreal, QC, Canada
(Hameed, Aedy) Saint Catharines General Hospital, Catharines, ON, Canada
(Daba, Farquharson) Northwest GTA Cardiovascular and Heart Rhythm Program,
Vaughan, ON, Canada
(Siddiqui, Carvalho, Lopes, Hueb, Takiuti) Heart Institute (InCor),
University of Sao Paulo, Sao Paulo, Brazil
(Rezende, Silva, Hueb, Smanio, Caetano) Instituto Dante Pazzanese de
Cardiologia, Sao Paulo, Brazil
(de Quadros) Instituto de Cardiologia de Porto Alegre, Porto Alegre,
Brazil
(Kalil, Deiro, da Costa Vieira, Muller, Grossmann, de Moraes, de Oliveira,
Ascoli, Bridi, Poletti, Savaris, Vitola) Quanta Diagnostico & Terapia,
Curitiba, Brazil
(Cerci, Zier, Farias, Veiga, Fernandes, Marin-Neto) Hospital das Clinicas
da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo,
Ribeirao Preto, Brazil
(Schmidt, de Oliveira Lima Filho, da Cunha, Oliveira, Chierice, Polanczyk,
Rucatti) Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
(Furtado, Igansi, Smidt, Haeffner, Carvalho, Almeida) Unifesp - Hospital
Sao Paulo, Sao Paulo, Brazil
(Pucci, de Souza, Lyra, Alves, Almeida) Fundacao Bahiana de Cardilogia,
Salvador, Brazil
(dos Santos, Dracoulakis, Oliveira) Hospital da Bahia, Salvador, Brazil
(Lima, Figueiredo, Azevedo) Hospital Lifecenter, Belo Horizonte, Brazil
(Caramori, Santos) Hospital Sao Lucas da Pontificia Universidade Catolica
do Rio Grande do Sol, Porto Alegre, Brazil
(Germann, Gomes, Homem, Magedanz, Tumelero, Laimer) Hospital Sao Vicente
de Paulo Fundo, Brazil
(Tognon, Dall'Orto) Hospital Maternidade e Pronto Socorro Santa Lucia,
Pocos de Caldas, Brazil
(Mesquita, Santos) Hospital Pro-Cardiaco Botafogo, Brazil
(Colafranseschi, Oliveira, Carvalho, Palazzo, Sousa, da Silva) Hospital
TotalCor, Sao Paulo, Brazil
(de Barros e Silva, Okada, de Padua Silva Baptista, Batista, Rodrigues,
Rabaca, de Resende, Saraiva, Trama) Hospital Celso Pierro, Sao Paulo,
Brazil
(Silva, de Souza Ormundo, Vicente, Costantini, Pinheiro, Pracon) Hospital
Cardiologico Costantini, Curitiba, Brazil
(Komar, Ruzyllo, Szwed, Demkow, Pracon) Coronary and Structural Heart
Diseases Department, Institute of Cardiology, Warsaw, Poland
(Kepka, Teresinska, Walesiak, Kryczka, Malinowska, Henzel, Solecki,
Kaczmarska, Mazurek, Maksym) Medical University of Warsaw, Warszawa,
Poland
(Wojtera, Fojt, Szczerba, Drozdz) Cardiology Clinic, Medical University in
Lodz, Lodz, Poland
(Czarniak, Frach, Szymczyk, Niedzwiecka, Sobczak, Ciurus, Jakubowski,
Misztal-Teodorczyk, Teodorczyk, Swiderek, Fratczak, Wojtala, Szkopiak,
Lebioda, Wlodarczyk, Plachcinska, Kusmierek, Miller, Marciniak,
Wojtczak-Soska, Luczak, Tarchalski, Cichocka-Radwan, Szwed, Karwowski)
National Institute of Cardiology, Warsaw, Warsaw, Poland
(Szulczyk, Witkowski) Department of Interventional Cardiology & Angiology,
Institute of Cardiology, Warsaw, Poland
(Kukula, Celinska-Spodar, Zalewska, Gajos) Department of Coronary Disease,
John Paul II Hospital, Jagiellonian University Medical College, Krakow,
Poland
(Bury, Pruszczyk, Labyk) Department of Internal Medicine and Cardiology,
Infant Jesus Teaching Hospital, Medical University of Warsaw, Warszawa,
Poland
(Roik, Szramowska, Zdonczyk, Loboz-Grudzien, Jaroch) T.Marciniak Hospital,
Wroclaw, Poland
(Sokalski, Brzezinska, Lesiak) Szpital Kliniczny Przemienienia Panskiego,
Poznan, Poland
(Lanocha, Reczuch, Kolodziej) Military Hospital, Medical University,
Wroclaw, Poland
(Kalarus) Medical University of Silesia, School of Medicine, The Division
of Dentistry, Department of Cardiology, Congenital Heart Diseases and
Electrotherapy, Silesian Center for Heart Diseases, Zabrze, Poland
(Swiatkowski, Szulik, Musial, Marcinkiewicz-Siemion) University Hospital
in Bialystok, Bialystok, Poland
(Bockeria, Bockeria) National Medical Research Center for Cardiovascuar
Surgery, Moscow, Russian Federation
(Petrosyan, Kudzoeva, Trifonova, Aripova, Chernyavskiy, Naryshkin)
E.Meshalkin National Medical Research Center, The Ministry of Health of
the Russian Federation, Novosibirsk, Russian Federation
(Kretov, Kuleshova, Grazhdankin, Malaev, Bershtein) North-Western State
Medical University, Saint Petersburg, Russian Federation
(Sayganov, Subbotina, Kuzmina-Krutetskaya, Gumerova, Zbyshevskaya,
Katamadze, Demchenko, Nikolaeva) Federal Almazov North-West Medical
Research Centre, Saint Petersburg, Russian Federation
(Kozlov, Kozulin, Lubinskaya, Lopez-Sendon, Castro, Lopez-Sendon,
Fernandez-Figares) Hospital La Paz. IdiPaz, Madrid, Spain
(Castro, Salicio, Guzman, Galeote, Valbuena, Peteiro) Complexo
Hospitalario Universitario A Coruna (CHUAC) Sergas, Department of
Cardiology, INIBIC A Coruna. CIBER-CV., Universidad de A Coruna, A Coruna,
Spain
(Martinez-Ruiz, Perez-Fernandez, Blanco-Calvo, Cuenca-Castillo,
Alonso-Alvarez, Flores-Rios, Garcia-Gonzalez, Prada-Delgado,
Barge-Caballero, Juanatey, Amigo) Hospital Clinico Universitario de
Santiago, Santiago de Compostela, Spain
(Bayarri, Nunez, Sanchez, Alvarez, Gil, Monzonis, Sionis, Martinez)
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
(Perales, Padro, Penaranda, Picart, Iglesias, Marimon, Llado, Costa, Miro,
Igual) Hospital Universitario y Politecnico La Fe, Valencia, Spain
(Diez, Calvillo, Ortuno) HUVA, Hospital Clinico Universitario Virgen De La
Arrixaca, Murcia, Spain
(Chavarri, Giner, Montolliu, Aniorte, Bermudez, Caravaca, De La Morena,
Blancas, Canavate) Hospital De Bellvitge, Barcelona, Spain
(Guerrero, Riera, Luena, Luena) Hospital Universitario Miguel Servet,
Zaragoza, Spain
(Lasala, Fernandez-Aviles, Lorenzo) Hospital General Universitario
Gregorio Maranon, Madrid, Spain
(Sobrino, Vazquez, Jiang, Chen, Dong) Guangdong General Hospital,
Guangzhou, China
(He, Xia, Yang, Zhong, Wu, Tian) Chinese Academy of Medical Sciences,
Fuwai Hospital, Beijing, China
(Li) First Affiliated Hospital of Xinjiang Medical University, Urumqi,
China
(Ma, Li, Yang, Ma, Yu, Zhao, Ji, Li) Tangshan Gongren Hospital, Tangshan,
China
(Zhang, Zhao, Zhu, Yang, Chen) Beijing Chao-yang Hospital, Capital Medical
University, Beijing, China
(Chi, Wang, Zhang, Lin, Jing) TEDA International Cardiovascular Hospital,
Tianjing, China
(Liu, Zeng, Zhou) Tongji Medical College, Wuhan, China
(Xu, Li, Li, Xiong, Fu, Gao) The First Affiliated Hospital of Zhengzhou
University, Zhengzhou, China
(Jiang, Leng, Wang, Yuan, Zhang, Yang, Bai) Shanxi Cardiovascular
Hospital, Taiyuan, China
(Li, Qi, Wang, Wang, Yang, Yue, Zhang, Wang, Dong) Qingdao Fuwai Hospital,
Qingdao, China
(Mao, Zhang, Cheng, Li) Shanxi Provincial People's Hospital, Xian, China
(Yao, Zhong, Zhou, Zhao, Huang) The Second Affiliated Hospital of
Zhengzhou University, Zhengzhou, China
(Zhou, Fang, Su) Liangxiang Hospital, Beijing, Fangshan District, Beijing,
China
(Zeng, Kunwu) Wuhan Union Hospital, Tongji Medical College, Huazhong
Science and Tech University, Wuhan, China
(Peng, Su, Su, Wang) Wuhan Asia Heart Hospital, Wuhan, China
(Zhao, Li, Geng) Affiliated Hospital of Jining Medical University, Jining,
China
(Wang, Nie, Fan) Beijing Anzhen Hospital, Beijing, China
(Feng, Wang, Yan, Zhang, Yu, Chi) Affiliated Zhongshan Hospital of Dalian
University, Dalian, China
(Liu, Wang, Chen) The Second Affiliated Hospital Zhejiang University
School of Medicine, Hangzhou, China
(Jiang, Li, Wang, Han) Peking Union Medical College Hospital, Beijing,
China
(Xu, Zhang, Liu, Liu, Chen, Hu, Maggioni, Perna, Pietrucci) Cardiology and
CCU - Ospedali Riuniti Ancona, Ancona, Italy
(Marini, Gabrielli, Provasoli, Di Donato) Ospedale di Circolo e Fondazione
Macchi, Varese, Italy
(Verna, Monti) Humanitas Research Hospital, Rozzano (MI), Rozzano, Italy
(Nardi, Di Chiara, Pezzetta) Azienda Servizi Sanitaria n.3 Alto
Friuli-Collinare-Medio Friuli, Tolmezzo, Italy
(Mortara, Casali) Policlinico di Monza, Monza, MB, Monza, Italy
(Galvani, Attanasio) Ospedale "G.B. Morgagni - L. Pierantoni" Forli (AUSL
della Romagna), Forli, Italy
(Ottani, Sicuro, Leone) Ospedale Regionale Umberto Parini, Aosta, Italy
(Pisano, Bare, Calabro, Fimiani) AORN Dei Colli "V. Monaldi" UOC
Cardiologia Universita della Campania "L.Vanvitelli", Napoli, Italy
(Formisano, Tarantini, Barioli) University of Padua- Cardiology Clinic,
Padua, Italy
(Cucchini, Ramani, Andres, Racca, Rolfo) Azienda Ospedaliera S. Croce e
Carle, Cuneo, Italy
(Goletto, Briguori, De Micco) Clinica Mediterranea, Naples, Italy
(Amati, Di Marco) UO Cardiologia Ospedale SS Cosma e Damiano, Pescia,
Italy
(Vergoni, Tricoli, Russo, Villella) IRCCS "Casa Sollievo della
Sofferenza", San Giovanni Rotondo, Italy
(Fanelli, White, Alsweiler, Poh) National University Heart Center
Singapore, Singapore, Singapore
(Chai, Lau, Loh, Tay, Teoh, Tan, Teo, Sia, Ong, Leong, Wong, Loh, Kofidis,
Chan, Chan, Foo, Yan) Tan Tock Seng Hospital, Singapore, Singapore
(Kong, Er, Jafary, Chua, Ismail) National Heart Centre Singapore,
Singapore, Singapore
(Kyaw, Yip, Doerr) Praxisklinik Herz und Gefaesse, Dresden, Germany
(Stumpf, Grahl, Matschke, Guenther, Simonis, Bonin, Kadalie, Sechtem,
Wenzelburger) Robert-Bosch-Krankenhaus, Stuttgart, Germany
(Ong, Gruensfelder, Schulze) University Hospital Jena, Jena, Germany
(Goebel, Lenk, Nickenig, Sinning) Universitatsklinikum Bonn, Bonn, Germany
(Weber, Werner, Lang, Huber, Schuchlenz, Steinmaurer) LKH Graz West, Graz,
Austria
(Weikl, Lang, Winter) Medical University of Vienna, Department of
Cardiology, Vienna, Austria
(Andric) Wilhelminen Hospital Vienna, Vienna, Austria
(Huber, Maximilian, Gabriele, Claudia, Bernhard, Florian, Keltai, Vertes,
Sebo) Eszszk- Szent Istvan Hospital, Budapest, Hungary
(Davidovits, Matics, Varga, Agoston) University of Szeged, Szeged, Hungary
(Fontos, Dekany) George Gottsegen National Institute of Cardiology,
Budapest, Hungary
(Merkely, Bartykowszki) Heart and Vascular Center, Semmelweis University,
Budapest, Hungary
(Maurovich-Horvat, Kerecsen, Jakal) Military Hospital, Budapest, Budapest,
Hungary
(Hinic, Djokic) University Hospital Center Bezanijska Kosa, Belgrade,
Serbia
(Zdravkovic, Mudrenovic, Crnokrak, Beleslin) Faculty of Medicine,
University of Belgrade, Cardiology Clinic, Clinical Center of Serbia,
Belgrade, Serbia
(Boskovic, Djordjevic-Dikic, Petrovic, Giga, Dobric, Stepanovic, Markovic,
Mladenovic, Cemerlic-Adjic, Velicki) Institute of Cardiovascular Diseases
Vojvodina, Sremska Kamenica, Serbia
(Pupic, Davidovic, Simovic) Clinical Center Kragujevac, Kragujevac, Serbia
(Vucic, Dekleva, Martinovic) University Clinical Hospital Zvezdara,
Belgrade, Serbia
(Stevanovic, Stankovic, Dobric) Clinical Center of Serbia, Belgrade,
Serbia
(Apostolovic, Martinovic) Clinic for Cardiovascular Diseases, Clinical
Center Nis, Nis, Serbia
(Stanojevic, Escobedo, de Jesus-Perez, Juarez) Instituto Mexicano del
Seguro Social, Mexico
(Baleon-Espinosa, Campos-Santaolalla, Duran-Cortes, Flores-Palacios,
Garcia-Rincon, Jimenez-Santos, Penafiel, Ortega-Ramirez,
Valdespino-Estrada, Rosas, Brassetti, Selvanayagam) Instituto Nacional de
Cardiologia "Ignacio Chavez", Mexico City, Mexico
(Anaya, Garcia, Juarez, Rovalo, Rodriguez, Selvanayagam, Rankin, Murphy,
Lee) Flinders Medical Centre, Adelaide, Australia
(Joseph, Thomas, Thambar, Chaplin) John Hunter Hospital, New Lambton
Heights, Australia
(Boer, Beltrame, Stansborough) The Queen Elizabeth Hospital, Woodville
South, Australia
(Black, Hillis, Bonner) Royal Perth Hospital, Perth, Australia
(Ireland, Venn-Edmonds, Steg, Abergel, Juliard, Thobois) C.H. Louis
Pasteur, Chartres, France
(Thuaire, Tachot, Dutoiu, Laure, Vassaliere, Steg, Abergel) Bichat
Hospital, Paris, France
(Juliard, Fuentes, Slama, Eliahou) Antoine-Beclere Hospital, Clamart
Cedex, France
(Mahmoud, Dubourg) Ambroise Pare Hospital, Boulogne, France
(Michaud, Nicollet, Hadjih) Centre Hospitalier Sud Francilien,
Corbeil-Essonnes Cedex, France
(Goube, Brito, Barone-Rochette, Barone-Rochette) Grenoble University
Hospital, Grenoble, France
(Furber, Cornet) Centre Hospitalier Universitaire d'Angers, Angers Cedex
9, France
(Biere, Rautureau, Juceviciene) Vilnius University Hospital Santariskes
Clinic, Vilnius, Lithuania
(Kalibataite-Rutkauskiene, Keinaite, Laucevicius, Laukyte, Celutkiene,
Mikolaitiene, Smigelskaite, Tamasauskiene, Urboniene, Kedhi) Isala
Klinieken, Zwolle, Netherlands
(Timmer, Bouwhuis, Hermanides, Nijmeijer, Kaplan, Riezebos) Cardio
Research Hartcentrum OLVG, Amsterdam, Netherlands
(Samadi, Schoep, van Dongen, Janzen, Niehe, Suryapranata, Ahoud)
Radboudumc, Nijmegen, Netherlands
(van Vugt, Ramos) Hospital de Santa Marta, Lisbon, Portugal
(Cacela, Santana, Fiarresga, Sousa, Marques, Patricio, Selas, Bernanrdes,
Silva, Rio, Freixo, Carvalho, Ferreira, Silva, Rodrigues, Modas, Portugal,
Fragata, Pinto, Cabrita) Santa Maria University Hospital, Cardiology
Department, CHLN, Lisbon, Portugal
(Menezes, Rocha, Lopes, Figueiras, Almeida, Coelho, Silva, Capinha, Nobre,
Caetano, Francisco, Silva, Ferreira) Centro Hospitalar de Vila Nova de
Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal
(Lopes, Diaz, Guzman, Tinnirello) Instituto Medico DAMIC, Cordoba,
Argentina
(Figal, Mungo) Fundacion Favaloro, Ciudad Autonoma de Buenos Aires,
Argentina
(Mendiz, Cortes, Favaloro, Alvarez, Garcia) Hospital Italiano Regional del
Sur Bahia Blanca, Bahia Blanca, Argentina
(Courtis, Godoy) Clinica Romagosa and Clinica De La Familia, Cordoba,
Spain
(Zeballos, Schiavi, Actis) Clinica Del Prado, Cordoba, Spain
(Rubio) Clinica Privada Velez Sarsfield, Cordoba, Spain
(Scaro, Devlin, Low) Waikato Hospital, Hamilton, New Zealand
(Fisher, Scales, Abercrombie, Stewart) Auckland City Hospital, Auckland,
New Zealand
(Howell, Patten, Benatar, Kedev, Held) University Clinic of Cardiology,
Skopje, North Macedonia
(Mitevska, Kostovska, Pejkov, Held) Uppsala University, Uppsala, Sweden
(Eggers, Frostfelt, Bjorklund, Johnston, Andreasson, Olsowka, Essermark,
Akerblom, Soveri, Aspberg, Persson, Sharir) Karolinska Institutet,
Danderyd Hospital, Stockholm, Sweden
(Beyar, Nikolsky, Sharir, Harel) Assuta Medical Centers, Tel-Aviv, Israel
(Elian, Kerner, Bentzvi) Rambam Medical Center, Haifa, Israel
(Massalha, Helmer, Kohsaka, Fukuda, Ueda) Keio University, Shinjuku-ku,
Japan
(Kohsaka, Fujita, Yasuda, Furukawa) National Cerebral and Cardiovascular
Center, Kanae Hirase, RN, -4, Suita-shi, Japan
(Nagai, Otsuka, Nishimura, Nakano) Saitama Medical University, Hidaka,
Japan
(Van de Werf, Goetschalckx, Robesyn) University Hospital Leuven, Leuven,
Belgium
(Van de Werf, Claes, Hung, Yang) Mackay Memorial Hospital, Taipei City,
Taiwan (Republic of China)
(Yun, Hou, Kuo, Yeh, Hung, Li, Chien, Tsai, Liu, Yu, Lin, Lan, Yen, Tsai,
Sung, Ntsekhe) Groote Schuur Hospital, University of Cape Town, Cape Town,
South Africa
(Pandie, Philander, Viljoen, Mtana, De Andrade, Maggioni, Moccetti,
Anesini) Cardiocentro, Lugano, Switzerland
(Rossi, Maspoli, Mombelli, Abdelhamid, Talaat) Cairo University, Cairo,
Egypt
(Adel, Kamal, Mahrous, El Kaffas, El Fishawy, Pop) Emergency County
Hospital Baia Mare, Bucharest, Romania
(Claudia, Popescu) Emergency Institute of Cardiovascular Diseases ''Prof.
Dr. C. C. Iliescu'', Bucharest, Romania
(Ginghina, Rosca, Deleanu, Beladan, Iliescu, Al-Mallah, Zahrani) King
AbdulAziz Cardiac Center, Central Province, Saudi Arabia
(Aljzeeri, Najm, Alghamdi, Ramos) Instituto Neuro Cardiovascular De Las
Americas, Mirafloes, Peru
(Davila, Kuanprasert) Maharaj Nakorn Chiang Mai Hospital, Chiang Mai,
Thailand
(Prommintikul, Nawarawong, Khwakhong, Woragidpoonpol, Chaiyasri, Tepsuwan,
Mekara, Taksaudom, Kulthawong, Rimsukcharoenchai, Amaritakomol,
Euathrongchit, Wannasopha, Yamwong, Panpunuan) Ramathibodi Hospital,
Bangkok, Thailand
(Sritara, Aramcharoen, Meemuk, White, Alsweiler, Khairuddin, Mokhtar)
Institut Jantung Negara, Kuala Lumpur, Malaysia
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: ISCHEMIA (International Study of Comparative Health
Effectiveness With Medical and Invasive Approaches) did not find an
overall reduction in cardiovascular events with an initial invasive versus
conservative management strategy in chronic coronary disease; however,
there were conservative strategy participants who underwent invasive
coronary angiography early postrandomization (within 6 months).
Identifying factors associated with angiography in conservative strategy
participants will inform clinical decision-making in patients with chronic
coronary disease. METHOD(S): Factors independently associated with
angiography performed within 6 months of randomization were identified
using Fine and Gray proportional subdistribution hazard models, including
demographics, region of randomization, medical history, risk factor
control, symptoms, ischemia severity, coronary anatomy based on
protocol-mandated coronary computed tomography angiography, and medication
use. RESULT(S): Among 2591 conservative strategy participants,
angiography within 6 months of randomization occurred in 8.7% (4.7% for a
suspected primary end point event, 1.6% for persistent symptoms, and 2.6%
due to protocol nonadherence) and was associated with the following
baseline characteristics: enrollment in Europe versus Asia (hazard ratio
[HR], 1.81 [95% CI, 1.14-2.86]), daily and weekly versus no angina (HR,
5.97 [95% CI, 2.78-12.86] and 2.63 [95% CI, 1.51-4.58], respectively),
poor to fair versus good to excellent health status (HR, 2.02 [95% CI,
1.23-3.32]) assessed with Seattle Angina Questionnaire, and new/more
frequent angina prerandomization (HR, 1.80 [95% CI, 1.34-2.40]). Baseline
low-density lipoprotein cholesterol <70 mg/dL was associated with a lower
risk of angiography (HR, 0.65 [95% CI, 0.46-0.91) but not baseline
ischemia severity nor the presence of multivessel or proximal left
anterior descending artery stenosis >70% on coronary computed tomography
angiography. CONCLUSION(S): Among ISCHEMIA participants randomized to
the conservative strategy, angiography within 6 months of randomization
was performed in <10% of patients. It was associated with frequent or
increasing baseline angina and poor quality of life but not with objective
markers of disease severity. Well-controlled baseline low-density
lipoprotein cholesterol was associated with a reduced likelihood of
angiography. These findings point to the importance of a comprehensive
assessment of symptoms and a review of guideline-directed medical therapy
goals when deciding the initial treatment strategy for chronic coronary
disease. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique
identifier: NCT01471522. GRAPHIC ABSTRACT: A graphic abstract is available
for this article. Copyright © 2024 American Heart Association,
Inc.

<62>
Accession Number
2030462565
Title
Addition of an erector spinae plane block to intercostal nerve blockade
for postoperative analgesia after video-assisted thoracic surgery: a
preliminary retrospective institutional review.
Source
Canadian Journal of Anesthesia. 71(8) (pp 1183-1185), 2024. Date of
Publication: August 2024.
Author
Bondzi-Simpson A.; Lindo C.J.; Rajendran L.; Campbell J.; Cheung V.;
Parente D.N.; Ahn R.; Ko M.
Institution
(Bondzi-Simpson, Lindo, Rajendran) Faculty of Medicine, University of
Toronto, Toronto, ON, Canada
(Bondzi-Simpson, Rajendran) Division of General Surgery, Department of
Surgery, University of Toronto, Toronto, ON, Canada
(Campbell, Ahn) Department of Anesthesia and Pain Management, St. Joseph's
Health Centre, University of Toronto, Toronto, ON, Canada
(Cheung, Parente, Ko) Division of Thoracic Surgery, Department of Surgery,
St. Joseph's Health Centre, University of Toronto, Toronto, ON, Canada
Publisher
Springer

<63>
Accession Number
2029397282
Title
Remimazolam to prevent hemodynamic instability during catheter ablation
under general anesthesia: a randomized controlled trial.
Source
Canadian Journal of Anesthesia. 71(8) (pp 1067-1077), 2024. Date of
Publication: August 2024.
Author
Yim S.; Choi C.I.; Park I.; Koo B.W.; Oh A.Y.; Song I.-A.
Institution
(Yim, Park, Koo, Oh, Song) Department of Anesthesiology and Pain Medicine,
Seoul National University Bundang Hospital, Seongnam, South Korea
(Choi) Department of Anesthesiology and Pain Medicine, Yonsei University
College of Medicine, Seoul, South Korea
(Choi) Department of Anesthesiology and Pain Medicine, Yongin Severance
Hospital, Yongin, South Korea
(Koo, Oh, Song) Department of Anesthesiology and Pain Medicine, Seoul
National University College of Medicine, Seoul, South Korea
Publisher
Springer
Abstract
Purpose: Maintaining hemodynamic stability during cardiac ablation under
general anesthesia is challenging. Remimazolam, a novel ultrashort-acting
benzodiazepine, is characterized by maintaining comparatively stable blood
pressure and does not influence the cardiac conduction system, which
renders it a reasonable choice for general anesthesia for cardiac
ablation. We aimed to evaluate whether remimazolam is associated with a
decreased incidence of intraoperative hypotension compared with
desflurane. Method(s): In this single-centre, parallel-group,
prospective, single-blind, randomized clinical trial, we randomized
patients (1:1) into a remimazolam group (remimazolam-based total
intravenous anesthesia) or desflurane group (propofol-induced and
desflurane-maintained inhalational anesthesia) during cardiac ablation
procedures for arrhythmia. The primary outcome was the incidence of
intraoperative hypotensive events, defined as mean arterial pressure of <
60 mm Hg at any period. Result(s): Overall, we enrolled 96 patients
between 2 August 2022 and 19 May 2023 (47 and 49 patients in the
remimazolam and desflurane groups, respectively). The remimazolam group
showed a significantly lower incidence of hypotensive events (14/47, 30%)
than the desflurane group (29/49, 59%; relative risk [RR], 0.5; 95%
confidence interval [CI], 0.31 to 0.83; P = 0.004). Remimazolam was
associated with a lower requirement for bolus or continuous vasopressor
infusion than desflurane was (23/47, 49% vs 43/49, 88%; RR, 0.56; 95% CI,
0.41 to 0.76; P < 0.001). No between-group differences existed in the
incidence of perioperative complications such as nausea, vomiting, oxygen
desaturation, delayed emergence, or pain. Conclusion(s): Remimazolam
was a viable option for general anesthesia for cardiac ablation.
Remimazolam-based total intravenous anesthesia was associated with
significantly fewer hypotensive events and vasopressor requirements than
desflurane-based inhalational anesthesia was, without significantly more
complications. Study registration: ClinicalTrials.gov (NCT05486377); first
submitted 1 August 2022. Copyright © Canadian Anesthesiologists'
Society 2024.

<64>
Accession Number
2030379379
Title
The Benefits of Physical Activity on Patients with Heart Failure:
Meta-analysis.
Source
Revista de la Federacion Argentina de Cardiologia. 53(1) (pp 24-31), 2024.
Date of Publication: 26 Mar 2024.
Author
Mandias R.J.; Maramis J.; Korengkeng L.C.; Ruku D.M.
Institution
(Mandias, Maramis, Korengkeng, Ruku) Faculty of Nursing, Klabat
University, Manado 95371, Indonesia
(Korengkeng) Department of Public Health, Adventist University of the
Philippines, Silang Cavite, Putting Kahoy 4118, Philippines
Publisher
Federacion Argentina de Cardiologia
Abstract
Objective: this study aimed to compare the impact of physical activity
(PA) on improving exercise capacity (EC), functional capacity (FC), and
physical function (PF), as well as its influence on left ventricle
ejection fraction (LVEF) and age (middle-aged, or elderly) in patients
with heart failure (HF). Method(s): this study used five databases
namely Embase, MEDLINE, CINAHL, PEDro, Cochrane, and additional resources,
following PRISMA guidelines. Furthermore, the analysis was carried out
using RevMan 5.4 software. Result(s): a total of 27 articles with
randomized control trial (RCT) design were included in this review. PA had
a significant effect on increasing EC (SDM: 0.32, 95% CI:-0.01 to 0.65,
I2: 82%), FC (SDM: 0.65, 95% CI: 0.29 to 1.01, I2: 81%), and PF (SDM:
0.36, 95% CI: 0.06 to 0.65, I2: 60%). Additionally, there was a
significant effect on LVEF <45% (SDM: 0.46, 95% CI: 0.23 to 0.69, I2:
80%), LVEF >45% (SDM: 0.54, 95% CI: 0.32 to 0.76, I2: 45%), elderly
patients (SDM: 0.52, 95% CI: 0.29 to 0.74, I2: 79%), and middle-aged
patients (SDM: 0.36, 95% CI: 0.05 to 0.67, I2: 66%) with HF using the Six
Minutes Walking Test measurement (6MWT). Conclusion(s): PA is highly
beneficial for HF patients, serving as cardiac rehabilitation in improving
EC, FC, and PF, including patients with LVEF <45% or LVEF >45%, as well as
for middle-aged and elderly patients. Copyright © 2024,
Federacion Argentina de Cardiologia. All rights reserved.

<65>
Accession Number
2030342606
Title
Ultrasound-guided vs. Standard Coronary Access in Coronary Angiography: A
Systematic Review and Meta-analysis.
Source
Journal of the Saudi Heart Association. 36(2) (no pagination), 2024.
Article Number: 8. Date of Publication: 2024.
Author
Omer I.; Bukhari M.; Alsharif M.; Alsamadani A.; Alahmadi D.; Alsudais
A.S.; Abdulkareem A.; Alamir H.A.
Institution
(Omer, Bukhari, Alsamadani, Alahmadi, Alsudais, Abdulkareem, Alamir)
College of Medicine, King Saud Bin Abdulaziz University for Health
Sciences, Jeddah, Saudi Arabia
(Omer, Bukhari, Alsamadani, Alahmadi, Alsudais, Abdulkareem, Alamir) King
Abdullah International Medical Research Center, Jeddah, Saudi Arabia
(Alsharif) Department of Medicine, Batterjee Medical College for Health
Sciences and Technology, Jeddah, Saudi Arabia
Publisher
Saudi Heart Association
Abstract
Objectives: Coronary angiography is a procedure performed during cardiac
catheterization to define the coronary anatomy and determine the extent of
coronary artery disease (CAD). The use of a cheap, relatively available
tool like an ultrasound machine to assist in vascular access might reduce
the risks associated with blind access. This study aimed to explore the
efficacy and associated complications of ultrasound-guided coronary artery
catheterization. Method(s): This systematic review of randomized
controlled trials (RCTs) was conducted according to the Preferred
Reporting Item for Systematic Reviews and Meta-Analysis (PRISMA) and was
registered in PROSPERO (CRD42022365518). A systematic search was performed
for all published studies without language or country restrictions and all
study variables were extracted into prefilled sheets by two independent
reviewers. Result(s): This meta-analysis identified 10 RCTs. The
results confirmed statistically significantly reductions of total
complications (RR 1/4 0.53, 95% CI 0.39e0.72, P < .001), and hematoma >5
cm formation (RR 1/4 0.43, 95% CI 0.25e0.75, P 1/4 0.003) in patients who
underwent ultrasound-guided coronary artery catheterization.
 Conclusion(s): Ultrasound with catheterization, as opposed to
landmark-based catheterization, significantly improved the
peri-catheterization operative outcomes, providing evidence for further
research to be conducted and consideration for its implementation within
the medical setting. Copyright © 2024 Saudi Heart Association.

<66>
Accession Number
2029066453
Title
Nonclinical factors affecting intraoperative red blood cell transfusion: a
systematic review.
Source
Canadian Journal of Anesthesia. 71(7) (pp 1023-1036), 2024. Date of
Publication: July 2024.
Author
Lenet T.; Berthelot P.; Grudzinski A.L.; Banks A.; Tropiano J.; McIsaac
D.I.; Tinmouth A.; Patey A.M.; Fergusson D.A.; Martel G.
Institution
(Lenet, Banks, Tropiano) Department of Surgery, The Ottawa Hospital,
Ottawa, ON, Canada
(Lenet, Patey, Fergusson, Martel) Clinical Epidemiology Program, The
Ottawa Hospital Research Institute, Ottawa, ON, Canada
(Berthelot) Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
(Grudzinski, McIsaac) Department of Anesthesiology and Pain Medicine,
University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada
(Tinmouth) Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada
(Tinmouth, Fergusson) Canadian Blood Services, Ottawa, ON, Canada
(Martel) Department of Surgery, The Ottawa Hospital, 501 Smyth Rd, CCW
1667, General Campus, Ottawa, ON K1H 8L6, Canada
Publisher
Springer
Abstract
Purpose: There is significant variability in intraoperative red blood cell
(RBC) transfusion practice. We aimed to use the theoretical domains
framework (TDF) to categorize nonclinical and behavioural factors driving
intraoperative RBC transfusion practice in a systematic review of the
literature. Source: We searched electronic databases from inception until
August 2021 to identify studies evaluating nonclinical factors affecting
intraoperative RBC transfusion. Using the Mixed Methods Appraisal Tool, we
assessed the quality of included studies and identified relevant
nonclinical factors, which were coded into TDF domains by two independent
reviewers using NVivo (Lumivero, QSR International, Burlington, MA, USA).
We identified common themes within domains and sorted domains based on the
frequency of reported factors. Principal findings: Our systematic review
identified 18 studies: nine retrospective cohort studies, six
cross-sectional surveys, and three before-and-after studies. Factors
related to the social influences, behavioural regulation, environmental
context/resources, and beliefs about consequences domains of the TDF were
the most reported factors. Key factors underlying the observed variability
in transfusion practice included the social effects of peers, patients,
and institutional culture on decision-making (social influences), and
characteristics of the practice environment including case volume,
geographic location, and case start time (environmental
context/resources). Studies reported variable beliefs about the
consequences of both intraoperative transfusion and anemia (beliefs about
consequences). Provider- and institutional-level audits, educational
sessions, and increased communication between surgeons/anesthesiologists
were identified as strategies to optimize intraoperative transfusion
decision-making (behavioural regulation). Conclusion(s): Our
systematic review has synthesized the literature on nonclinical and
behavioural factors impacting intraoperative transfusion decision-making,
categorized using the TDF. These findings can inform evidence-based
interventions to reduce intraoperative RBC transfusion variability. Study
registration: Open Science Framework
(https://osf.io/pm8zs/?view_only=166299ed28964804b9360c429b1218c1; first
posted, 3 August 2022) Copyright © Canadian Anesthesiologists'
Society 2024.

<67>
Accession Number
2028980675
Title
Right ventricular outflow tract obstruction in twin-to-twin transfusion
syndrome undergoing laser surgery: A systematic review and meta-analysis.
Source
Acta Obstetricia et Gynecologica Scandinavica. 103(8) (pp 1513-1521),
2024. Date of Publication: August 2024.
Author
Mustafa H.J.; Jawwad M.; IqbalMansoor A.; Pagani G.; D'Antonio F.; Khalil
A.
Institution
(Mustafa) Division of Maternal-Fetal Medicine, Indiana University School
of Medicine, Indianapolis, IN, United States
(Mustafa) The Fetal Center at Riley Children's and Indiana University
Health, Indianapolis, IN, United States
(Jawwad, Iqbal Mansoor) Department of Medicine and Surgery, Dow University
of Health and Sciences, Karachi, Pakistan
(Pagani) Maternal Fetal Medicine Unit, Department of Obstetrics and
Gynecology, ASST-Papa Giovanni XXIII, Bergamo, Italy
(D'Antonio) Center for Fetal Care and High-Risk Pregnancy, Department of
Obstetrics and Gynecology, University Hospital of Chieti, Chieti, Italy
(Khalil) Fetal Medicine Unit, St George's Hospital, St George's University
of London, London, United Kingdom
(Khalil) Vascular Biology Research center, Molecular and Clinical Sciences
Research Institute, St George's University of London, London, United
Kingdom
(Khalil) Twins Trust center for Research and Clinical Excellence, St
George's University of London, London, United Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Introduction: We aimed to investigate the incidence, prenatal factors and
outcomes of twin-to-twin transfusion (TTTS) with right ventricular outflow
tract obstruction (RVOTO). Material(s) and Method(s): A systematic
search was conducted to identify relevant studies published until February
2023 in English using the databases PubMed, Scopus and Web of Science.
Studies reporting on pregnancies with TTTS and RVOTO were included. The
random-effect model pooled the mean differences or odds ratios (OR) and
the corresponding 95% confidence intervals. Heterogeneity was assessed
using the I2 value. Result(s): A total of 17 studies
encompassing 4332 TTTS pregnancies, of which 225 cases had RVOTO, were
included. Incidence of RVOTO at time of TTTS diagnosis was 6%. In all,
134/197 (68%) had functional pulmonary stenosis and 62/197 (32%) had
functional pulmonary atresia. Of these, 27% resolved following laser and
55% persisted after birth. Of those persisting, 27% required cardiac valve
procedures. Prenatal associations were TTTS stage III (53% vs 39% in
no-RVOTO), stage IV TTTS (28% in RVOTO vs 12% in no-RVOTO) and ductus
venosus reversed a-wave (60% in RVOTO vs 19% in no-RVOTO). Gestational age
at laser and gestational age at delivery were comparable between groups.
Survival outcomes were also comparable between groups, including fetal
demise of 26%, neonatal death of 12% and 6-month survival of 82% in RVOTO
group. Findings were similar when subgroup analysis was done for studies
including head-to-head analysis. Conclusion(s): RVOT occurs in about
6% of the recipient twins with TTTS, especially in stages III and IV and
those with reversed ductus venosus a-wave. The findings from this
systematic review support the need for a thorough cardiac assessment of
pregnancies complicated by TTTS, both before and after laser, to maximize
perinatal outcome, and the importance of early diagnosis of TTTS and
timely management. Copyright © 2024 The Authors. Acta Obstetricia
et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf
of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

<68>
Accession Number
644794047
Title
Preoperative statin therapy for adults undergoing cardiac surgery.
Source
Cochrane Database of Systematic Reviews. 2024(7) (no pagination), 2024.
Article Number: CD008493. Date of Publication: 22 Jul 2024.
Author
Marques Antunes M.; Nunes-Ferreira A.; Duarte G.S.; Gouveia e Melo R.;
Sucena Rodrigues B.; Guerra N.C.; Nobre A.; Pinto F.J.; Costa J.; Caldeira
D.
Institution
(Marques Antunes, Gouveia e Melo) Centro Cardiovascular da Universidade de
Lisboa - CCUL@RISE, Faculdade de Medicina da Universidade de Lisboa,
Lisbon, Portugal
(Marques Antunes) Department of Cardiology, Hospital de Santa Marta,
Centro Hospitalar Universitario Lisboa Central (CHULC), Centro Clinico
Academico de Lisboa (CCAL), Lisbon, Portugal
(Nunes-Ferreira, Pinto, Caldeira) Department of Cardiology/Heart and
Vessels, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa
Norte (CHULN), CAML, CCUL@RISE, Faculdade de Medicina, Universidade de
Lisboa, Lisbon, Portugal
(Duarte, Costa) Laboratory of Clinical Pharmacology and Therapeutics,
Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
(Duarte) Hospital da Luz Lisboa, Lisbon, Portugal
(Gouveia e Melo) Department of Vascular Surgery, Hospital de Santa Maria,
Centro Hospitalar Universitario Lisboa Norte (CHULN), CAML, CCUL@RISE,
Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, Lisbon,
Portugal
(Sucena Rodrigues) Department of Intensive Care Medicine, Hospital de
Loures, Lisbon, Portugal
(Guerra, Nobre) Department of Cardiothoracic Surgery, Hospital
Universitario de Santa Maria (CHLN), CAML, Centro Cardiovascular da
Universidade de Lisboa - CCUL@RISE, Lisbon, Portugal
(Caldeira) Laboratorio de Farmacologia Clinica e Terapeutica / Centro
Cardiovascular da Universidade de Lisboa - CCUL@RISE / CEMBE - Centro de
Estudos de Medicina Baseada na Evidencia, Faculdade de Medicina,
Universidade de Lisboa, Lisbon, Portugal
Publisher
John Wiley and Sons Ltd
Abstract
Background: Despite significant advances in surgical techniques and
perioperative care, people undertaking cardiac surgery due to
cardiovascular disease are more prone to the development of postoperative
adverse events. Statins (5-hydroxy-3-methylglutaryl-co-enzyme A (HMG-CoA)
reductase inhibitors) are well-known for their anti-inflammatory and
antioxidant effects and are established for primary and secondary
prevention of coronary artery disease. In addition, statins are thought to
have clinical benefits in perioperative outcomes in people undergoing
cardiac surgery. This review is an update of a review that was first
published in 2012 and updated in 2015. Objective(s): To evaluate the
benefits and harms of preoperative statin therapy in adults undergoing
cardiac surgery compared to standard of care or placebo. Search
Method(s): We performed a search of the Cochrane Central Register of
Controlled Trials (CENTRAL) (Issue 9, 2023), Ovid MEDLINE (1980 to 14
September 2023), and Ovid Embase (1980 to 2023 (week 36)). We applied no
language restrictions. Selection Criteria: We included all randomised
controlled trials (RCTs) comparing any statin treatment before cardiac
surgery, for any given duration and dose, versus no preoperative statin
therapy (standard of care) or placebo. We excluded trials without a
registered trial protocol and trials without approval by an institutional
ethics committee. Data Collection and Analysis: We used standard
Cochrane methodology. Primary outcomes were short-term mortality and major
adverse cardiovascular events. Secondary outcomes were myocardial
infarction, atrial fibrillation, stroke, renal failure, length of
intensive care unit (ICU) stay, length of hospital stay and adverse
effects related to statin therapy. We reported effect measures as risk
ratios (RRs) or mean differences (MDs) with corresponding 95% confidence
intervals (CIs). We used the RoB 1 tool to assess the risk of bias in
included trials, and GRADE to assess the certainty of the evidence.
 Main Result(s): We identified eight RCTs (five new to this review)
including 5592 participants. Pooled analysis showed that statin treatment
before surgery may result in little to no difference in the risk of
postoperative short-term mortality (RR 1.36, 95% CI 0.72 to 2.59;
I2 = 0%; 6 RCTs, 5260 participants; low-certainty evidence;
note 2 RCTs reported 0 events in both groups so RR calculated from 4 RCTs
with 5143 participants). We are very uncertain about the effect of statins
on major adverse cardiovascular events (RR 0.93, 95% CI 0.77 to 1.13; 1
RCT, 2406 participants; very low-certainty evidence). Statins probably
result in little to no difference in myocardial infarction (RR 0.88, 95%
CI 0.73 to 1.06; I2 = 0%; 5 RCTs, 4645 participants;
moderate-certainty evidence), may result in little to no difference in
atrial fibrillation (RR 0.87, 95% CI 0.72 to 1.05; I2 = 60%; 8
RCTs, 5592 participants; low-certainty evidence), and may result in little
to no difference in stroke (RR 1.47, 95% CI 0.90 to 2.40; I2 =
0%; 4 RCTs, 5143 participants; low-certainty evidence). We are very
uncertain about the effect of statins on renal failure (RR 1.04, 95% CI
0.80 to 1.34; I2 = 57%; 4 RCTs, 4728 participants; very
low-certainty evidence). Additionally, statins probably result in little
to no difference in length of ICU stay (MD 1.40 hours, 95% CI -1.62 to
4.41; I2 = 43%; 3 RCTs, 4528 participants; moderate-certainty
evidence) and overall hospital stay (MD -0.31 days, 95% CI -0.64 to 0.03;
I2 = 84%; 5 RCTs, 4788 participants; moderate-certainty
evidence). No study had any individual risk of bias domain classified as
high. However, two studies were at high risk of bias overall given the
classification of unclear risk of bias in three domains. Authors'
conclusions: In this updated Cochrane review, we found no evidence that
statin use in the perioperative period of elective cardiac surgery was
associated with any clinical benefit or worsening, when compared with
placebo or standard of care. Compared with placebo or standard of care,
statin use probably results in little to no difference in MIs, length of
ICU stay and overall hospital stay; and may make little to no difference
to mortality, atrial fibrillation and stroke. We are very uncertain about
the effects of statins on major harmful cardiac events and renal failure.
The certainty of the evidence validating this finding varied from moderate
to very low, depending on the outcome. Future trials should focus on
assessing the impact of statin therapy on mortality and major adverse
cardiovascular events. Copyright © 2024 The Cochrane
Collaboration. Published by John Wiley & Sons, Ltd.

<69>
Accession Number
2033509928
Title
A Bright Future for Tricuspid Repair Success.
Source
Journal of the American College of Cardiology. 84(7) (pp 617-619), 2024.
Date of Publication: 13 Aug 2024.
Author
Sorajja P.; Hamid N.
Institution
(Sorajja, Hamid) Valve Science Center, Minneapolis Heart Institute
Foundation, and the Allina Health Minneapolis Heart Institute at Abbott
Northwestern Hospital, Minneapolis, MN, United States
Publisher
Elsevier Inc.

<70>
[Use Link to view the full text]
Accession Number
2033489974
Title
Nanotechnology-based Strategies for Molecular Imaging, Diagnosis, and
Therapy of Organ Transplantation.
Source
Transplantation. 108(8) (pp 1730-1748), 2024. Date of Publication: 01 Aug
2024.
Author
Sun R.; Wang N.; Zheng S.; Wang H.; Xie H.
Institution
(Sun, Wang, Zheng, Wang, Xie) Division of Hepatobiliary and Pancreatic
Surgery, Department of Surgery, First Affiliated Hospital, School of
Medicine, Zhejiang University, Zhejiang Province, Hangzhou, China
(Sun, Wang, Zheng, Wang, Xie) NHC Key Laboratory of Combined Multi-organ
Transplantation, Zhejiang Province, Hangzhou, China
(Sun, Wang, Zheng, Wang, Xie) Key Laboratory of the Diagnosis and
Treatment of Organ Transplantation, CAMS, Zhejiang Province, Hangzhou,
China
(Sun, Wang, Zheng, Wang, Xie) Key Laboratory of Organ Transplantation,
Zhejiang Province, Hangzhou, China
(Sun, Wang, Zheng, Wang, Xie) State Key Laboratory for Diagnosis and
Treatment of Infectious Diseases, Zhejiang Province, Hangzhou, China
Publisher
Lippincott Williams and Wilkins
Abstract
Organ transplantation is the preferred paradigm for patients with
end-stage organ failures. Despite unprecedented successes, complications
such as immune rejection, ischemia-reperfusion injury, and graft
dysfunction remain significant barriers to long-term recipient survival
after transplantation. Conventional immunosuppressive drugs have limited
efficacy because of significant drug toxicities, high systemic immune
burden, and emergence of transplant infectious disease, leading to poor
quality of life for patients. Nanoparticle-based drug delivery has emerged
as a promising medical technology and offers several advantages by
enhancing the delivery of drug payloads to their target sites, reducing
systemic toxicity, and facilitating patient compliance over free drug
administration. In addition, nanotechnology-based imaging approaches
provide exciting diagnostic methods for monitoring molecular and cellular
changes in transplanted organs, visualizing immune responses, and
assessing the severity of rejection. These noninvasive technologies are
expected to help enhance the posttransplantation patient survival through
real time and early diagnosis of disease progression. Here, we present a
comprehensive review of nanotechnology-assisted strategies in various
aspects of organ transplantation, including organ protection before
transplantation, mitigation of ischemia-reperfusion injury, counteraction
of immune rejection, early detection of organ dysfunction
posttransplantation, and molecular imaging and diagnosis of immune
rejection. Copyright © 2024 Lippincott Williams and Wilkins. All
rights reserved.

<71>
Accession Number
2033446359
Title
The Klotho protein and FGF23 as well-known players in the aging process
but underestimated in the process of individual development and selected
diseases of childhood and adolescence - a systematic review.
Source
Pediatria i Medycyna Rodzinna. 20(1) (pp 17-28), 2024. Date of
Publication: 2024.
Author
Wiernik A.; Hyla-Klekot L.; Brauner P.; Kudela G.; Partyka M.; Koszutski
T.
Institution
(Wiernik, Hyla-Klekot, Brauner, Kudela, Koszutski) Department of
Paediatric Surgery and Urology, Medical University of Silesia, Katowice,
Poland
(Partyka) Department of Laboratory Diagnostics, Upper Silesian Children's
Health Centre named after Saint John Paul II, Independent Public Clinical
Hospital No. 6, Medical University of Silesia, Katowice, Poland
Publisher
Medical Communications
Abstract
Introduction and objective: The FGF23-Klotho endocrine axis plays a
pivotal role not only in processes associated with aging but also in
metabolic pathways, with implications for paediatric disorders. The aim of
this study was to systematically review the existing literature on Klotho
and FGF23 in the paediatric population. Material(s) and Method(s):
Based on the PubMed and Web of Science databases, we conducted a
PRISMA-guided search using (klotho) AND (children); (FGF23) AND
(children), adhering strictly to the PRISMA guidelines, and assessed
evidence quality. Result(s): The systematic review included 66
studies. Altered Klotho and FGF23 serum levels were observed in paediatric
metabolic conditions (chronic kidney disease, diabetes), cardiovascular,
and growth and musculoskeletal disorders. In some of them, Klotho and
FGF23 serum levels changed with disorder treatment. Elevated FGF23 and
Klotho deficiency in renal failure adversely impacted the cardiovascular
system. Lower Klotho levels were found in preterm neonates, especially
with bronchopulmonary dysplasia. Early Klotho supplementation in a
bronchopulmonary dysplasia model mitigated lung tissue changes and
improved the cardiac function. Children with lower Klotho levels
undergoing cardiac surgeries faced a higher risk of postoperative
complications, especially acute kidney injury. In X-linked
hypophosphataemia, excess FGF23 led to musculoskeletal consequences. FGF23
serum levels aided the diagnosis of hypophosphataemic rickets, and
anti-FGF23 antibody emerged as a common X-linked hypophosphataemia
treatment. Conclusion(s): Klotho and FGF23 serve as promising early
markers for paediatric metabolic disorders, offering a valuable tool for
assessing complication risks. Klotho supplementation holds promise as a
treatment method for specific paediatric disorders, while anti-FGF23
antibody is already established in X-linked hypophosphataemia
treatment. Copyright © 2024 Wiernik et al.

<72>
[Use Link to view the full text]
Accession Number
2033440639
Title
Combined Melanocytic Nevus and Nevus Sebaceus: A Case Series and Review of
the Literature.
Source
American Journal of Dermatopathology. 46(8) (pp 525-529), 2024. Date of
Publication: 01 Aug 2024.
Author
Schroedl L.M.; Lullo J.J.; De Luzuriaga A.M.R.; Shea C.R.
Institution
(Schroedl, Lullo, De Luzuriaga, Shea) University of Chicago Section of
Dermatology, Chicago, IL, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Nevus sebaceus is a rare congenital hamartoma with clinical and
histopathological features that change with puberty. It has been
associated with a number of secondary neoplasms, most of which are thought
to derive from follicular germ cells. In this article, the authors
describe a total of 3 cases of combined melanocytic nevus and nevus
sebaceus to highlight this rare finding. Copyright © 2024 Wolters
Kluwer Health, Inc. All rights reserved.

<73>
Accession Number
2033427770
Title
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Source
New England Journal of Medicine. 391(3) (pp 213-223), 2024. Date of
Publication: 18 Jul 2024.
Author
Peyrin-Biroulet L.; Chapman J.C.; Colombel J.-F.; Caprioli F.; D'Haens G.;
Ferrante M.; Schreiber S.; Atreya R.; Danese S.; Lindsay J.O.; Bossuyt P.;
Siegmund B.; Irving P.M.; Panaccione R.; Cao Q.; Neimark E.; Wallace K.;
Anschutz T.; Kligys K.; Duan W.R.; Pivorunas V.; Huang X.; Berg S.; Shu
L.; Dubinsky M.
Institution
(Peyrin-Biroulet) The Department of Gastroenterology, INFINY Institute,
INSERM NGERE, Centre Hospitalier Regional Universitaire de Nancy,
Vandoeuvre-les-Nancy, France
(Peyrin-Biroulet) The Division of Gastroenterology and Hepatology, McGill
University Health Centre, Montreal, Canada
(Panaccione) The Inflammatory Bowel Disease Unit, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, AB,
Canada
(Chapman) The Crohn's and Colitis Center, The Baton Rouge General and the
GI Alliance, Baton Rouge, LA, United States
(Colombel) The Henry D. Janowitz Division of Gastroenterology, Department
of Medicine, Icahn School of Medicine, Mount Sinai, NY, United States
(Dubinsky) The Susan and Leonard Feinstein IBD Center, Icahn School of
Medicine, Mount Sinai, NY, United States
(Caprioli) The Department of Pathophysiology and Transplantation,
Universita degli Studi di Milano, The Unit of Gastroenterology and
Endoscopy, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico di
Milano, Milan, Italy
(Danese) Department of Gastroenterology and Endoscopy, IRCCS Ospedale San
Raffaele, University Vita-Salute San Raffaele, Milan, Italy
(D'Haens) The Department of Gastroenterology, Amsterdam University Medical
Centers, Amsterdam, Netherlands
(Ferrante) The Department of Gastroenterology and Hepatology, University
Hospitals Leuven, KU Leuven, Leuven, Belgium
(Bossuyt) The Imelda GI Clinical Research Center, Department of
Gastroenterology, Imelda General Hospital, Bonheiden, Belgium
(Schreiber) The Department of Medicine I, University Hospital
Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany
(Atreya) The Department of Medicine 1, Friedrich-Alexander-Universitat
Erlangen-Nurnberg, Erlangen, Germany
(Siegmund) The Department of Gastroenterology, Infectious Diseases and
Rheumatology, Charite-Universitatsmedizin Berlin, Humboldt-Universitat zu
Berlin, Berlin, Germany
(Lindsay) The Centre for Immunobiology, Barts and the London School of
Medicine and Dentistry, Queen Mary University of London, London, United
Kingdom
(Irving) The Department of Gastroenterology, Guy's and St Thomas' NHS
Foundation Trust, London, United Kingdom
(Irving) The School of Immunology and Microbial Sciences, King's College
London, London, United Kingdom
(Cao) The Department of Gastroenterology, Sir Run Run Shaw Hospital,
College of Medicine, Zhejiang University, Hangzhou, China
(Neimark, Wallace, Anschutz, Kligys, Duan, Pivorunas, Huang, Berg, Shu)
AbbVie, North Chicago, IL, United States
Publisher
Massachussetts Medical Society
Abstract
BACKGROUND The efficacy and safety of risankizumab as compared with
ustekinumab in patients with Crohn's disease are unknown. METHODS In this
phase 3b, multicenter, open-label, randomized, controlled trial with
blinded assessment of end points, patients with moderate-to-severe Crohn's
disease who had had an inadequate response to anti-tumor necrosis factor
(TNF) therapy or unacceptable side effects with such therapy were randomly
assigned to receive risankizumab or ustekinumab at standard doses for 48
weeks. The two primary end points, which were tested sequentially, were
clinical remission at week 24 (defined as a Crohn's Disease Activity Index
score of <150 [range, 0 to 600, with higher scores indicating more severe
disease activity]), which was analyzed in the first 50% of patients to
complete the week 24 visit, with a noninferiority margin of 10 percentage
points; and endoscopic remission at week 48 (defined as a score of <=4, a
decrease of >=2 points from baseline, and no subscore >1 in any individual
variable on the Simple Endoscopic Score for Crohn's Disease [range, 0 to
56, with higher scores indicating more severe disease]), which was
analyzed for superiority in 100% of the patients. Safety was assessed in
all patients who received at least one dose of risankizumab or
ustekinumab. RESULTS In the full intention-to-treat population for the
efficacy analysis, 230 of 255 patients (90.2%) who received risankizumab
and 193 of 265 patients (72.8%) who received ustekinumab completed all the
assigned treatments. Both primary end points were met; risankizumab was
noninferior to ustekinumab with respect to clinical remission at week 24
(58.6% vs. 39.5%; adjusted difference, 18.4 percentage points; 95%
confidence interval [CI], 6.6 to 30.3) and superior to ustekinumab with
respect to endoscopic remission at week 48 (31.8% vs. 16.2%; adjusted
difference, 15.6 percentage points; 95% CI, 8.4 to 22.9; P<0.001). The
incidence of adverse events appeared to be similar in the two groups.
CONCLUSIONS In this head-to-head clinical trial of risankizumab and
ustekinumab involving patients with moderate-to-severe Crohn's disease who
had had unacceptable side effects with anti-TNF therapy or an inadequate
response to such therapy, risankizumab was noninferior to ustekinumab with
respect to clinical remission at week 24 and superior with respect to
endoscopic remission at week 48. Copyright © 2024 Massachusetts
Medical Society.

<74>
Accession Number
2033404456
Title
Comparative Efficacy of Percutaneous Coronary Intervention Versus Coronary
Artery Bypass Grafting in the Treatment of Ischemic Heart Disease: A
Systematic Review and Meta-Analysis of Recent Randomized Controlled
Trials.
Source
Cardiology Research. 15(3) (pp 153-168), 2024. Date of Publication: 2024.
Author
Llerena-Velastegui J.; Zumbana-Podaneva K.; Velastegui-Zurita S.;
Mejia-Mora M.; Perez-Tomassetti J.; Cabrera-Cruz A.; Haro-Arteaga P.; de
Jesus A.C.F.S.; Coelho P.M.; Sanahuja-Montiel C.
Institution
(Llerena-Velastegui, Zumbana-Podaneva, Velastegui-Zurita, Mejia-Mora)
Pontifical Catholic University of Ecuador, Medical School, Quito, Ecuador
(Llerena-Velastegui) Center for Health Research in Latin America (CISeAL),
Research Center, Quito, Ecuador
(Perez-Tomassetti) University of the Americas, Medical School, Quito,
Ecuador
(Cabrera-Cruz) Catholic University of Santiago de Guayaquil, Medical
School, Guayaquil, Ecuador
(Haro-Arteaga) University of La Rioja, Logrono, Spain
(de Jesus, Coelho) Faculdade de Minas - FAMINAS-BH, Medical School, Belo
Horizonte, Brazil
(Sanahuja-Montiel) University of Medical Sciences, Medical School, San
Jose, Costa Rica
Publisher
Elmer Press
Abstract
Background: Ischemic heart disease (IHD) is a major global health issue
and a leading cause of death. This study compares the effectiveness of
percutaneous coronary intervention (PCI) and coronary artery bypass
grafting (CABG) in the management of IHD, focusing on their impact on
revascularization, myocardial infarction (MI), and post-procedural stroke.
This study aimed to evaluate and compare the effectiveness of PCI and CABG
in treating IHD based on an exhaustive literature review of the past 5
years, emphasizing recent advancements and outcomes in IHD management.
 Method(s): A comprehensive literature review analyzed 32 randomized
controlled trials (RCTs) retrieved from databases such as PubMed, Cochrane
Library, and Google Scholar. The study specifically assessed the
incidences of revascularization, stroke, and MI in patients treated with
either PCI or CABG. The comparison between CABG and PCI exclusively
focused on lesions with a SYNTAX score exceeding 32. Result(s): Our
findings highlight CABG's significant efficacy over PCI in reducing
revascularization and MI. The aggregated Mantel-Haenszel (M-H) value for
revascularization was 1.85 (95% confidence interval (CI): 1.65 - 2.07),
signifying CABG's advantage. Additionally, CABG demonstrated superior
performance in diminishing MI occurrences (M-H = 2.71, 95% CI: 1.13 -
6.53). In contrast, PCI was more effective in reducing stroke (M-H = 0.80,
95% CI: 0.60 - 1.10). Conclusion(s): The study confirms CABG's
superiority in reducing revascularization and MI in IHD patients,
highlighting PCI's effectiveness in reducing stroke risk. These findings
underscore the importance of personalized treatment strategies in IHD
management and emphasize the need for ongoing research and evidence-based
guidelines to aid in treatment selection for IHD patients. Copyright
© Journal compilation

<75>
Accession Number
2030711393
Title
Editorial: Spontaneous coronary artery dissection: current state of
diagnosis and treatment.
Source
Frontiers in Cardiovascular Medicine. 11 (no pagination), 2024. Article
Number: 1455983. Date of Publication: 2024.
Author
Apostolovic S.; Aleksandric S.; Beleslin B.
Institution
(Apostolovic) Cardiology Clinic, University Clinical Center of Nis, Nis,
Serbia
(Apostolovic) Medical Faculty, University of Nis, Nis, Serbia
(Aleksandric, Beleslin) Cardiology Clinic, University Clinical Center of
Serbia, Belgrade, Serbia
(Aleksandric, Beleslin) Faculty of Medicine, University of Belgrade,
Belgrade, Serbia
Publisher
Frontiers Media SA

<76>
Accession Number
2030680274
Title
Use of colloids and crystalloids for perioperative clinical infusion
management in cardiac surgery patients and postoperative outcomes: a
meta-analysis.
Source
Perioperative Medicine. 13(1) (no pagination), 2024. Article Number: 83.
Date of Publication: December 2024.
Author
Chen S.-D.; Ma Y.-T.; Wei H.-X.; Ou X.-R.; Liu J.-Y.; Tian Y.-L.; Zhang
C.; Xu Y.-J.; Kong Y.
Institution
(Chen, Ma, Ou, Liu, Tian, Zhang) Center for Evidence-Based Medicine and
Clinical Research, Taihe Hospital, Hubei University of Medicine, No.32,
Renmin South Road, Hubei, Shiyan 442000, China
(Chen, Wei) Department of Anesthesia, Taihe Hospital, Hubei University of
Medicine, No.32, Renmin South Road, Hubei, Shiyan 442000, China
(Xu) Department of Pediatric, Taihe Hospital, Hubei University of
Medicine, No.32, Renmin South Road, Hubei, Shiyan 442000, China
(Kong) Department of Spine, Taihe Hospital, Hubei University of Medicine,
No.32, Renmin South Road, Hubei, Shiyan 442000, China
Publisher
BioMed Central Ltd
Abstract
Background: The optimal fluid management strategy for patients undergoing
cardiac surgery was controversial regarding fluid volume and
intraoperative fluid types. This study aimed to assess the correlation
between colloids and crystalloids used for perioperative fluid therapy in
cardiac surgery patients and postoperative prognosis. Method(s): The
Ovid MEDLINE(R) ALL, Embase, and Cochrane Central Register of Controlled
Trials databases were searched for eligible studies on fluid management
strategies using colloids and crystalloids for cardiac surgery patients
published before August 25th, 2023. Result(s): Ten randomized
controlled trials met the eligibility criteria. Compared to the use of
crystalloids, the use of colloids, including hydroxyethyl starch (HES),
albumin, and gelatine, did not show any differences in mortality,
transfusion, acute kidney injury, and atrial fibrillation rates,
postoperative blood loss, the length of hospital stay, or the length of
intensive care unit (ICU) stay. The results of this meta-analysis showed
that the crystalloid group had significantly reduced postoperative chest
tube output compared to the colloid group. In the subgroup analysis, the
amount of fresh frozen plasma (FFP) infused was significantly lower when
using fluid management in the ICU and when using isotonic crystalloids
compared to the colloids. In addition, when using fluid management in the
ICU, patients in the colloid group had a significant increase in urine
volume 24 h after surgery. However, other related factors, including the
type of crystalloid solution, type of colloidal solution, and timing of
liquid management, did not affect most outcomes. Conclusion(s): Both
colloids and crystalloids could be used as alternatives for perioperative
fluid management after cardiac surgery. The use of crystalloids
significantly reduced the postoperative chest tube output, and the need
for FFP infusion decreased significantly with the use of isotonic
crystalloids or fluid management during the ICU stay. ICU patients in the
colloid group had higher urine output 24 h after surgery. In addition,
although the infusion method was not related to most outcomes, the rates
of red blood cell and FFP transfusion and postoperative blood loss in the
crystalloid group seemed to be lower, which needed to be further studied
in high-quality and large-sample RCTs. Trial registration: PROSPERO,
CRD42023415234. Copyright © The Author(s) 2024.

<77>
Accession Number
2033505379
Title
Attenuation of hemodynamic responses to endotracheal extubation with
different doses of Diltiazem with Lignocaine: A randomized control study.
Source
European Journal of Cardiovascular Medicine. 13(4) (pp 496-507), 2023.
Date of Publication: 2023.
Author
Atram S.; Dhruv M.K.
Institution
(Atram) dept of anaesthesia, grant govt medical college Mumbai, India
(Dhruv) dept.of anaesthesia, grant govt medical college Mumbai, India
Publisher
Healthcare Bulletin
Abstract
Background: Endotracheal extubation is one of the frequently performed
procedure in the practice of Anaesthesia. This study was done to observe
the haemodynamic responses during tracheal extubation and to compare the
efficacy of IV diltiazem 0.3 mg/kg wih IV Lidocaine 1 mg/kg versus 0.2
mg/kg and 0.1 mg /kg IV Diltiazem with 1mg/kg IV Lignocaine in attenuating
the hemodynamic response to tracheal extubation. Method(s): 120
patients aged 20 to 60 yrs, belonging to ASA I and II, normotensive were
included in the study and they were randomly allocated into 3 groups of 40
each. *Group -I The patient who receive injection Diltiazem 0.1mg/kg and
inj Lignocaine 1mg/kg i.v. (n=40) * Grade -II The patients who receive
injection Diltiazem 0.2mg/kg and inj.Lignocaine 1mg/kg i.v. (n=40) *Group
-III The patients who receive injection Diltiazem 0.3mg/kg and
inj.Lignocaine 1mg/kg i.v. (n=40) 2 min before extubation. At the end of
the surgery, heart rate (HR), systolic blood pressure (SBP) diastolic
blood pressure (DBP) and mean arterial pressure [MAP] were recorded served
as base line values. Result(s): After tracheal extubation, all the
haemodynamic parameters increase from base line,0.3 mg/kg inj. Diltiazem
along with 1mg/kg inj Lignocaine provide better haemodynamic stability
when compared with 0.1 mg/kg and 0.2 mg/kg inj Diltiazem along with inj.
Lignocaine 1mg/kg each. 0.2 mg/kg inj.Diltiazem along with 1mg/kg inj
Lignocaine provide better haemodynamic stability when compared with 0.1 mg
inj Diltiazem with inj. Lignocaine 1mg/kg. Conclusion(s): Based on
the findings of our study, we concluded that combination effect of Inj.
Lignocaine and Inj. Diltiazem, Attenuate the hemodynamic response to
extubation. 0.3mg/kg Diltiazem with 1mg/kg Lignocaine is superior to
0.2mg/kg and 0.1 mg/kg Diltiazem with 1mg/kg Lignocaine in attenuating the
hemodynamic response to extubation. 0.2mg/kg Diltiazem with 1mg/kg
Lignocaine is superior to 0.1mg/kg Diltiazem with 1mg /kg lignocaine in
attenuating the hemodynamic response to extubation. Further studies are
required to evaluate the advantage, beneficial effect and safety of
Diltiazem in comparison with other drugs when used for the purpose of
attenuating the hemodynamic changes associated with
extubation. Copyright © 2023 Healthcare Bulletin. All rights
reserved.

<78>
Accession Number
2033500609
Title
Comparing Left Bundle Branch Area vs Right-Ventricular Septal Pacing in
High-Degree Conduction Disease After Transcatheter Aortic Valve
Replacement: Randomized Trial Study Protocol.
Source
CJC Open. (no pagination), 2024. Date of Publication: 2024.
Author
Liskov S.; Olleik F.; Jarrett H.; Abramson S.; Kowey P.; Schaller R.D.;
Vijayaraman P.; Habibi M.; Bansal S.; Heimann M.; Cox S.; Keramati A.R.
Institution
(Liskov) Section of Cardiac Electrophysiology, Division of Cardiology,
Johns Hopkins Hospital, Baltimore, MD, United States
(Liskov, Jarrett, Abramson, Kowey, Bansal, Keramati) Lankenau Institute
for Medical Research, Wynnewood, PA, United States
(Olleik, Jarrett, Abramson, Kowey, Heimann, Cox, Keramati) Lankenau Heart
Institute, Lankenau Medical Center, Wynnewood, PA, United States
(Abramson, Kowey) Sidney Kimmel Medical College of Thomas Jefferson
University, Philadelphia, PA, United States
(Schaller) Electrophysiology Section, Cardiovascular Medicine Division,
Hospital of the University of Pennsylvania, Philadelphia, PA, United
States
(Vijayaraman) Geisinger Heart Institute, Wilkes-Barre, PA, United States
(Habibi) Valley Health System, Paramus, NJ, United States
Publisher
Elsevier Inc.
Abstract
Left bundle branch area pacing (LBBAP) is a novel method of
conduction-system pacing in the muscular interventricular septum. Although
LBBAP has been shown to produce physiologic electrical and mechanical
intraventricular synchrony, superiority of LBBAP, compared to right
ventricular septal pacing (RVSP) at preserving normal left-ventricular
(LV) systolic function after transcatheter aortic valve replacement (TAVR)
has not been demonstrated. Left Bundle BRAVE is an investigator-initiated,
multicentre, prospective, double-blinded, randomized, crossover study
investigating the superiority of LBBAP, compared to RVSP, with respect to
preservation of systolic function in patients with high-degree conduction
disease after TAVR. Adults with severe aortic stenosis and normal systolic
function who sustain high-grade atrioventricular block within 4 weeks of
TAVR are eligible. All subjects receive a biventricular pacemaker
generator with RVSP, and LBBAP leads. Participants are randomly assigned
to 9 months of each pacing mode, in series. The primary endpoint is change
in global longitudinal strain, tested in series with change in LV ejection
fraction, comparing RVSP to LBBAP. Secondary endpoints include the
following: echocardiographic markers of interventricular synchrony and
right ventricular performance; heart failure functional status and symptom
classification; 6-minute walk test results; pacemaker and lead
performance; and brain natriuretic peptide concentration. The Left Bundle
BRAVE study is designed to identify an upstream and clinically relevant
marker of superiority in LBBAP, compared to RVSP, at preventing
deterioration of LV function in patients with a high ventricular pacing
burden after TAVR. ClinicalTrials.gov identifier:
NCT05541679 Copyright © 2024 The Authors

<79>
Accession Number
2033478692
Title
Improving Cardiac Rehabilitation Adherence in Patients with Lower
Socioeconomic Status: A Randomized Clinical Trial.
Source
JAMA Internal Medicine. (no pagination), 2024. Date of Publication: 2024.
Author
Gaalema D.E.; Khadanga S.; Savage P.D.; Yant B.; Katz B.R.; Desarno M.;
Ades P.A.
Institution
(Gaalema, Yant, Katz) Department of Psychiatry, University of Vermont,
Larner College of Medicine, Burlington, United States
(Gaalema) Department of Medicine, Division of Cardiology, University of
Texas Medical Branch, Galveston, United States
(Khadanga, Savage, Ades) Department of Medicine, Division of Cardiology,
University of Vermont, Burlington, United States
(Desarno) Biomedical Statistics Research Core, University of Vermont,
Burlington, United States
Publisher
American Medical Association
Abstract
Importance: Participation in cardiac rehabilitation is associated with
significant decreases in morbidity and mortality. Despite the proven
benefits, cardiac rehabilitation is severely underutilized in certain
populations, specifically those with lower socioeconomic status (SES).
 Objective(s): To assess the efficacy of early case management and/or
financial incentives for increasing cardiac rehabilitation adherence among
patients with lower SES. Design, Setting, and Participant(s): This
randomized clinical trial enrolled patients from December 2018 to December
2022. Participants were followed up for 1 year with assessors and cardiac
rehabilitation staff blinded to study condition. Patients with lower SES
with a cardiac rehabilitation-qualifying diagnosis (myocardial infarction,
coronary artery bypass graft, percutaneous coronary intervention, heart
valve replacement/repair, or stable systolic heart failure) were
recruited. Then patients attended one of 3 cardiac rehabilitation programs
at 1 university or 2 community-based hospitals. A consecutively recruited
sample was randomized and stratified by age (<57 vs >=57 years) and
smoking status (current smoker vs nonsmoker or former smoker).
 Intervention(s): Participants were randomized 2:3:3:3 to either a
usual care control, case management starting in-hospital, financial
incentives for completing cardiac rehabilitation sessions, or both
interventions (case management plus financial incentives). Interventions
were in place for 4 months following informed consent. Main Outcomes
and Measures: The main outcome was cardiac rehabilitation adherence
(proportion of patients completing >=30 sessions). The a priori hypothesis
was that interventions would improve adherence, with the combined
intervention performing best. Result(s): Of 314 individuals
approached, 11 were ineligible, and 94 declined participation. Of the 209
individuals who were randomized, 17 were withdrawn. A total of 192
individuals (67 [35%] female; mean [SD] age, 58 [11] years) were included
in the analysis. Interventions significantly improved cardiac
rehabilitation adherence with 4 of 36 (11%), 13 of 51 (25%), 22 of 53
(42%), and 32 of 52 (62%) participants completing at least 30 sessions in
the usual care, case management, financial incentives, and case management
plus financial incentives conditions, respectively. The financial
incentives and case management plus financial incentives conditions
significantly improved cardiac rehabilitation adherence vs usual care
(adjusted odds ratio [AOR], 5.1 [95% CI, 1.5-16.7]; P =.01; AOR, 13.2 [95%
CI, 4.0-43.5]; P <.001, respectively), and the case management plus
financial incentives condition was superior to both case management or
financial incentives alone (AOR, 5.0 [95% CI, 2.1-11.9]; P <.001; AOR, 2.6
[95% CI, 1.2-5.9]; P =.02, respectively). Interventions were received well
by participants: 86 of 105 (82%) in the financial incentives conditions
earned at least some incentives, and 96 of 103 participants (93%) assigned
to a case manager completed the initial needs assessment. Conclusion and
Relevance: In this randomized clinical trial, financial incentives
improved cardiac rehabilitation adherence in a population with higher risk
and lower SES with additional benefit from adding case management. Trial
Registration: ClinicalTrials.gov Identifier: NCT03759873. Copyright
© 2024 American Medical Association. All rights reserved.

<80>
Accession Number
2033297679
Title
Addressing the Need to Improve Long Term Survival Following Lower
Extremity Revascularisation in a Randomised Controlled Trial.
Source
European Journal of Vascular and Endovascular Surgery. (no pagination),
2024. Date of Publication: 2024.
Author
Krievins D.; Erglis A.; Zarins C.K.
Institution
(Krievins) Department of Vascular Surgery, Pauls Stradins Clinical
University Hospital, Riga, Latvia
(Krievins, Erglis) Faculty of Medicine, University of Latvia, Riga, Latvia
(Erglis) Department of Cardiology, Pauls Stradins Clinical University
Hospital, Riga, Latvia
(Zarins) HeartFlow Inc., Mountain View, CA, United States
Publisher
W.B. Saunders Ltd

<81>
Accession Number
2033413332
Title
The utility of the Montreal cognitive assessment (MoCA) in detecting
cognitive impairment in surgical populations - A systematic review and
meta-analysis.
Source
Journal of Clinical Anesthesia. 97 (no pagination), 2024. Article Number:
111551. Date of Publication: October 2024.
Author
Danquah M.O.; Yan E.; Lee J.W.; Philip K.; Saripella A.; Alhamdah Y.; He
D.; Englesakis M.; Chung F.
Institution
(Danquah, Yan, Philip, Saripella, Alhamdah, He, Chung) Department of
Anesthesia and Pain Management, Toronto Western Hospital, University
Health Network, University of Toronto, Toronto, ON, Canada
(Yan, Alhamdah, Chung) Institute of Medical Science, Temerty Faculty of
Medicine, University of Toronto, ON, Canada
(Lee) University of Saskatchewan College of Medicine, Saskatoon, SK,
Canada
(He) Department of Anesthesiology and Pain Medicine, Mount Sinai Hospital,
Sinai Health, Toronto, ON, Canada
(Englesakis) Library & Information Services, University Health Network,
Toronto, ON, Canada
Publisher
Elsevier Inc.
Abstract
Study objective: To determine the diagnostic accuracy of the Montreal
Cognitive Assessment (MoCA) in detecting cognitive impairment (CI) and
assess the association of MoCA scores with adverse postoperative outcomes
in surgical populations. Design(s): Systematic review and
meta-analysis. Setting(s): Perioperative setting. Patient(s):
Adults undergoing elective or emergent surgery screened for CI
preoperatively using the MoCA. Measurements: The outcomes included the
diagnostic accuracy of the MoCA in screening for CI and the pooled
prevalence of CI in various surgical populations. CI and its association
with adverse events including delirium, hospital length-of-stay (LOS),
postoperative complications, discharge destination, and mortality was
determined. Main Result(s): Twenty-six studies (5059 patients, 18
non-cardiac studies, 8 cardiac studies) were included. With a MoCA cut-off
score of <26, the prevalence of preoperative CI was 48% (95% CI: 41%-54%).
The MoCA had 0.87 (95% CI: 0.79-0.93) sensitivity, 0.72 (95% CI:
0.62-0.80) specificity, PPV of 0.74 (95% CI: 0.65-0.81), and NPV of 0.86
(95% CI: 0.77-0.92) when validated against Petersen criteria, the
Diagnostic and Statistical Manual of Mental Disorders, or the National
Institute on Aging and the Alzheimer's Association criteria to identify
CI. Using the MoCA as a screening tool, the LOS was 3.75 (95% CI:
-0.03-7.53, P = 0.05, not significant) days longer in the CI group after
non-cardiac surgeries and 3.33 (95% CI: 1.24-5.41, P < 0.002) days longer
after cardiac surgeries than the non-cognitively impaired group.
 Conclusion(s): MoCA had been validated in the surgical population.
MoCA with a cut-off score of <26 was shown to have 87% sensitivity and 72%
specificity in identifying CI. A positive screen in MoCA was associated
with a 3-day longer hospital LOS in cardiac surgery in the CI group than
in the non-CI group. Copyright © 2024

<82>
Accession Number
2033394327
Title
Efficacy of aromatherapy with Lavandula angustifolia oil on postoperative
pain after cardiac surgery: A randomized clinical trial.
Source
Explore. 20(6) (no pagination), 2024. Article Number: 103034. Date of
Publication: 01 Nov 2024.
Author
Silva L.C.D.M.A.; dos Santos K.V.G.; dos Santos J.J.D.S.; Camara
R.P.D.P.O.A.; Bezerra e Silva S.Y.; Silva H.M.M.D.; Ribeiro K.R.B.; Dantas
D.V.; Dantas R.A.N.
Institution
(Silva, dos Santos, Camara, Bezerra e Silva, Silva, Ribeiro, Dantas,
Dantas) Graduate Program in Nursing, Department of Nursing, Federal
University of Rio Grande do Norte, 59078-970, Rio Grande do Norte, Natal,
Brazil
(dos Santos) Natal Heart Hospital, Natal 59075-050, Rio Grande do Norte,
Brazil
Publisher
Elsevier Inc.
Abstract
Objective: To evaluate the effect of aromatherapy through inhalation of
Lavandula angustifolia essential oil in relieving pain during the
immediate postoperative period of patients undergoing cardiac surgery.
 Method(s): A single-blind, randomized and controlled clinical trial,
with 52 patients in the immediate postoperative period of cardiac surgery
were randomly distributed into experimental (n = 26) and control (n = 26)
groups. The primary outcome was whether or not pain was relieved and
secondary outcomes included changes in vital signs, sleep and facial
relaxation. The control group received industry standard care and
application of an essential oil-free ceramic diffuser necklace. The
experimental group received the inhalation intervention with pure
Lavandula angustifolia essential oil, with a drop of the oil on a ceramic
diffuser necklace at a distance of 15-20 cm from the patient's nose for 30
min. Pain was measured using the Numerical Visual Scale, and vital signs
using the multiparametric monitor before the intervention, 10 minutes
after its start and 30 minutes after the total end of inhalation. Face
relaxation was assessed before and after the intervention and sleep was
assessed at the end of inhalation. Result(s): There was a decrease in
pain levels (p < 0.001) 30 min after the end of inhalation in the
Experimental Group, with a decrease in the measurements of Mean Blood
Pressure (p= 0.008) and Respiratory Rate (p = 0.011). Furthermore, facial
relaxation and sleep had a large effect size of 2.54 and 1.28,
respectively. Conclusion(s): Lavandula angustifolia essential oil was
effective in relieving pain, causing sleep and relaxation, proving to be a
low-cost and easy-to-use tool that the nursing team can use in their
care. Copyright © 2024 The Author(s)

<83>
Accession Number
2030114893
Title
Percutaneous repair of moderate-to-severe or severe functional mitral
regurgitation in patients with symptomatic heart failure: Baseline
characteristics of patients in the RESHAPE-HF2 trial and comparison to
COAPT and MITRA-FR trials.
Source
European Journal of Heart Failure. 26(7) (pp 1608-1615), 2024. Date of
Publication: July 2024.
Author
Anker S.D.; Friede T.; von Bardeleben R.S.; Butler J.; Khan M.S.; Diek M.;
Heinrich J.; Geyer M.; Placzek M.; Ferrari R.; Abraham W.T.; Alfieri O.;
Auricchio A.; Bayes-Genis A.; Cleland J.G.F.; Filippatos G.; Gustafsson
F.; Haverkamp W.; Kelm M.; Kuck K.-H.; Landmesser U.; Maggioni A.P.; Metra
M.; Ninios V.; Petrie M.C.; Rassaf T.; Ruschitzka F.; Schafer U.; Schulze
P.C.; Spargias K.; Vahanian A.; Zamorano J.L.; Zeiher A.; Karakas M.;
Koehler F.; Lainscak M.; Oner A.; Mezilis N.; Theofilogiannakos E.K.;
Ninios I.; Chrissoheris M.; Kourkoveli P.; Papadopoulos K.; Smolka G.;
Wojakowski W.; Reczuch K.; Pinto F.J.; Zmudka K.; Kalarus Z.; Adamo M.;
Santiago-Vacas E.; Ruf T.F.; Gross M.; Tongers J.; Hasenfuss G.;
Schillinger W.; Ponikowski P.
Institution
(Anker, Diek, Haverkamp) Department of Cardiology (CVK) of German Heart
Center Charite; Institute of Health Center for Regenerative Therapies
(BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site
Berlin, Charite Universitatsmedizin, Berlin, Germany
(Anker, Diek, Hasenfus, Schillinger) Department of Cardiology and
Pneumology, University Medical Centre Gottingen, Georg August University
of Gottingen, Gottingen, Germany
(Anker, Diek, Hasenfus) German Centre for Cardiovascular Research (DZHK),
Partner Site Gottingen, Gottingen, Germany
(Friede, Placzek) Department of Medical Statistics, University Medical
Center Gottingen, Gottingen, Germany
(Friede, Placzek) German Centre for Cardiovascular Research (DZHK),
partner site Gottingen, Gottingen, Germany
(von Bardeleben, Geyer, Ruf) Department of Cardiology, University Medical
Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
(Butler) Department of Medicine, University of Mississippi Medical Center,
Jackson, MS, United States
(Butler) Baylor Scott and White Research Institute, Dallas, TX, United
States
(Khan) Division of Cardiology, Duke University School of Medicine, Durham,
NC, United States
(Heinrich) Clinical Trial Unit, University Medical Center Gottingen,
Gottingen, Germany
(Ferrari) Department of Translational Medicine, University of Ferrara,
Ferrara, Italy
(Abraham) Division of Cardiovascular Medicine, The Ohio State University,
Columbus, OH, United States
(Alfieri) Cardiac Surgery Unit, IRCCS San Raffaele Scientific Institute,
Milan, Italy
(Auricchio) Department of Cardiology, Cardiocentro Ticino Institute-EOC,
Lugano, Switzerland
(Bayes-Genis, Santiago-Vacas) Heart Institute, Hospital Universitari
Germans Trias i Pujol, Barcelona, Spain
(Cleland, Petrie) School of Cardiovascular and Metabolic Health,
University of Glasgow, British Heart Foundation Glasgow Cardiovascular
Research Centre, Glasgow, United Kingdom
(Filippatos) Department of Cardiology, Attikon University Hospital, School
of Medicine, National and Kapodistrian University of Athens, Athens,
Greece
(Gustafsson) Department of Cardiology, Copenhagen University Hospital -
Rigshospitalet, Copenhagen, Denmark
(Kelm) Department of Cardiology, Pulmonology and Vascular Medicine,
University Hospital Dusseldorf, Medical Faculty of the Heinrich Heine
University Dusseldorf, Dusseldorf, Germany
(Kelm) CARID, Cardiovascular Research Institute, Medical Faculty and
University Hospital Dusseldorf, Heinrich-Heine University, Dusseldorf,
Germany
(Kuck) Department of Rhythmology, University Heart Center Lubeck,
University Hospital Schleswig-Holstein, Lubeck, Germany
(Landmesser) Department of Cardiology, Angiology and Intensive Care
Medicine, Deutsches Herzzentrum der Charite, Campus Benjamin Franklin,
Berlin, Germany
(Landmesser) Berlin Institute of Health, Berlin, Germany
(Landmesser, Koehler) DZHK (German Centre for Cardiovascular Research),
Partner Site Berlin, Berlin, Germany
(Maggioni) ANMCO Research Center, Heart Care Foundation, Florence, Italy
(Metra, Adamo) Institute of Cardiology, ASST Spedali Civili and Department
of Medical and Surgical Specialties, Radiological Sciences and Public
Health, University of Brescia, Brescia, Italy
(Ninios, Ninios, Papadopoulos) European Interbalkan Medical Center,
Thessaloniki, Greece
(Rassaf) West German Heart and Vascular Center, Department of Cardiology
and Vascular Medicine, University Hospital Essen, University
Duisburg-Essen, Essen, Germany
(Ruschitzka) Department of Cardiology, University Heart Center, University
Hospital Zurich and University of Zurich, Zurich, Switzerland
(Ruschitzka) Center for Translational and Experimental Cardiology (CTEC),
Department of Cardiology, University Hospital Zurich, University of
Zurich, Zurich, Switzerland
(Schafer) Heart and Vascular Centre, Bad Bevensen, Germany
(Schulze) Department of Internal Medicine I, Cardiology, University
Hospital Jena, Jena, Germany
(Spargias, Chrissoheris, Kourkoveli, Papadopoulos) Department of
Transcatheter Heart Valves, HYGEIA Hospital, Athens, Greece
(Vahanian) UFR Medecine, Universite de Paris-Cite, site Bichat, GH Bichat,
Paris, France
(Zamorano) Department of Cardiology, Hospital Universitario Ramon y Cajal,
Madrid, Spain
(Zamorano) CIBERCV, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
(Zeiher) Institute for Cardiovascular Regeneration, Goethe University
Frankfurt, Frankfurt am Main, Germany
(Zeiher) German Center of Cardiovascular Research (DZHK), Partner Site
Rhein-Main, Frankfurt am Main, Germany
(Karakas) Department of Intensive Care Medicine, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany
(Karakas) German Centre for Cardiovascular Research (DZHK), Partner Site
Hamburg/Kiel/Lubeck, Hamburg, Germany
(Koehler) Deutsches Herzzentrum der Charite (DHZC), Department of
Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte,
Berlin, Germany
(Koehler) Center for Cardiovascular Telemedicine, Charite -
Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin
and Humboldt-Universitat zu Berlin, Berlin, Germany
(Lainscak) Division of Cardiology, General Hospital Murska Sobota, Murska
Sobota, Slovenia
(Lainscak) Faculty of Medicine, University of Ljubljana, Ljubljana,
Slovenia
(Oner) Department of Cardiology, Rostock University Medical Centre,
Rostock, Germany
(Mezilis, Theofilogiannakos) Department of Cardiology, St Luke's Hospital,
Thessaloniki, Greece
(Smolka, Wojakowski) Division of Cardiology and Structural Heart Diseases,
Medical University of Silesia, Katowice, Poland
(Reczuch) Institute of Heart Diseases, Medical University and University
Hospital, Wroclaw, Poland
(Pinto, Ponikowski) Centro Academico de Medicina de Lisboa, CCUL@RISE,
Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
(Zmudka) Clinic of Interventional Cardiology, John Paul II Hospital,
Krakow, Poland
(Kalarus) Department of Cardiology, Congenital Heart Diseases and
Electrotherapy, Medical University of Silesia, Katowice, Poland
(Gross) Department of Medicine, Heart and Vascular Center, Division of
Cardiology and Vascular Medicine, Johanniter Hospital Stendal, Stendal,
Germany
(Tongers) Mid-German Heart Center, Department of Cardiology, Angiology and
Intensive Care Medicine, University Hospital Halle/Saale, Halle, Germany
(Schillinger) Heart Center, Department of Cardiology,
Georg-August-University Gottingen, Gottingen, Germany
Publisher
John Wiley and Sons Ltd
Abstract
Aim: The RESHAPE-HF2 trial is designed to assess the efficacy and safety
of the MitraClip device system for the treatment of clinically important
functional mitral regurgitation (FMR) in patients with heart failure (HF).
This report describes the baseline characteristics of patients enrolled in
the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR
trials. Methods and Results: The RESHAPE-HF2 study is an
investigator-initiated, prospective, randomized, multicentre trial
including patients with symptomatic HF, a left ventricular ejection
fraction (LVEF) between 20% and 50% with moderate-to-severe or severe FMR,
for whom isolated mitral valve surgery was not recommended. Patients were
randomized 1:1 to a strategy of delivering or withholding MitraClip. Of
506 patients randomized, the mean age of the patients was 70 +/- 10 years,
and 99 of them (20%) were women. The median EuroSCORE II was 5.3 (2.8-9.0)
and median plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP)
was 2745 (1407-5385) pg/ml. Most patients were prescribed beta-blockers
(96%), diuretics (96%), angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin
inhibitors (82%) and mineralocorticoid receptor antagonists (82%). The use
of sodium-glucose cotransporter 2 inhibitors was rare (7%). Cardiac
resynchronization therapy (CRT) devices had been previously implanted in
29% of patients. Mean LVEF, left ventricular end-diastolic volume and
effective regurgitant orifice area (EROA) were 31 +/- 8%, 211 +/- 76 ml
and 0.25 +/- 0.08 cm2, respectively, whereas 44% of patients
had mitral regurgitation severity of grade 4+. Compared to patients
enrolled in COAPT and MITRA-FR, those enrolled in RESHAPE-HF2 were less
likely to have mitral regurgitation grade 4+ and, on average, HAD lower
EROA, and plasma NT-proBNP and higher estimated glomerular filtration
rate, but otherwise had similar age, comorbidities, CRT therapy and LVEF.
 Conclusion(s): Patients enrolled in RESHAPE-HF2 represent a third
distinct population where MitraClip was tested in, that is one mainly
comprising of patients with moderate-to-severe FMR instead of only severe
FMR, as enrolled in the COAPT and MITRA-FR trials. The results of
RESHAPE-HF2 will provide crucial insights regarding broader application of
the transcatheter edge-to-edge repair procedure in clinical
practice. Copyright © 2024 The Authors. European Journal of Heart
Failure published by John Wiley & Sons Ltd on behalf of European Society
of Cardiology.

<84>
Accession Number
626985735
Title
Treat stroke to target trial design: First trial comparing two LDL targets
in patients with atherothrombotic strokes.
Source
European Stroke Journal. 4(3) (pp 271-280), 2019. Date of Publication: 01
Sep 2019.
Author
Amarenco P.; Kim J.S.; Labreuche J.; Giroud M.; Lee B.-C.; Mahagne M.-H.;
Nighoghossian N.; Simon T.; Steg P.G.; Touboul P.-J.; Vicaut E.; Yelles
N.; Bruckert E.
Institution
(Amarenco, Touboul) Assistance Publique-Hopitaux de Paris (APHP),
Department of Neurology and Stroke Center, Bichat Hospital, INSERM
LVTS-U1148, DHU FIRE, Universite Paris-Diderot, Sorbonne-Paris Cite,
Paris, France
(Kim) Department of Neurology, Asan Medical Center, Seoul, South Korea
(Labreuche) Universite Lille, CHU Lille, EA 2694 - Sante publique:
epidemiologie et qualite des soins, Lille F-59000, France
(Giroud) Department of Neurology, INSERM, Universite Bourgogne, Dijon,
France
(Lee) Department of Neurology, Hallym University Sacred Heart Hospital,
Anyang, South Korea
(Mahagne) Stroke Unit, Pasteur hospital, Nice, France
(Nighoghossian) Hospices Civils de Lyon, Department of Neurology and
Stroke center, Lyon University, Lyon, France
(Simon) APHP, Department of Clinical Pharmacology and Clinical Research
Platform of East of Paris (CRC-CRB-URC), Saint Antoine University
Hospital, Paris, France
(Steg) APHP, Department of Cardiology, INSERM LVTS-U1148, DHU FIRE,
Universite Paris-Diderot, Sorbonne-Paris Cite, Hopital Bichat, Paris,
France
(Vicaut) APHP, Department of Biostatistics, Universite Paris-Diderot,
Sorbonne-Paris Cite, Fernand Widal hospital, Paris, France
(Yelles) APHP, Centre de Pharmaco-epidemiologie de l'AP-HP (CEPHEPI),
Hopital Pitie-Salpetriere, Paris, France
(Bruckert) APHP, Pitie-Salpetriere University Hospital, Pierre and Marie
Curie University, Sorbonne-Paris Cite, Paris, France
(Simon) Sorbonne University, France
(Steg) NHLI Imperial College, ICMS Royal Brompton Hospital London, United
Kingdom
Publisher
SAGE Publications Ltd
Abstract
Background: In patients with non-cardio-embolic stroke, atorvastatin 80
mg/day reduced the relative risk of recurrent stroke by 16%, and a post
hoc analysis showed that achieving an LDL-c of less than 70 mg/dL reduced
the relative risk by 28% as compared to an on-treatment LDL of 100 mg/dL
or more. Current guidelines from the French drug agency recommend treating
with a statin after an ischaemic stroke to a target of less than 100
mg/dL, but no study directly tested LDL-c targets. The Treat Stroke to
Target (TST) trial will compare the efficacy of achieving an LDL-c of less
than 70 mg/dL versus an achieved LDL-c of 100 +/- 10 mg/dL for secondary
prevention in patients with recent ischaemic stroke of atherosclerotic
origin. Main hypothesis: An achieved on-treatment LDL-c of less than 70
mg/dL will reduce by 25% the risk of recurrent ischaemic stroke,
myocardial infarction, urgent coronary or carotid revascularisation
following new symptoms requiring hospitalisation, and vascular death
compared with on-treatment LDL-c of 100 +/- 10 mg/dL. Design(s):
Patients are randomised to either LDL-c levels, and the investigator who
is not blinded can use the lipid-lowering agent of his/her choice
available on the market (including statins and ezetimibe), in order to
achieve the assigned LDL-c level. To be eligible for enrolment, patients
have a recent ischaemic stroke or TIA of atherosclerotic origin with at
least one arterial stenosis of a cerebral artery, enrolled between acute
phase of the qualifying stroke (once the neurological deficit is
stabilised) and three months. The initial planned sample size of 3760
participants followed three years was amended to allow follow-up of all
enrolled patients until 385 primary efficacy outcome events have occurred,
and no later than 31 December 2019. Patients will be recruited in 76 sites
in two countries (France and South Korea) between March 2010 and December
2018 (last included patient followed up to one year). Safety outcomes will
include haemorrhagic strokes and new onset diabetes. All primary endpoints
will be adjudicated by an endpoint committee, blinded to the assigned
LDL-c level. Two sub-studies assess (1) the relative effect of assigned
LDL-c levels on occurrence of new atherosclerotic plaque as detected by
carotid ultrasound during follow-up, using M'ATH software for
repositioning and (2) the genetic and biomarker drivers of recurrent
primary endpoints according to assigned LDL-c lowering arm, in
atherosclerotic strokes. Summary: The TST trial is evaluating the
benefits of achieving an LDL-c less than 70 mg/dL for secondary stroke
prevention in ischaemic stroke patients of atherosclerotic origin. Main
results are anticipated in 2020 or earlier (ClinicalTrials.gov
NCT01252875). Copyright © European Stroke Organisation 2019.

<85>
Accession Number
2033426675
Title
Post-sternotomy movement strategies in adults: a scoping review.
Source
European Journal of Cardiovascular Nursing. 23(5) (pp 435-440), 2024. Date
of Publication: 01 Jul 2024.
Author
Wiens K.; Hayden K.A.; Park L.; Colwell S.; Coltman C.; King-Shier K.M.
Institution
(Wiens, King-Shier) Faculty of Nursing, University of Calgary, 2500
University Dr NW, Calgary, AB T2N 1N4, Canada
(Wiens, Park, Colwell, Coltman) Foothills Medical Center, Alberta Health
Services, 1403 29 St NW, Calgary, AB T2N 2T9, Canada
(Wiens, Park, Colwell, Coltman, King-Shier) Libin Cardiovascular Institute
of Alberta, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N
4N1, Canada
(Hayden) Libraries and Cultural Resources, University of Calgary, 2500
University Dr NW, Calgary, AB T2N 1N4, Canada
(King-Shier) Department of Community Health Sciences, Cumming School of
Medicine, University of Calgary, 2500 University Dr NW, Calgary, AB T2N
1N4, Canada
Publisher
Oxford University Press
Abstract
Aims Post-sternotomy movement strategies for adults should be an
evidence-informed approach and support a safe, independent return to daily
activity. Recent new movement strategies have emerged. The aim of this
scoping review was to identify and summarize the available evidence for
post-sternotomy movement strategies in adults. Methods and results The
electronic databases searched included MEDLINE, Embase, Sport Discus,
CINAHL, Academic Search Complete, the Cochrane Library, Scopus, and PEDro.
The search did not have a date limit. After 2405 duplicates were removed,
2978 records were screened, and 12 were included; an additional 2 studies
were identified through reference searching for a total of 14 included
studies. A data extraction table was used, and the findings are summarized
in a tabular and narrative form. Three post-sternotomy movement strategies
were identified in the literature: sternal precautions (SP), modified SP,
and Keep Your Move in the Tube (KYMITTTM). The authors suggested that the
practice of SP was based on expert opinion and not founded in evidence.
However, the evidence from the identified articles suggested that new
movement strategies are safe and allow patients to choose an increased
level of activity that promotes improved functional status and confidence.
Conclusion More prospective cohort studies and multi-centred randomized
control trials are needed; however, the current evidence suggests that
modified SP and KYMITTTM are as safe as SP and can promote a
patient-centred approach. Copyright © The Author(s) 2024.

<86>
Accession Number
2033405345
Title
Pulmonary artery catheter use and in-hospital outcomes in cardiac surgery:
a systematic review and meta-analysis.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 39(1) (no
pagination), 2024. Article Number: ivae129. Date of Publication: 01 Jul
2024.
Author
Rong L.Q.; Luhmann G.; Franco A.D.; Dimagli A.; Perry L.A.; Martinez A.P.;
Demetres M.; Mazer C.D.; Bellomo R.; Gaudino M.
Institution
(Rong, Luhmann, Martinez) Department of Anesthesiology, Weill Cornell
Medicine, New York, NY, United States
(Franco, Dimagli, Gaudino) Department of Cardiothoracic Surgery, Weill
Cornell Medicine, New York, NY, United States
(Perry) Department of Anaesthesia and Pain Management, Royal Melbourne
Hospital, Melbourne, VIC, Australia
(Perry, Bellomo) Department of Critical Care, University of Melbourne,
Melbourne, VIC, Australia
(Demetres) Samuel J. Wood Library and C.V. Starr Biomedical Information
Centre, Weill Cornell Medicine, New York, NY, United States
(Mazer) Departments of Anaesthesia and Critical Care, Keenan Research
Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St
Michael's Hospital, Toronto, ON, Canada
(Mazer) Department of Anesthesia, University of Toronto, Toronto, ON,
Canada
(Bellomo) Department of Intensive Care, Royal Melbourne Hospital,
Melbourne, VIC, Australia
(Bellomo) Australian and New Zealand Intensive Care Research Centre,
Monash University, Melbourne, VIC, Australia
Publisher
Oxford University Press
Abstract
OBJECTIVES: To determine the association of intraoperative pulmonary
artery catheter (PAC) use with in-hospital outcomes in cardiac surgical
patients. METHOD(S): MEDLINE, Embase, and Cochrane Library (Wiley)
databases were screened for studies that compared cardiac surgical
patients receiving intraoperative PAC with controls and reporting
in-hospital mortality. Secondary outcomes included intensive care unit
length of stay, cost of hospitalization, fluid volume administered,
intubation time, inotropes use, acute kidney injury (AKI), stroke,
myocardial infarction (MI), and infections. RESULT(S): Seven studies
(25 853 patients, 88.6% undergoing coronary artery bypass graft surgery)
were included. In-hospital mortality was significantly increased with PAC
use [odds ratio (OR) 1.57; 95% confidence interval (CI) 1.12-2.20, P 1/4
0.04]; PAC use was also associated with greater intraoperative inotrope
use (OR 2.61; 95% CI 1.54-4.41) and costs [standardized mean difference
(SMD) 1/4 0.20; 95% CI 0.16-0.23], longer intensive care unit stay (SMD
1/4 0.29; 95% CI 0.25-0.33), and longer intubation time (SMD 1/4 0.44; 95%
CI 0.12-0.76). CONCLUSION(S): PAC use is associated with
significantly increased odds of in-hospital mortality, but the amount and
quality of the available evidence is limited. Prospective randomized
trials testing the effect of PAC on the outcomes of cardiac surgical
patients are urgently needed. Copyright © The Author(s) 2024.

<87>
Accession Number
2033404793
Title
Remote ischemic conditioning reduces postoperative bleeding in adult
cardiac surgical patients: a systematic review and meta-analysis.
Source
Journal of Cardiovascular Surgery. 65(3) (pp 280-288), 2024. Date of
Publication: June 2024.
Author
Chen L.-L.; Yao Y.-T.
Institution
(Chen) Department of Anesthesiology, Fuwai Hospital Chinese Academy of
Medical Sciences, Guangdong, Shenzhen, China
(Yao) Department of Anesthesiology, Fuwai Hospital, National Center for
Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of
Medical Sciences, Beijing, China
Publisher
Edizioni Minerva Medica
Abstract
INTRODUCTION: The current study was designed to systemically investigate
the impact of remote ischemic conditioning (RIC) on intra- and
postoperative bleeding and transfusion in patients undergoing cardiac
surgery. EVIDENCE ACQUISITION: We included all randomized controlled
trials (RCTs) comparing RIC with control on intra- and postoperative blood
loss and blood transfusion. The inclusion criteria were as follows: 1)
adult patients undergoing cardiac surgery; 2) RCT; 3) perioperative
administration of RIC compared to control; 4) outcomes of interest
reported. Exclusion criteria included: 1) case reports, reviews, or
abstracts; 2) animal or cell studies; 3) duplicate publications; 4)
studies lacking information about outcomes of interest. EVIDENCE
SYNTHESIS: Databases search yielded 24 RCTs including 3530 patients, 1765
patients were allocated into RIC group and 1765 into control group. The
current study suggested that RIC administration was associated with
reduced postoperative blood loss (WMD=-57.89; 95% CI: -89.89 to -25.89;
P=0.0004). RIC did not affect the volume of intraoperative blood loss
(WMD=-4.02; 95% CI: -14.09 to 6.05; P=0.43), the volume of intra- and
postoperative transfusion of red blood cell (RBC) (WMD=-15.66; 95% CI:
-39.35 to 8.03; P=0.20), the re-exploration for bleeding (WMD=-0.01; 95%
CI: -0.03 to 0.01; P=0.21). CONCLUSION(S): The current study
demonstrated that, RIC reduced post-operative blood loss in adult patients
undergoing cardiac surgeries. It also indicated that, RIC reduced
intra-operative RBC transfusion in adult patients undergoing coronary
artery bypass grafting. However, RIC did not influence intra-operative
bleeding, post-operative blood transfusion. Copyright © 2024
EDIZIONI MINERVA MEDICA.

<88>
Accession Number
2030665607
Title
Effects of starting one lung ventilation and applying individualized PEEP
right after patients are placed in lateral decubitus position on
intraoperative oxygenation for patients undergoing thoracoscopic pulmonary
lobectomy: study protocol for a randomized controlled trial.
Source
Trials. 25(1) (no pagination), 2024. Article Number: 500. Date of
Publication: December 2024.
Author
Wang Q.-Y.; Zhou Y.; Wang M.-R.; Jiao Y.-Y.
Institution
(Wang, Zhou, Wang, Jiao) Department of Anesthesiology, Peking University
Third Hospital, NO. 49, North Garden Road, Haidian District, Beijing,
China
Publisher
BioMed Central Ltd
Abstract
Background: For patients receiving one lung ventilation in thoracic
surgery, numerous studies have proved the superiority of lung protective
ventilation of low tidal volume combined with recruitment maneuvers (RM)
and individualized PEEP. However, RM may lead to overinflation which
aggravates lung injury and intrapulmonary shunt. According to CT results,
atelectasis usually forms in gravity dependent lung regions, regardless of
body position. So, during anesthesia induction in supine position,
atelectasis usually forms in the dorsal parts of lungs, however, when
patients are turned into lateral decubitus position, collapsed lung tissue
in the dorsal parts would reexpand, while atelectasis would slowly
reappear in the lower flank of the lung. We hypothesize that applying
sufficient PEEP without RM before the formation of atelectasis in the
lower flank of the lung may beas effective to prevent atelectasis and thus
improve oxygenation as applying PEEP with RM. Method(s): A total of
84 patients scheduled for elective pulmonary lobe resection necessitating
one lung ventilation will be recruited and randomized totwo parallel
groups. For all patients, one lung ventilation is initiated the right
after patients are turned into lateral decubitus position. For patients in
the study group, individualized PEEP titration is started the moment one
lung ventilation is started, while patients in the control group will
receive a recruitment maneuver followed by individualized PEEP titration
after initiation of one lung ventilation. The primary endpoint will be
oxygenation index measured at T4. Secondary endpoints will include
intrapulmonary shunt, respiratory mechanics, PPCs, and hemodynamic
indicators. Discussion(s): Numerous previous studies compared the
effects of individualized PEEP applied alone with that applied in
combination with RM on oxygenation index, PPCs, intrapulmonary shunt and
respiratory mechanics after atelectasis was formed in patients receiving
one lung ventilation during thoracoscopic surgery. In this study, we will
apply individualized PEEP before the formation of atelectasis while not
performing RM in patients allocated to the study group, and then we're
going to observe its effects on the aspects mentioned above. The results
of this trial will provide a ventilation strategy that may be conductive
to improving intraoperative oxygenation and avoiding the detrimental
effects of RM for patients receiving one lung ventilation. Trial
registration: www.Chictr.org.cn ChiCTR2400080682. Registered on February
5, 2024. Copyright © The Author(s) 2024.

<89>
Accession Number
644761403
Title
Preoperative coronary interventions for preventing acute myocardial
infarction in the perioperative period of major open vascular or
endovascular surgery.
Source
Cochrane Database of Systematic Reviews. 2024(7) (no pagination), 2024.
Article Number: CD014920. Date of Publication: 03 Jul 2024.
Author
Botelho F.E.; Flumignan R.L.G.; Shiomatsu G.Y.; de Castro-Santos G.;
Cacione D.G.; Leite J.O.; Baptista-Silva J.C.C.
Institution
(Botelho, Shiomatsu, de Castro-Santos) Department of Surgery, Universidade
Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
(Flumignan, Cacione, Baptista-Silva) Department of Surgery, Division of
Vascular and Endovascular Surgery, Universidade Federal de Sao Paulo, Sao
Paulo, Brazil
(Flumignan, Baptista-Silva) Cochrane Brazil, Universidade Federal de Sao
Paulo, Sao Paulo, Brazil
(Leite) Department of Surgery, University of Cincinnati, Cincinnati, OH,
United States
Publisher
John Wiley and Sons Ltd
Abstract
Background: Postoperative myocardial infarction (POMI) is associated with
major surgeries and remains the leading cause of mortality and morbidity
in people undergoing vascular surgery, with an incidence rate ranging from
5% to 20%. Preoperative coronary interventions, such as coronary artery
bypass grafting (CABG) or percutaneous coronary interventions (PCI), may
help prevent acute myocardial infarction in the perioperative period of
major vascular surgery when used in addition to routine perioperative
drugs (e.g. statins, angiotensin-converting enzyme inhibitors, and
antiplatelet agents), CABG by creating new blood circulation routes that
bypass the blockages in the coronary vessels, and PCI by opening up
blocked blood vessels. There is currently uncertainty around the benefits
and harms of preoperative coronary interventions. Objective(s): To
assess the effects of preoperative coronary interventions for preventing
acute myocardial infarction in the perioperative period of major open
vascular or endovascular surgery. Search Method(s): We searched the
Cochrane Vascular Specialised Register, CENTRAL, MEDLINE Ovid, Embase
Ovid, LILACS, and CINAHL EBSCO on 13 March 2023. We also searched the
World Health Organization International Clinical Trials Registry Platform
and ClinicalTrials.gov. Selection Criteria: We included all
randomised controlled trials (RCTs) or quasi-RCTs that compared the use of
preoperative coronary interventions plus usual care versus usual care for
preventing acute myocardial infarction during major open vascular or
endovascular surgery. We included participants of any sex or any age
undergoing major open vascular surgery, major endovascular surgery, or
hybrid vascular surgery. Data Collection and Analysis: We used
standard Cochrane methods. Our primary outcomes of interest were acute
myocardial infarction, all-cause mortality, and adverse events resulting
from preoperative coronary interventions. Our secondary outcomes were
cardiovascular mortality, quality of life, vessel or graft secondary
patency, and length of hospital stay. We reported perioperative and
long-term outcomes (more than 30 days after intervention). We assessed the
certainty of the evidence using the GRADE approach. Main Result(s):
We included three RCTs (1144 participants). Participants were randomised
to receive either preoperative coronary revascularisation with PCI or CABG
plus usual care or only usual care before major vascular surgery. One
trial enrolled participants if they had no apparent evidence of coronary
artery disease. Another trial selected participants classified as high
risk for coronary disease through preoperative clinical and laboratorial
testing. We excluded one trial from the meta-analysis because participants
from both the control and the intervention groups were eligible to undergo
preoperative coronary revascularisation. We identified a high risk of
performance bias in all included trials, with one trial displaying a high
risk of other bias. However, the risk of bias was either low or unclear in
other domains. We observed no difference between groups for perioperative
acute myocardial infarction, but the evidence is very uncertain (risk
ratio (RR) 0.28, 95% confidence interval (CI) 0.02 to 4.57; 2 trials, 888
participants; very low-certainty evidence). One trial showed a reduction
in incidence of long-term (> 30 days) acute myocardial infarction in
participants allocated to the preoperative coronary interventions plus
usual care group, but the evidence was very uncertain (RR 0.09, 95% CI
0.03 to 0.28; 1 trial, 426 participants; very low-certainty evidence).
There was little to no effect on all-cause mortality in the perioperative
period when comparing the preoperative coronary intervention plus usual
care group to usual care alone, but the evidence is very uncertain (RR
0.79, 95% CI 0.31 to 2.04; 2 trials, 888 participants; very low-certainty
evidence). The evidence is very uncertain about the effect of preoperative
coronary interventions on long-term (follow up: 2.7 to 6.2 years)
all-cause mortality (RR 0.74, 95% CI 0.30 to 1.80; 2 trials, 888
participants; very low-certainty evidence). One study reported no adverse
effects related to coronary angiography, whereas the other two studies
reported five deaths due to revascularisations. There may be no effect on
cardiovascular mortality when comparing preoperative coronary
revascularisation plus usual care to usual care in the short term (RR
0.07, 95% CI 0.00 to 1.32; 1 trial, 426 participants; low-certainty
evidence). Preoperative coronary interventions plus usual care in the
short term may reduce length of hospital stay slightly when compared to
usual care alone (mean difference -1.17 days, 95% CI -2.05 to -0.28; 1
trial, 462 participants; low-certainty evidence). We downgraded the
certainty of the evidence due to concerns about risk of bias, imprecision,
and inconsistency. None of the included trials reported on quality of life
or vessel graft patency at either time point, and no study reported on
adverse effects, cardiovascular mortality, or length of hospital stay at
long-term follow-up. Authors' conclusions: Preoperative coronary
interventions plus usual care may have little or no effect on preventing
perioperative acute myocardial infarction and reducing perioperative
all-cause mortality compared to usual care, but the evidence is very
uncertain. Similarly, limited, very low-certainty evidence shows that
preoperative coronary interventions may have little or no effect on
reducing long-term all-cause mortality. There is very low-certainty
evidence that preoperative coronary interventions plus usual care may
prevent long-term myocardial infarction, and low-certainty evidence that
they may reduce length of hospital stay slightly, but not cardiovascular
mortality in the short term, when compared to usual care alone. Adverse
effects of preoperative coronary interventions were poorly reported in
trials. Quality of life and vessel or graft patency were not reported. We
downgraded the certainty of the evidence most frequently for high risk of
bias, inconsistency, or imprecision. None of the analysed trials provided
significant data on subgroups of patients who could potentially experience
more substantial benefits from preoperative coronary intervention (e.g.
altered ventricular ejection fraction). There is a need for evidence from
larger and homogeneous RCTs to provide adequate statistical power to
assess the role of preoperative coronary interventions for preventing
acute myocardial infarction in the perioperative period of major open
vascular or endovascular surgery. Copyright © 2024 The Cochrane
Collaboration. Published by John Wiley & Sons, Ltd.

<90>
Accession Number
2033440759
Title
Weekly Journal Scan: transcatheter aortic valve implantation in patients
with small aortic annulus.
Source
European Heart Journal. 45(28) (pp 2476-2477), 2024. Date of Publication:
21 Jul 2024.
Author
Vergallo R.; Pedicino D.
Institution
(Vergallo) Interventional Cardiology Unit, Cardiothoracic and Vascular
Department (DICATOV), IRCCS Ospedale Policlinico San Martino, Largo R.
Benzi, 10, Genova 16132, Italy
(Vergallo) Department of Internal Medicine and Medical Specialties (DIMI),
Universita di Genova, Viale Benedetto XV 6, Genova 16132, Italy
(Pedicino) Department of Cardiovascular Medicine, Fondazione Policlinico
Universitario A. Gemelli-IRCCS, Rome, Italy
Publisher
Oxford University Press

<91>
Accession Number
2033440373
Title
Effects of intranasal dexmedetomidine versus intranasal midazolam as
premedication in children with tetralogy of Fallot undergoing corrective
cardiac surgery: A randomized trial.
Source
Annals of Pediatric Cardiology. 17(2) (pp 109-115), 2024. Date of
Publication: 2024.
Author
Srivastava S.; Das S.; Makhija N.; Chauhan S.
Institution
(Srivastava, Das, Makhija, Chauhan) Department of Cardiac Anaesthesia and
Critical Care, All India Institute of Medical Sciences, New Delhi, India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: This prospective, randomized, double-blind trial was done to
compare intranasal dexmedetomidine and intranasal midazolam as
premedication for sedation and ease of child-parent separation in
pediatric patients of tetralogy of Fallot (TOF) undergoing corrective
cardiac surgery. Materials and Methods : Forty children with TOF, between
1 and 10 years, undergoing corrective cardiac surgery were included in the
study and, after randomization, were given intranasal midazolam (0.2
mg/kg) or intranasal dexmedetomidine (1 microg/kg), 30 min before shifting
to the operation room (OR). Patients were assessed for sedation and
child-parent separation, along with hemodynamic parameters, respiratory
rate, and oxygen saturation (SpO2) 30 min after drug administration, at
the time of shifting inside the OR, and at the time of induction of
anesthesia. Results : Both groups had comparable child-parent scores,
hemodynamic parameters, SpO2, and respiratory rate. However, the
dexmedetomidine group had significantly better sedation levels than the
midazolam group patients at the time of shifting inside the OR
(dexmedetomidine group: 3.55 +/- 0.82 vs. midazolam group: 2.80 +/- 0.83;
P = 0.007) and at the time of induction of anesthesia (dexmedetomidine
group: 3.40 +/- 0.75 vs. midazolam group: 2.70 +/- 0.86; P = 0.009).
 Conclusion(s): Intranasal dexmedetomidine provides better sedation
than midazolam, with similar child-parent separation scores and
hemodynamic parameters, respiratory rate, and SpO2. No adverse events were
observed in both groups. A study on a larger population will help in
further establishing the safety and superiority of dexmedetomidine and
will further its regular use as an intranasal premedication. Copyright
© 2024 Annals of Pediatric Cardiology Published by Wolters
Kluwer - Medknow.

<92>
Accession Number
2033427107
Title
Sirolimus-eluting or everolimus-eluting stents for coronary artery
disease: 5-year outcomes of the randomised BIOFLOW-IV trial.
Source
EuroIntervention. 18(14) (pp 1197-1200), 2023. Date of Publication:
February 2023.
Author
Slagboom T.; Toelg R.; Witzenbichler B.; Haude M.; Masotti M.; Salmeron
R.R.; Witkowski A.R.; Uematus M.; Takahashi A.; Waksman R.; Saito S.
Institution
(Slagboom) Cardiology Unit, OLVG, Amsterdam, Netherlands
(Toelg) Segeberger Kliniken, Bad Segeberg, Germany
(Witzenbichler) Department of Cardiology and Pneumology, Helios
Amper-Klinikum, Dachau, Germany
(Haude) Lukaskrankenhaus Medizinische Klinik I, Stadtische Kliniken Neuss,
Neuss, Germany
(Masotti) Department of Cardiology, Hospital Clinic de Barcelona,
Barcelona, Spain
(Salmeron) Haemodynamic Unit, Hospital Universitario Virgen Macarena,
Seville, Spain
(Witkowski) National Institute of Cardiology, Warsaw, Poland
(Uematus) Kansai Rosai Hospital Cardiovascular Center, Amagasaki, Japan
(Takahashi) Sakurakai Takahashi Hospital, Kobe, Japan
(Waksman) MedStar Health Research Institute, Washington, DC, United States
(Saito) Okinawa Tokushukai Shonan Kamakura General Hospital, Kamakura,
Japan
Publisher
Europa Group

<93>
Accession Number
2033470996
Title
Hypoattenuated Leaflet Thickening: A Comprehensive Review of Contemporary
Data.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Samadzadeh Tabrizi N.; Fishberger G.; Musuku S.R.; Shapeton A.D.
Institution
(Fishberger) University of South Florida Morsani College of Medicine,
Tampa, FL, United States
(Samadzadeh Tabrizi, Musuku) Department of Anesthesiology, Albany Medical
Center, Albany, NY, United States
(Shapeton) Veterans Affairs Boston Healthcare System, Department of
Anesthesia, Critical Care and Pain Medicine, and Tufts University School
of Medicine, Boston, MA, United States
Publisher
W.B. Saunders
Abstract
Nearly one-third of patients who undergo surgical aortic valve replacement
(SAVR) or transcatheter aortic valve replacement (TAVR) develop
hypoattenuated leaflet thickening (HALT) within a year. HALT typically
represents subclinical leaflet thrombosis in asymptomatic patients, and as
a result it often is detected incidentally. However, HALT also may worsen
in severity, resulting in leaflet immobility and/or valve deterioration.
The clinical significance of HALT is a topic of ongoing debate, and
currently there is no consensus on the screening and management of HALT in
patients following TAVR or SAVR. This review provides a comprehensive
evaluation of the available evidence on risk factors, preventative
measures, treatment, and prognosis for this growing patient
cohort. Copyright © 2024 Elsevier Inc.

<94>
[Use Link to view the full text]
Accession Number
643680148
Title
A commentary on 'Efficacy and safety of vitamin C for atrial fibrillation
after cardiac surgery: a meta-analysis with trial sequential analysis of
randomized controlled trials'.
Source
International journal of surgery (London, England). 110(7) (pp 4416-4417),
2024. Date of Publication: 01 Jul 2024.
Author
Wang C.; Sun Z.; Zhou W.
Institution
(Wang) Graduate School of Tianjin University of Traditional Chinese
Medicine, China
(Sun) School of Chinese Materia Medica, Beijing University of Chinese
Medicine, Beijing, China
(Zhou) Second Affiliated Hospital of Tianjin University of Traditional
Chinese Medicine, Tianjin, China

<95>
Accession Number
644814300
Title
Ct-based diagnosis of sarcopenia as a prognostic factor for postoperative
mortality after elective open-heart surgery in older patients: a
cohort-based systematic review and meta-analysis.
Source
Frontiers in public health. 12 (pp 1378462), 2024. Date of Publication:
2024.
Author
Yang T.-R.; Ji P.; Deng X.; Feng X.-X.; He M.-L.; Wang R.-R.; Li X.-H.
Institution
(Yang, Feng, He, Wang, Li) Department of Anesthesiology, West China
Hospital, Sichuan University, Chengdu, Sichuan, China
(Yang, Feng, He, Wang, Li) Research Units of West China
(2018RU012)-Chinese Academy of Medical Sciences, West China Hospital,
Sichuan University, Chengdu, Sichuan, China
(Ji) Department of Critical Care Medicine, West China Hospital, Sichuan
University, Chengdu, Sichuan, China
(Deng) Department of Anesthesiology, West China Second University
Hospital, Sichuan University, Chengdu, Sichuan, China
(Deng) Key Laboratory of Birth Defects and Related Diseases of Women and
Children, Ministry of Education, Sichuan University, Chengdu, Sichuan,
China
(Wang) Department of Anesthesiology, Chengdu Shang Jin Nan Fu
Hospital/Shang Jin Hospital of West China Hospital, Sichuan University,
Chengdu, Sichuan, China
Abstract
Background: Cardiac open-heart surgery, which usually involves thoracotomy
and cardiopulmonary bypass, is associated with a high incidence of
postoperative mortality and adverse events. In recent years, sarcopenia,
as a common condition in older patients, has been associated with an
increased incidence of adverse prognosis. Method(s): We conducted a
search of databases including PubMed, Embase, and Cochrane, with the
search date up to January 1, 2024, to identify all studies related to
elective cardiac open-heart surgery in older patients. We used the Grading
of Recommendations, Assessment, Development, and Evaluation (GRADE)
approach to assess the certainty of evidence. Result(s): A total of
12 cohort studies were included in this meta-analysis for analysis. This
meta-analysis revealed that patients with sarcopenia had a higher risk of
postoperative mortality. Furthermore, the total length of hospital stay
and ICU stay were longer after surgery. Moreover, there was a higher
number of patients requiring further healthcare after discharge. Regarding
postoperative complications, sarcopenia patients had an increased risk of
developing renal failure and stroke. Conclusion(s): Sarcopenia served
as a tool to identify high-risk older patients undergoing elective cardiac
open-heart surgery. By identifying this risk factor early on, healthcare
professionals took targeted steps to improve perioperative function and
made informed clinical decisions.Systematic review registration:
https://www.crd.york.ac.uk/prospero/, identifier
CRD42023426026. Copyright © 2024 Yang, Ji, Deng, Feng, He, Wang
and Li.

<96>
Accession Number
2033464034
Title
Preoperative localization for lung nodules: a meta-analysis of
bronchoscopic versus computed tomography guidance.
Source
Wideochirurgia I Inne Techniki Maloinwazyjne. 17(4) (pp 601-610), 2022.
Date of Publication: 2022.
Author
Du J.; Fu Y.-F.; Lv Y.-N.
Institution
(Du, Fu) Department of Radiology, Xuzhou Central Hospital, Xuzhou, China
(Lv) Xuzhou Universal View Medical Imaging Diagnostic Center, Xuzhou,
China
Publisher
Termedia Publishing House Ltd.
Abstract
Introduction: Both computed tomography (CT)-guided and bronchoscopic
localization strategies have been utilized prior to video-assisted
thoracic surgery (VATS) as a means of achieving high lung nodule (LN)
wedge resection success rates. Aim(s): The present meta-analysis was
thus developed for the assessment of the efficacy and safety of
preoperative CT-guided and bronchoscopic LN localization approaches.
 Material(s) and Method(s): The PubMed, Cochrane Library, Embase, and
Wanfang databases were searched for all relevant studies published through
May 2022, with RevMan v5.3 being used to conduct pooled analyses of data
pertaining to all endpoints of interest. Result(s): In total, this
meta-analysis incorporated data from 7 retrospective studies including 321
patients bearing 353 LNs that underwent CT-guided localization and 220
patients bearing 244 LNs that underwent bronchoscopic localization. When
comparing the CT and bronchoscopic localization approaches, pooled rates
of technical success (p = 0.20) and duration of localization (p = 0.20)
were comparable. However, bronchoscopic localization was associated with
significantly lower pooled rates of pneumothorax (p < 0.001) and pulmonary
hemorrhage (p = 0.005) relative to CT-guided localization. In the CT
group, the pooled VATS duration was significantly shorter compared with
the bronchoscopic group (p = 0.04), although the pooled duration of
postoperative hospitalization was comparable in both groups (p = 0.69).
The heterogeneity was significant with respect to both the duration of
localization (I2= 97%) and the duration of postoperative
hospitalization (I2= 74%). Conclusion(s): Relative to a
CT-guided localization approach, the bronchoscopic localization of LNs can
achieve similar clinical efficacy and superior safety. Copyright
© 2022 Termedia Publishing House Ltd.. All rights reserved.

<97>
Accession Number
644812407
Title
Effect of nitric oxide delivery via cardiopulmonary bypass circuit on
postoperative oxygenation in adults undergoing cardiac surgery (NOCARD
trial): a randomised controlled trial.
Source
European journal of anaesthesiology. (no pagination), 2024. Date of
Publication: 29 May 2024.
Author
Azem K.; Novakovsky D.; Krasulya B.; Fein S.; Iluz-Freundlich D.; Uhanova
J.; Kornilov E.; Eidelman L.A.; Kaptzon S.; Gorfil D.; Aravot D.; Barac
Y.; Aranbitski R.
Institution
(Azem) From the Department of Anaesthesia (KA, DN, BK, SF, DI-F, EK, LAE,
RA), Department of Cardiovascular and Thoracic Surgery, Rabin Medical
Centre, Beilinson Hospital, Petah Tikva (SK, DG, DA, YB), Department of
Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba
(JU), Department of Neurobiology, Weizmann Institute of Science, Rehovot
(EK), and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,
Israel (KA, DN, BK, SF, DI-F, EK, LAE, SK, DG, DA, YB, RA)
Abstract
BACKGROUND: Cardiac surgery involving cardiopulmonary bypass induces a
significant systemic inflammatory response, contributing to various
postoperative complications, including pulmonary dysfunction, myocardial
and kidney injuries. OBJECTIVE(S): To investigate the effect of
Nitric Oxide delivery via the cardiopulmonary bypass circuit on various
postoperative outcomes. DESIGN: A prospective, single-centre,
double-blinded, randomised controlled trial. SETTING: Rabin Medical
Centre, Beilinson Hospital, Israel. PATIENTS: Adult patients scheduled for
elective cardiac surgery were randomly allocated to one of the study
groups. INTERVENTIONS: For the treatment group, 40 ppm of nitric oxide was
delivered via the cardiopulmonary bypass circuit. For the control group,
nitric oxide was not delivered. OUTCOME MEASURES: The primary outcome was
the incidence of hypoxaemia, defined as a paO2/FiO2 ratio less than 300
within 24 h postoperatively. The secondary outcomes were the incidences of
low cardiac output syndrome and acute kidney injury within 72 h
postoperatively. RESULT(S): Ninety-eight patients were included in
the final analysis, with 47 patients allocated to the control group and 51
to the Nitric Oxide group. The Nitric Oxide group exhibited significantly
lower hypoxaemia rates at admission to the cardiothoracic intensive care
unit (47.1 vs. 68.1%), P = 0.043. This effect, however, varied in patients
with or without baseline hypoxaemia. Patients with baseline hypoxaemia who
received nitric oxide exhibited significantly lower hypoxaemia rates (61.1
vs. 93.8%), P = 0.042, and higher paO2/FiO2 ratios at all time points, F
(1,30) = 6.08, P = 0.019. Conversely, this benefit was not observed in
patients without baseline hypoxaemia. No significant differences were
observed in the incidence of low cardiac output syndrome or acute kidney
injury. No substantial safety concerns were noted, and toxic
methaemoglobin levels were not observed. CONCLUSION(S): Patients with
baseline hypoxaemia undergoing cardiac surgery and receiving nitric oxide
exhibited lower hypoxaemia rates and higher paO2/FiO2 ratios. No
significant differences were found regarding postoperative pulmonary
complications and overall outcomes. TRIAL REGISTRATION: This trial was
registered at ClinicalTrials.gov (NCT04807413). Copyright © 2024
European Society of Anaesthesiology and Intensive Care. Unauthorized
reproduction of this article is prohibited.

<98>
Accession Number
644811732
Title
Risk Factors of Ischemic Stroke in Patients With Atrial Fibrillation Post
Transcatheter Aortic Valve Implantation From the Randomized ENVISAGE-TAVI
AF Trial.
Source
The American journal of cardiology. (no pagination), 2024. Date of
Publication: 18 Jul 2024.
Author
Hengstenberg C.; Unverdorben M.; Mollmann H.; Van Mieghem N.M.; Thiele H.;
Nordbeck P.; Rassaf T.; Moreno R.; Mehran R.; Jin J.; Lang I.; Veltkamp
R.; Dangas G.D.
Institution
(Hengstenberg, Lang) Department of Internal Medicine II, Division of
Cardiology, Vienna General Hospital, Medical University, Vienna, Austria
(Unverdorben, Jin) Daiichi Sankyo, Inc., Basking Ridge, NJ, United States
(Mollmann) Department of Internal Medicine, St. Johannes Hospital,
Dortmund, Germany
(Van Mieghem) Department of Cardiology, Cardiovascular Institute,
Thoraxcenter, Erasmus University Medical Center, Rotterdam, Netherlands
(Thiele) Department of Internal Medicine/Cardiology, Heart Center Leipzig
at University of Leipzig, Leipzig, Germany
(Nordbeck) Department of Internal Medicine I, University Hospital
Wurzburg, Wurzburg, Germany
(Rassaf) Clinic for Cardiology and Vascular Medicine, Westgerman Heart-
and Vascular Center, University Duisburg-Essen, Essen, Germany
(Moreno) Department of Cardiology, University Hospital La Paz, Madrid,
Spain
(Mehran) Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai
Hospital, New York, NY, USA
(Veltkamp) Department of Neurology, Alfried Krupp Krankenhaus, Essen,
Germany; Department of Neurology, University Hospital Heidelberg,
Heidelberg, Germany; Department of Brain Sciences, Imperial College
London, London, UK
(Dangas) Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai
Hospital, New York, NY, USA; National and Kapodistrian University of
Athens, School of Medicine, Athens, Greece
Abstract
In patients with prevalent or incident atrial fibrillation (AF) after
successful transcatheter aortic valve implantation (TAVI) enrolled in the
ENVISAGE-TAVI AF trial, the incidence of ischemic stroke (IS) and any
stroke was numerically lower in the edoxaban group vs. the vitamin K
antagonist (VKA) group. The current study aimed to identify risk factors
associated with IS in an on-treatment subanalysis of patients from
ENVISAGE-TAVI AF who received >=1 dose of edoxaban or VKA. Baseline
patient characteristics were compared in patients with vs. without IS.
Numerical variables were compared using a 1-way analysis of variance;
categorical variables were compared using Fisher's exact test. Stepwise
Cox regression determined patient characteristics associated with the
first IS event. Of 1377 patients, 41 (3.0%) experienced an IS, and 1336
(97.0%) did not; baseline demographics and clinical characteristics were
well-balanced between groups. Most ISs occurred within 180 days of TAVI
for edoxaban (57.9%) and VKA (68.2%). The rate of IS was 2.0 per 100
person-years for edoxaban vs. 2.7 per 100 person-years for VKA.
Independently associated with IS were history of systemic embolic events
(SEEs; hazard ratio [HR], 2.96; 95% confidence interval [CI], 1.26-7.00;
P=0.01) and pre-TAVI use of VKAs (HR, 2.17; 95% CI, 1.12-4.20; P=0.02). In
conclusion, while the overall incidence of IS was low for patients with AF
on edoxaban or VKA after successful TAVI, patients with a history of SEEs
or pre-TAVI use of VKAs may have a higher risk of IS following
TAVI. Copyright © 2024. Published by Elsevier Inc.

EPICORE Embase Updates

Saturday, August 3, 2024

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

No comments:

Post a Comment

Followers

Blog Archive

About Me